Clinical trial NCT02851797
Conditions: Duchenne Muscular Dystrophy
Keywords: Dystrophy DMD Givinostat
Sponsor: Italfarmaco
Start date: 2017-06-06; Completion date: 2022-02-22
Enrollment: 179 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Primary Objective

The primary objective of the study was to establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects.

Secondary Objectives

The secondary objectives of this study were:

* To assess the safety and tolerability of givinostat versus placebo administered chronically in DMD subjects
* To evaluate the PK profile of givinostat administered chronically in DMD subjects
* To evaluate the impact on quality of life (QoL) and activities of daily living of givinostat versus placebo administered chronically.

Detailed description:
This was a phase 3, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant subjects with DMD. This study included ambulant male paediatric subjects aged ≥ 6 years at baseline affected by DMD.

A total of 179 male ambulant subjects was randomized 2:1 (givinostat: placebo).

Subjects were stratified for their concomitant use of steroids in 4 strata:

1. Deflazacort daily regimen
2. Deflazacort intermittent regimen
3. Other steroids daily regimen
4. Other steroids intermittent regimen. The study duration was planned to be 19 months.

Givinostat or placebo oral suspension (10 mg/mL) was administered orally as 2 oral doses daily while the subject were in fed state, according to the child's weight.

Study drug should have been permanently stopped if any of the following occurred:

* severe drug-related diarrhoea;
* any drug-related Serious Adverse Event;
* QTcF \>500 msec;
* platelets count ≤50 x 10\^9/L.
* white blood cells ≤2.0 x 10\^9/L
* hemoglobin ≤8.0 g/dL

Study drug should have been temporarily stopped if any of the following occurred:

* moderate or severe diarrhoea.
* platelets count \<75 x 10\^9/L but \>50 x 10\^9/L (the treatment should been temporarily stopped and a platelets count was to be performed and re-tested until platelets normalized);
* white blood cell \<3.0 x 10\^9/L but \>2.0 x 10\^9/L (the treatment should be temporarily stopped and white blood cells had to be measured by 1 week and re-tested until white blood cells normalized);
* hemoglobin \<10.0 g/dL but \> 8.0 g/dL (the treatment should be temporarily stopped and hemoglobin had to be measured by 1 week and re-tested until hemoglobin normalized);
* Triglycerides \>300 mg/dL (3.42 mmol/L) in fasting condition (the treatment should be temporarily stopped and triglycerides measured every 2 weeks until triglycerides returned to levels below 300mg/dL (3.42 mmol/L)

In case the study drug was temporarily stopped, the study drug could be resumed at a level 20% smaller than the one at which the Adverse Event leading to temporary stop occurred, once platelets and/or white blood cell and/or hemoglobin normalized and/or triglycerides returned to levels below 300 mg/dL (3.42 mmol/L) or diarrhoea was mild.

In addition, in case a subject had a consistent (e.g., at least 2 consecutive evaluations) platelets count ≤150 x 10\^9/L and didn't meet the stopping criteria for platelets, the Investigator should have to reduce the dose by 20% of the current dose.

Only one dose reduction was allowed during the treatment period.

This trial design a single planned interim analysis. The interim was governed by an IDMC in order to solely assess futility.

Arms: arm 1: Givinostat oral suspension (10 mg/mL) twice daily arm 2: Placebo oral suspension (10 mg/mL) twice daily
Interventions: intervention 1: givinostat intervention 2: placebo
Intervention descriptions: intervention 1: The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below:

Givinostat or placebo starting dose

* \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid
* \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid
* \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid
* \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid
* \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid
* \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid
* \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid
* \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid
* \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid intervention 2: The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.

Protocol documents:
Prot_000.pdf: 
 
 
 
 
 
ITALFARMACO 
 
CLINICAL STUDY PROTOCOL 
Protocol Number: DSC/14/2357/48 
Protocol Title: Randomised, double blind, placebo controlled, multicentre 
study to evaluate the efficacy and safety of givinostat in ambulant patients 
with Duchenne Muscular Dystrophy. 
 
 
IND Number: 
 
126598 
EudraCT Number: 
2016-000401-36 
Name of Product: 
Givinostat 
Phase of Development: 
3 
Indication: 
Duchenne Muscular Dystrophy (DMD) 
Sponsor: 
Paolo Bettica, MD, PhD 
Director of Clinical Research and 
Development  
ITALFARMACO  S.p.A. 
54, Via dei Lavoratori 
20092 Cinisello Balsamo, Italy 
Tel: 
+ 39 02 64431 
Fax:  + 39 02 644346 
Protocol Version: 
8.0  
Protocol Date: 
  08 APR 2020 
-CONFIDENTIAL- 
This document and its contents are the property of and confidential to 
Italfarmaco S.p.A.  Any unauthorized copying or use of this document is 
prohibited. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 2 of 120 
 
SPONSOR APPROVAL PAGE 
 
 
Date: 
10 April 2020 
Paolo Bettica, MD, PhD 
Director of Clinical Research and 
Development 
 
 
 
 
 
 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 3 of 120 
INVESTIGATOR PROTOCOL AGREEMENT PAGE 
 
I agree: 
 
To assume responsibility for the proper conduct of the study at this site. 
 
To conduct the study in compliance with this protocol, any future amendments, and 
with any other study conduct procedures provided by Italfarmaco S.p.A. 
 
Not to implement any changes to the protocol without written agreement from 
Italfarmaco S.p.A and prior review and written approval from the Institutional Review 
Board/Independent Ethics Committee, except where necessary to eliminate an 
immediate hazard to subjects.  
 
That I am thoroughly familiar with the appropriate use of the study drug, as described 
in this protocol and any other information provided by Italfarmaco S.p.A including, 
but not limited to, the Investigator’s Brochure (IB).  
 
That I am aware of, and will comply with, GCP and all applicable regulatory 
requirements. 
 
To ensure that all persons assisting me with the study are adequately informed about 
the Italfarmaco S.p.A study drug and of their study-related duties and functions as 
described in the protocol. 
 
Signature: 
 
 
Date: 
 
 
Name 
(print): 
 
 
 
 
Site 
Number: 
Principal Investigator 
 
___________ 
 
 
 
 
 
 
 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 4 of 120 
  
1 
SYNOPSIS 
Title of Study: 
Randomised, double blind, placebo controlled, multicentre study to 
evaluate the efficacy and safety of givinostat in ambulant patients 
with Duchenne Muscular Dystrophy  
Acronym 
EPIDYS – Epigenetic Rescue of Dystrophin Dysfunction 
Protocol Number: 
DSC/14/2357/48 
Study Design: 
Randomised, double blind, parallel group, placebo controlled study.  
Subjects will be randomised 2:1 to givinostat or placebo. 
Investigators/Study 
Sites: 
Approximately 50 sites worldwide  
Phase of 
Development: 
3 
Objectives: 
Primary objective: 
 To establish the effects of givinostat versus placebo 
administered chronically over 18 months to slow disease 
progression in ambulant DMD subjects. 
Secondary objectives: 
 To assess the safety and tolerability of givinostat versus 
placebo administered chronically in DMD subjects.  
 To evaluate the pharmacokinetic (PK) profile of givinostat 
administered chronically in DMD subjects;  
 To evaluate the impact on quality of life and activities of daily 
living of givinostat versus placebo administered chronically. 
Secondary exploratory objectives: 
 To evaluate the correlation between PK profile of givinostat 
and pharmacodynamics (PD) data;  
 To explore whether the effects of givinostat versus placebo 
administered chronically may be related to the type of DMD 
mutation or to the biomarkers. 
Study Population 
and Subset 
Definition: 
Ambulant male paediatric subjects aged ≥6 years at baseline affected 
by DMD will be included in this study. 
Target population (Group A): subjects with a baseline vastus lateralis 
muscle fat fraction (VL MFF) assessed by MRS  in the range >5% 
and ≤30%. 
Off-target population (Group B): subjects with a baseline vastus 
lateralis muscle fat fraction (VL MFF) assessed by MRS  in the 
range ≤5% or >30%. 
MR Cohort: all subjects in the target population  who will perform 
the magnetic resonance assessment at baseline, 12 and 18 months. 
 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 5 of 120 
Selection of 
Subjects: 
 
 
 
 
 
 
 
 
 
Main Inclusion Criteria: 
Subjects must meet all the following inclusion criteria: 
1. 
Are ambulant males aged ≥6 years at randomisation with 
DMD characteristic clinical symptoms or signs (e.g., 
proximal muscle weakness, Gowers’ maneuver, elevated 
serum creatinine kinase level) already present at 
screening; 
2. 
Have DMD diagnosis confirmed by genetic testing;  
3. 
Are able to give informed assent and/or consent in writing 
signed by the subject and/or parent/legal guardian 
(according to local regulations); 
4. 
Are able to complete 2 Four Stairs Climb test (4SC) 
screening assessments; the results of these tests must be 
within ±1 second of each other; 
5. 
Have the mean of 2 screening 4SC assessments ≤8 
seconds; 
6. 
Have time to rise from floor between ≥3 and <10 seconds 
at screening; 
7. 
Have manual muscle testing (MMT) of quadriceps at 
screening ≥ Grade - 3; 
8. 
Have used systemic corticosteroids for a minimum of 
6 months immediately prior to the start of study 
treatment, with no significant change in corticosteroids 
type or dosage or dosing regimen (excluding changes 
related to body weight change) for a minimum of 6 
months immediately prior to start of study treatment and a 
reasonable expectation that dosage and dosing regimen 
will not change significantly for the duration of the study. 
9. 
Subjects must be willing to use adequate contraception.  
Contraceptive methods must be used from Randomization 
Visit 3 through 3 months after the last dose of study drug, 
and include the following: 
• True abstinence (absence of any sexual intercourse), 
when in line with the preferred and usual lifestyle of the 
subject. Periodic abstinence (e.g. calendar, ovulation, 
symptothermal, postovulation methods) and withdrawal 
are not acceptable methods of contraception. 
• Condom with spermicide and the female partner must 
use an acceptable method of contraception, such as an 
oral, transdermal, injectable or implanted steroid-based 
contraceptive, or a diaphragm or a barrier method of 
contraception in conjunction with spermicidal jelly such 
as for example cervical cap with spermicide jelly. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 6 of 120 
Main Exclusion Criteria: 
Subjects presenting with any of the following criteria will not be 
included in the study: 
1. 
Have exposure to another investigational drug within 
3 months prior to the start of study treatment (only 
exception allowed is use of Deflazacort in US as part of 
the Expanded Access Program and in Canada as part of 
the Special Access Program); 
2. 
Have exposure to idebenone within 3 months prior to the 
start of  study treatment;  
3. 
Have exposure to any dystrophin restoration product (e.g., 
Ataluren, Exon-skipping) within 6 months prior to the 
start of study treatment; 
4. 
Use of any pharmacologic treatment, other than 
corticosteroids, that might have had an effect on muscle 
strength or function within 3 months prior to the start of 
study treatment (e.g., growth hormone); Vitamin D, 
calcium, and any other supplements will be allowed as 
long as their intake has been stable for 3 months prior to 
the start of study treatment; Testosterone will also be 
allowed if it is used as a replacement therapy for the 
treatment of delayed puberty, and testosterone dose and 
regimen have been stable for at least 6 months and 
circulating testosterone levels are within the normal 
ranges for the subject’s age; 
5. 
Have surgery that might have an effect on muscle 
strength or function within 3 months before study entry or 
planned surgery at any time during the study; 
6. 
Loss of ≥30 degrees of plantar flexion from the normal 
range of movement at the ankle joint due to contracture 
(i.e. fixed loss of more than 10 degrees of plantar flexion 
from plantigrade, assuming normal range of dorsiflexion 
of 20 degrees); 
7. 
Change in contracture treatment such as serial casting, 
contracture control devices, night splints, stretching 
exercises (passive, active, self) within 3 months prior to 
enrollment, or expected need for such intervention during 
the study; 
8. 
Have presence of other clinically significant disease, 
which, in the Investigator’s opinion, could adversely 
affect the safety of the subject, making it unlikely that the 
course of treatment or follow-up would be completed, or 
could impair the assessment of study results; 
9. 
Have a diagnosis of other uncontrolled neurological 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 7 of 120 
diseases or presence of relevant uncontrolled somatic 
disorders that are not related to DMD; 
10. 
Have platelets count, White Blood Cell and Hemoglobin 
at screening <Lower Limit of Normal (LLN) (for 
abnormal screening laboratory test results (<LLN), the 
platelets count, White Blood Cell and Hemoglobin will be 
repeated once; if the repeat test result is still <LLN, then 
exclusionary);  
11. 
Have symptomatic cardiomyopathy or heart failure (New 
York Heart Association Class III or IV) or left ventricular 
ejection fraction <50% at screening; 
12. 
Have a current or history of liver disease or impairment, 
including but not limited to an elevated total bilirubin (i.e. 
> 1.5 x ULN), unless secondary to Gilbert disease or 
pattern consistent with Gilbert's; 
13. 
Have inadequate renal function, as defined by serum 
Cystatin C >2 x the upper limit of normal (ULN). If the 
value is >2 x ULN, the serum Cystatin C will be repeated 
once; if the repeated test result is still >2 x ULN, the 
subject should be excluded);  
14. 
Have Triglycerides > 300 mg/dL (3.42 mmol/L) in fasting 
condition at screening visit; 
15. 
Have a positive test for hepatitis B surface antigen, 
hepatitis C antibody, or human immunodeficiency virus at 
screening; 
16. 
Have a baseline corrected QT interval, Fridericia’s 
correction (QTcF) >450 msec, (as the mean of 3 
consecutive readings 5 minutes apart) or history of 
additional risk factors for torsades de pointes (e.g., heart 
failure, hypokalemia, or family history of long QT 
syndrome); 
17. 
Have a psychiatric illness/social situations rendering the 
potential subject unable to understand and comply with 
the muscle function tests and/or with the study protocol 
procedures; 
18. 
Have any hypersensitivity to the components of study 
medication; 
19. 
Have a sorbitol intolerance or sorbitol malabsorption, or 
have the hereditary form of fructose intolerance. 
20. 
Have 
contraindications 
to 
MRI 
or 
MRS 
(e.g., 
claustrophobia, metal implants, or seizure disorder).  
At the discretion of the Investigator, subjects not meeting 
inclusion/exclusion criteria may be re-screened twice with an interval 
of at least 3 months between assessments. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 8 of 120 
Planned Sample 
Size: 
The primary, target population for formal statistical analysis and 
inference is those children with a baseline vastus lateralis muscle fat 
fraction (VL MFF) assessed by MRS  in the range >5% and ≤30% 
(Group A). A total of 110 male ambulant subjects in this target 
population will be randomised. Up to 50 subjects (about 35% of the 
overall population) outside of the target may also be recruited into 
the study (Group B).  The overall subject population (Group A + 
Group B)  will provide supportive data.   
Stratification: 
Subjects will be stratified for their concomitant use of steroids in 
4 strata: 
1. Deflazacort Daily regimen 
2. Deflazacort Intermittent regimen 
3. Other steroids Daily regimen 
4. Other steroids Intermittent regimen 
Randomisation 
ratio:  
2:1  
Study duration for 
participants: 
The study duration is planned for 19 months. 
The study comprises 2 phases: 
1. Screening period: starting 4 weeks before randomisation 
2. Treatment period: 18 months of treatment 
Reference 
Therapy: 
Givinostat or placebo oral suspension (10 mg/mL) twice daily (bid) 
(in a fed state) as described below: 
Placebo or Givinostat starting dose 
Weight 
(kg) 
≥10 
and 
<12.
5 
≥12.5 
and 
<20 
≥20 
and 
<25 
≥25 
and 
<30 
≥30 
and 
<40 
≥40 
and 
<50 
≥50 
and 
<60 
≥60 
and 
< 70 
≥70 
Dose 
(mg) 
bid 
13.3 
16.7 
20 
23.3 
26.7 
33.3 
36.7 
40 
46.7 
Oral 
suspen
sion 
(mL) 
bid 
1.3 
1.7 
2.0 
2.3 
2.7 
3.3 
3.7 
4 
4.7 
 
The subjects who were randomized under protocol version 4.0 will 
continue the current dose. 
If subjects (i.e. those already in treatment or those who will be 
randomized under protocol version 6.0, or 7.0 or 8.0) gain weight 
during the study the drug dose must be kept unchanged. If  subjects 
(i.e. those already in treatment or those who will be randomized 
under protocol version 6.0, or 7.0 or 8.0) lose weight during the 
study, the drug dose should be adjusted accordingly. 
Criteria for 
Evaluation: 
Efficacy: 
The primary efficacy assessment in the target population is the time 
to climb 4 standard stairs. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 9 of 120 
The secondary key efficacy assessments in the target population are: 
1. Time to rise from floor; 
2. Distance walked in 6 minutes using six-minute walking test 
(6MWT); 
3. Physical function assessed by North Star Ambulatory 
Assessment (NSAA); 
4. Muscle strength evaluated by knee extension, elbow flexion 
as measured by hand-held myometry (HHM). 
5. Fat fraction of vastus lateralis muscles evaluated by MRS 
technique (MR Cohort) 
The exploratory efficacy assessments are: 
 Time to walk/run 10 meters; 
 Quality of life assessed by Paediatric Outcomes Data 
Collection Instrument (PODCI);  
 %-predicted 6MWT; 
 MRI parameters (e.g., fat fraction of thigh muscles, cross 
sectional area (CSA) of vastus lateralis and other thigh 
muscles, etc.) only in the MR cohort; 
 Time to 10% persistent worsening in 6MWT (Baseline 
through end of study); 
 Proportion of subjects with ≥10% worsening in 6MWT at end 
of study; 
 Time to loss of standing (Baseline through end of study); 
 Proportion of subjects who loose ambulation during the study. 
 Evaluation of any correlation between the effect of Givinostat 
on disease progression and the type of DMD mutation, 
LTBP4 and Osteopontin genotype;  
 Evaluation of any possible DMD serum biomarker. 
Pharmacokinetic: 
The concentration of givinostat and its metabolites will be 
determined from the plasma samples using a validated analytical 
method. 
Safety: 
Safety and tolerability will be evaluated by monitoring hematology 
and blood chemistry, coagulation, urinalysis; by measurement of 
vital signs, physical examinations, weight, height, echocardiogram 
(ECHO) and electrocardiogram (ECG) recording; and by respiratory 
function evaluation, cognitive function evaluation, and by adverse 
events (AEs) recording to be performed at protocol-specified visits. 
In addition, the evaluation of acceptability/palatability of the oral 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 10 of 120 
suspension will be assessed. 
Study Endpoints: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary efficacy endpoints: 
 
Mean change in 4SC before and after 18 months of 
treatment of givinostat versus placebo. 
Key secondary efficacy endpoints: 
Function: 
 
Mean change in time to rise from floor; 
 
Mean change in 6MWT; 
 
Mean change in NSAA;  
 
Cumulative loss of function on the NSAA  
 
Mean change in muscle strength evaluated by knee 
extension, elbow flexion  as measured by HHM;  
Imaging: 
 
Mean change in vastus lateralis muscles fat fraction; 
The above endpoints will be formally assessed after 18 months of 
treatment 
 
Safety endpoints: 
 
Number of subjects experiencing treatment-emergent 
adverse events (TEAEs) and serious adverse events 
(SAEs) (Baseline through end of study [EOS]); 
 
Type, incidence, and severity of TEAEs and SAEs 
(Baseline through EOS); 
 
Changes from baseline to end of study of:  
 
Vital signs and clinical laboratory tests (blood chemistry 
and hematology); 
 
Respiratory function evaluated by forced vital capacity 
(FVC), forced expiratory volume at 1 second (FEV1), 
FVC/FEV1, Peak Expiratory Flow (PEF); 
 
Cardiac function evaluated by ECG and ECHO; 
 
Cognitive function evaluated by the Raven coloured 
progressive matrices; 
 
Weight, height, and body mass index (BMI). 
 
Evaluation of acceptability/palatability of the oral 
suspension. 
Pharmacokinetic Endpoints:   
 
Description of the PK of givinostat and its major 
metabolites: ITF2374 and ITF2375 in the subject 
population; 
 
Identification 
of 
the 
relevant 
demographic 
and 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 11 of 120 
pathophysiological covariates influencing the PK of 
givinostat. 
Exploratory endpoints: 
 
Mean changes in:  
 
time to walk/run 10 meters; 
 
PODCI scores; 
 
%-predicted 6MWT;  
 
Only in the MR cohort: MRI parameters (e.g., fat fraction 
of thigh muscles, CSA of vastus lateralis and other thigh 
muscles).  
 
Time to 10% persistent worsening in 6MWT (Baseline 
through end of study); 
 
Proportion of subjects with ≥10% worsening in 6MWT at 
end of study; 
 
Time to loss of standing (Baseline through end of study); 
 
Proportion of subjects who loose ambulation during the 
study; 
 
Evaluation of any correlation between the effect of 
Givinostat on disease progression and the type of DMD 
mutation, LTBP4 and Osteopontin genotype;  
 
Evaluation of any possible DMD serum biomarker; 
 
PK-PD analyses: relationships between metrics of 
exposure and efficacy/safety endpoints of givinostat. 
Rules for cessation 
of randomised 
treatment in an 
individual 
participant: 
Individual subjects may cease taking randomised treatment at the 
discretion of the Investigator. 
Study drug should be permanently stopped if any of the following 
occur: 
 severe drug-related diarrhoea (i.e., increase of ≥7 stools per 
day);  
 any drug-related SAE; 
 QTcF >500 msec; 
 platelets count ≤50 x 109/L (to avoid laboratory errors and 
anomalous values, platelets count ≤50 x 109/L must be 
confirmed with a repeated test performed on the next working 
day.  The treatment should be stopped until the retest result 
becomes available.  If the repeated platelets count is still ≤50 
x 109/L, study drug must be permanently discontinued.  If the 
repeated test is acceptable, the subject can resume 
treatment.); 
 white blood cells  ≤2.0 x 109/L (to avoid laboratory errors and 
anomalous values, white blood cells  ≤2.0 x 109/L must be 
confirmed with a repeated test performed on the next working 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 12 of 120 
day.  The treatment should be stopped until the retest result 
becomes available.  If the repeated white blood cells is still 
≤2.0 x 109/L, study drug must be permanently discontinued.  
If the repeated test is acceptable, the subject can resume 
treatment.);   
 hemoglobin  ≤8.0 g/dL (to avoid laboratory errors and 
anomalous values, hemoglobin  ≤8.0 g/dL must be confirmed 
with a repeated test performed on the next working day.  The 
treatment should be stopped until the retest result becomes 
available.  If the repeated hemoglobin is still ≤8.0 g/dL, study 
drug must be permanently discontinued.  If the repeated test 
is acceptable, the subject can resume treatment.).  
Study drug should be temporarily stopped if any of the following 
occur: 
 moderate or severe diarrhoea (i.e., increase more than 4 stools 
per day); 
 platelets count <75 x 109/L but >50 x 109/L (the treatment 
should be temporarily stopped and a platelets count has to be 
performed by 1 week and re-tested until platelets will be 
normalized); 
 white blood cell  <3.0 x 109/L but >2.0 x 109/L (the treatment 
should be temporarily stopped and white blood cells have to 
be measured by 1 week and re-tested until white blood cells  
will be normalized); 
 hemoglobin  <10.0 g/dL but > 8.0 g/dL (the treatment should 
be temporarily stopped and hemoglobin has to be measured 
by 1 week and re-tested until hemoglobin will be 
normalized); 
 
Triglycerides >300 mg/dL (3.42 mmol/L) in fasting condition 
(the 
treatment 
should 
be 
temporarily 
stopped 
and  
triglycerides has to be measured every 2 weeks until 
triglycerides return to levels below 300mg/dL (3.42 mmol/L); 
Dose adjustment: 
In case the study drug is temporarily stopped, the study drug can be 
resumed at a level 20% smaller (see table below) than the one at 
which the AE leading to temporary stop occurred, once platelets 
and/or white blood cell and/or hemoglobin are normalized  and/or 
triglycerides return to levels below 300 mg/dL (3.42 mmol/L ) or 
diarrhoea is mild. 
Rules for Dose Reduction of 20%  
Starting Dose 
(mg) bid 
13.3 
16.7 
20 
23.3 
26.7 
33.3 
36.7 
40 
46.7 
Oral 
suspension 
(mL) bid 
1.3 
1.7 
2.0 
2.3 
2.7 
3.3 
3.7 
4 
4.7 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 13 of 120 
Reduced Dose 
(mg) bid 
10.6 
13.4 
16 
18.6 
21.4 
26.6 
29.4 
32 
37.4 
Oral 
suspension 
(mL) bid 
1.1 
1.3 
1.6 
1.9 
2.1 
2.7 
2.9 
3.2 
3.7 
In addition, in case a subject will have a consistent (e.g., at least 2 
consecutive evaluations) platelets count ≤150 x 109/L and not 
meeting the stopping criteria for platelets, the Investigator will have 
to reduce the dose by 20% of the current dose. 
Only one dose reduction is allowed during the treatment period. 
Subjects who were randomized under protocol version 4.0, will 
continue to follow the instructions of protocol version 4.0, related to 
starting dose and dose modifications:   
In case the study drug was temporarily stopped, the study drug can 
be resumed at a level 1/3 smaller (see table below) than the one at 
which the AE leading to temporary stop occurred, once platelets 
and/or white blood cell and/or hemoglobin are normalized  and/or 
triglycerides return to levels below 300 mg/dL (3.42 mmol/L) or 
diarrhoea is mild. 
Rules for Dose Reduction of 1/3  
Starting Dose 
(mg) bid 
20 
25 
30 
35 
40 
50 
55 
60 
70 
Oral 
suspension 
(mL) bid 
2.0 
2.5 
3.0 
3.5 
4.0 
5.0 
5.5 
6.0 
7.0 
Reduced 
Dose (mg) bid 
13.3 
16.7 
20 
23.3 
26.7 
33.3 
36.7 
40 
46.7 
Oral 
suspension 
(mL) bid 
1.3 
1.7 
2.0 
2.3 
2.7 
3.3 
3.7 
4 
4.7 
In addition, in case a subject will have a consistent (e.g., at least 2 
consecutive evaluations) platelets count ≤150 x 109/L and not 
meeting the stopping criteria for platelets, the Investigator will have 
to reduce the dose of 1/3 of the current dose. 
Moreover, for subjects who have already reduced the dose of 1/3 an 
additional reduction by 20%  is allowed for safety reasons.  
For all subjects, during the first month of treatment, platelets count 
assessment will be performed weekly, while during the second 
month it will be performed every 2 weeks, in order to strictly 
monitor this parameter for safety reasons. 
If the dose is reduced due to platelet count ≤150 x 109/L, and/or 
white blood cell  <3.0 x 109/L and/or hemoglobin <10.0 mg/dL, a 
complete blood count (i.e.CBC) test must be performed weekly for 8 
consecutive weeks. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 14 of 120 
Any decision relevant to the dose adjustment and/or modification of 
schedule of assessments can be discussed with the Medical Monitor, 
but the final decision remains with the Investigator only or its 
authorized designee 
Other: 
As the subjects to be randomised are on stable steroids, the 
recommended national immunisation schedule, including varicella 
immunity, should be completed (i.e., as recommended in the 
“Diagnosis and Management of Duchenne muscular dystrophy” 
DMD guideline4), before the Screening Visit. However, in case of 
live or live attenuated vaccines to be administered during the study, 
the Investigator can discuss, but it is not mandatory, the case with the 
Medical Monitor of the study and must carefully monitor the subject. 
Independent Data 
Monitoring 
Committee: 
An independent Data Monitoring Committee (IDMC) will review, 
evaluate and categorise safety findings every 3 months during the 
study and will be responsible for oversight of the formal interim 
analysis (see below).  The IDMC will have access to unblinded data, 
if necessary, and will operate according to the rules defined in the 
IDMC charter. 
Sample size 
calculation: 
The sample size (utilizing a 2:1 randomisation scheme) is calculated 
to provide 90% power and a 1-sided alpha of 2.5% to detect a true 
difference between givinostat and placebo in the target population, in 
4SC 18 month change from baseline, of 3 seconds, assuming a 
common standard deviation (SD) of 6 seconds. The estimated SD is 
based on publicly available Phase 3 study data on ataluren and 
drisapersen in subjects with DMD in addition to internal Italfarmaco 
S.p.A data. 
 
Vastus lateralis muscles fat fraction (VL MFF) assessed via MRS is 
the first key endpoint in the MR cohort and will be formally assessed 
in the target population at 12 months.  Based on internal Italfarmaco 
S.p.A. data, a total of N=99 subjects will be sufficient to provide 
80% power to detect a 55% reduction in the annual mean increase in 
MFF (of 6.6%) with givinostat as compared to placebo with a 1-
sided alpha of 2.5% and assuming an SD for the change from 
baseline in MFF of 6%. 
 
The pre-planned interim analysis was performed in January 2020, 
concluding that futility was not met and the trial should continue, and 
thus a pre-planned blinded sample size re-calculation was performed.  
The within treatment SD for the change in 4SC from baseline to 18 
month was estimated to be 3.094 seconds, approximately half of the 
SD that as assumed in the original power calculation.  With this 
revised SD estimate, N= 102 (on 2:1 basis) subjects is sufficient to 
provide 90% power to detect a true difference in 4SC of 2 seconds 
between givinostat and placebo in the target population at a 1-sided 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 15 of 120 
alpha of 2.5%.  With an estimated drop-out rate of 8%, a total of 110 
subjects in the target population (Group A) will be randomized. 
 
For the MR cohort, the blinded SD estimate was 5.941%, being in 
line with SD assumed in the original power calculation for VLFF, 
hence all the subjects in the target population will be included in the 
analysis of the MR cohort. 
 
Interim analysis: 
One formal interim analysis is planned and will be overseen by the 
IDMC in order to ensure study integrity ; this is to assess futility on 
VLFF and, if not futile, esecute a blinded sample size reestimation.  
Statistical Methods 
and Planned 
Analyses: 
An IDMC charter will be prepared to describe the role, function and 
operations of the IDMC and the rules to be used when reviewing 
interim data.  
 
The planned interim analysis will be performed when the first N=50 
subjects randomised in the target population have reached the 12 
month time point.  In this interim analysis, the IDMC will evaluate 
the effects of givinostat versus placebo on the VL MFF in terms of 
futility. Futility will be considered if VLMFF in the givinostat group 
is equal to or worse than that seen in the placebo group since the 
biologic plausibility of a subsequent treatment effect on 4SC time 
would be greatly diminished. The IDMC will only communicate to 
the Sponsor whether the study should proceed or it should be stopped 
having met the futility criteria.  
If the IDMC indicates that the study should proceed, a blinded 
sample size re-estimation will be conducted for MFF and 4SC in the 
target population as follows:  
 
To maintain the blind on the primary endpoint, the within treatment 
SD for the change from baseline will be estimated as  𝝈̂𝒘𝒊𝒕𝒉𝒊𝒏=
√𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍
𝟐
−(
𝜟
𝟐)
𝟐
 where 𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍  is the overall SD for the change 
from baseline in 4SC based on the n=50 subjects in the interim and 
𝛥 is the hypothesized treatment effect, i.e. 𝛥= 3 seconds.  
Dependent upon the blinded SD estimate, the sample size may be 
decreased or increased to maintain 90% power. Any increase in 
sample size for 4SC will be limited to 1.5 times maximum of the 
initial target population sample size, i.e., to a maximum of 
1.5 × 192 = 288 subjects.  For a 20% increase in the SD, this 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 16 of 120 
degree of increase in sample size will maintain 90% power, and for 
a 40% increase in SD power will be maintained at 80%.    
 With respect to VL MFF, a similar approach will be applied; 
the within treatment SD for the change from baseline will be 
estimated as 𝝈̂𝒘𝒊𝒕𝒉𝒊𝒏= √  𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍
𝟐
−(
𝜟
𝟐)
𝟐
 where 𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍  is the 
overall SD for the change from baseline in MFF and 𝛥 is the 
hypothesized treatment effect, i.e. 𝛥= 3.63% (i.e. 55% of 
6.6%).  Dependent upon the blinded SD estimate, the sample 
size may be decreased or increased to maintain 90% power. 
Any increase in sample size require to assess VL MFF will 
also be limited to 1.5 times the required target population 
sample size stated in the preceding power calculation, to a 
maximum of 1.5 × 99 = 150 subjects.  
At the interim futility analysis, there will be no efficacy assessment, 
no unblinded analysis of the primary endpoint and, hence, no alpha 
spend nor early stopping of the study for efficacy.  
The interim took place as planned on 14th January 2020 and included 
50 patients with 12 month data and 37 with 18 month data. The 
independent data monitoring committee (IDMC) meeting to review 
the VL MFF data for futility took place on 23rd January 2020 and 
concluded that futility was not met and the trial should continue. 
The sample size reassessment therefore took place, with estimated 
overall SDs of 3.094 seconds and 5.941% for the change from 
baseline in 4SC at 18 months and the change from baseline in VL 
MFF at 12 months respectively.   
 
The revised sample size (utilizing a 2:1 randomisation scheme) N= 
102 was calculated to provide 90% power and a 1-sided alpha of 
2.5% to detect a true difference between givinostat and placebo in 
the target population, in 4SC 18 month change from baseline, of 2 
seconds, with the blinded SD estimates during the interim analysis of 
3.094 seconds.  With an estimated drop-out rate of 8%, a total of 110 
subjects in the target population (Group A) will be randomized. 
For the MR cohort, since the blinded SD estimate was 5.941%, all 
the subjects in the target population will be part of the MR cohort. 
Since the interim only assessed futility on VLFF and executed  a 
blinded sample size reestimation, no alpha was spent and, hence the 
analysis of the primary endpoint conducted at the end of the trial will 
continue to be assessed at the 0.025 1-sided level.   
 
 
Statistical analysis: 
General 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 17 of 120 
All efficacy analyses will be performed on Intent-To-Treat (ITT) 
population. Formal efficacy analyses will be performed in the target 
population; overall population analyses will be supportive and 
informal.  Randomised subjects who have taken at least 1 dose of 
randomised therapy will be included in the relevant analyses.  
Descriptive statistics for qualitative data will include frequency 
tabulation and presentation of percentages.  Descriptive statistics for 
quantitative data will include mean and SD or geometric mean, 
coefficient of variation, median and interquartile range.  
A comprehensive SAP will be prepared prior to the planned interim 
analysis to provide full details of all planned analyses and 
methodology. 
Primary Efficacy Endpoint 
The change in 4-stairs climb (4SC) from baseline to 18 months will 
be evaluated in the target population. The data will be analyzed using 
an Analysis of Covariance (ANCOVA) model with the change in 
4SC from baseline to 18 months as the dependent variable and with 
terms for baseline 4SC value as a covariate and randomised 
treatment, concomitant steroid use and age at baseline as independent 
class variables.  Least squares means (Lsmeans) will be estimated for 
givinostat and placebo.  The treatment effect, being difference in 
Lsmeans, will be presented along with the associated 95% 
confidence interval and the p-value.   Significance will be achieved if 
the 1-sided p-value is ≤0.025.   
Analysis of   Key Secondary Endpoints 
Formal analyses of functional secondary endpoints  (i.e.,cumulative 
loss of function in the NSAA, change  in 6MWT, NSAA, time to rise 
from floor and muscle strength by knee extension and elbow flexion) 
and Vastus lateralis MFF will be performed in the target population 
at 18 months using the same approach as described for the primary 
endpoint.  Possible need for log transformation of these variables 
will be assessed prior to unblinding by assessment of ANCOVA 
model residuals without a treatment effect term.   
Safety Data 
Safety data will be evaluated descriptively.  All subjects (target and 
off-target population combined) who took at least 1 dose of study 
drug will be included in the summary of safety.  The following 
parameters will be summarized: rates of discontinuation, AEs, and 
laboratory abnormalities.  Adverse event data will be coded using the 
Medical Dictionary for Competent Activities (MedDRA).  Summary 
statistics will be presented for changes in vital signs.  Laboratory test 
values will be summarised similarly, but will also include tabulation 
of the number of subjects shifting from within the reference range at 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 18 of 120 
baseline to outside of the reference range on randomised treatment. 
 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 19 of 120 
2 
TABLE OF CONTENTS 
 
1 
SYNOPSIS ............................................................................................................. 4 
2 
TABLE OF CONTENTS ................................................................................... 19 
3 
LIST OF ABBREVIATIONS ............................................................................ 24 
4 
INTRODUCTION .............................................................................................. 27 
4.1 
Background on Duchenne Muscular Dystrophy ................................................... 27 
4.2 
Background on Givinostat .................................................................................... 28 
4.2.1 Nonclinical Studies ..................................................................................... 31 
4.2.2 Clinical Experience with Givinostat Including Risks and Benefits ............ 35 
4.2.3 Rationale of the study ................................................................................. 37 
5 
STUDY OBJECTIVES AND ENDPOINTS..................................................... 40 
5.1 
Study Objectives ................................................................................................... 40 
5.1.1 Primary Objective ....................................................................................... 40 
5.1.2 Secondary Objectives.................................................................................. 40 
5.1.3 Secondary Exploratory Objectives ............................................................. 40 
5.2 
Study Endpoints .................................................................................................... 40 
5.2.1 Primary Endpoint ........................................................................................ 40 
5.2.2 Key Secondary Endpoints ........................................................................... 41 
5.2.3 Safety Endpoints ......................................................................................... 41 
5.2.4 Pharmacokinetic Endpoints ........................................................................ 41 
5.2.5 Exploratory Endpoints ................................................................................ 41 
6 
INVESTIGATIONAL PLAN ............................................................................ 42 
6.1 
Description of Overall Study Design and Plan ..................................................... 42 
6.2 
Discussion of Study Design .................................................................................. 44 
7 
SELECTION AND WITHDRAWAL OF SUBJECTS ................................... 46 
7.1 
Inclusion Criteria .................................................................................................. 46 
7.2 
Exclusion Criteria ................................................................................................. 47 
7.3 
Withdrawal, Removal, and Replacement of Subjects ........................................... 49 
7.3.1 Safety Stopping Rules ................................................................................. 50 
8 
TREATMENTS .................................................................................................. 53 
8.1 
Details of Study Treatments ................................................................................. 53 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 20 of 120 
8.2 
Dosage .................................................................................................................. 53 
8.2.1 Rational for Dose Selection ........................................................................ 53 
8.2.2 Dosage Schedule ......................................................................................... 55 
8.3 
Study Treatment Assignment ................................................................................ 58 
8.4 
Blinding ................................................................................................................ 59 
8.5 
Drug Supply .......................................................................................................... 60 
8.5.1 Packaging .................................................................................................... 60 
8.5.2 Labelling ..................................................................................................... 60 
8.5.3 Storage ........................................................................................................ 61 
8.6 
Treatment Accountability and Compliance .......................................................... 62 
8.7 
Prior and Concomitant Illnesses and Medications ................................................ 62 
8.7.1 Prior and Concomitant Illnesses ................................................................. 62 
8.7.2 Prior and Concomitant Medications ........................................................... 63 
9 
STUDY PROCEDURES .................................................................................... 64 
9.1 
Procedures by Study Visit ..................................................................................... 68 
9.1.1 Visit 1 and Visit 2 - Screening (Week -4 ± 2 weeks) ................................. 68 
9.1.2 Visit 3 - Randomisation (Week 0) .............................................................. 69 
9.1.3 Visits 4 (Week 1, ±3 days) .......................................................................... 70 
9.1.4 Visits 5, 6 and 8 (Weeks 2, 3 and 6, ±3 days) ............................................. 70 
9.1.5 Visit 7 (Week 4, ±3 days) ........................................................................... 71 
9.1.6 Visits 9 (Week 8, ± 3 days) ......................................................................... 71 
9.1.7 Visits 10 – 14 (Weeks 12-60, ± 7 days) ...................................................... 72 
9.1.8 Visit 15: End of Study Visit (also named “EOS Visit”, Week 72 ± 7 days), 
and early withdrawal visit ................................................................. 73 
9.1.9 Follow up Visit (Week 76)( ± 7 days) ........................................................ 74 
9.1.10 Unscheduled Visits ..................................................................................... 75 
9.2 
Study Conclusion .................................................................................................. 75 
10 
EFFICACY ASSESSMENTS ............................................................................ 75 
10.1 
Primary Efficacy Assessment ............................................................................... 75 
10.2 
Secondary Efficacy Assessments (All Subjects) .................................................. 76 
11 
PHARMACOKINETICS ................................................................................... 78 
11.1 
Pharmacokinetic Sampling ................................................................................... 78 
11.1.1 Blood Samples ............................................................................................ 78 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 21 of 120 
11.2 
Pharmacokinetic Analytical Methodology ........................................................... 79 
12 
SAFETY ASSESSMENTS ................................................................................. 79 
12.1 
Vital Signs ............................................................................................................. 80 
12.2 
Physical Examination ........................................................................................... 80 
12.3 
Electrocardiogram ................................................................................................. 80 
12.4 
Echocardiogram .................................................................................................... 81 
12.5 
Respiratory Function Test ..................................................................................... 81 
12.6 
Cognitive Function Test ........................................................................................ 81 
12.7 
Acceptability/Palatability Evaluation ................................................................... 82 
12.8 
Laboratory Assessments ....................................................................................... 83 
12.9 
Adverse Events ..................................................................................................... 85 
12.9.1 Definitions................................................................................................... 85 
12.9.2 Adverse Event Reporting ............................................................................ 86 
12.9.3 Serious Adverse Event Reporting ............................................................... 89 
12.9.4 Overdose ..................................................................................................... 90 
12.9.5 Pregnancy reporting .................................................................................... 91 
13 
STATISTICAL ANALYSIS .............................................................................. 92 
13.1 
Overall Statistical Strategy ................................................................................... 92 
13.2 
Determination of Sample Size .............................................................................. 92 
13.3 
Analysis Population .............................................................................................. 93 
13.3.1 Intent-To-Treat Population ......................................................................... 93 
13.3.2 Safety Population ........................................................................................ 94 
13.4 
Demographic and Baseline Characteristics .......................................................... 94 
13.5 
Investigational Medicinal Products ..................................................................... 94 
13.6 
Prior and Concomitant Therapy ............................................................................ 94 
13.7 
Efficacy Analysis .................................................................................................. 95 
13.7.1 Analysis of the Primary Efficacy Endpoint ................................................ 95 
13.7.2 Analysis of Key Secondary Efficacy Endpoints ......................................... 95 
13.7.3 Analysis of Exploratory Efficacy Endpoints .............................................. 96 
13.8 
Pharmacokinetic Analysis ..................................................................................... 97 
13.9 
Safety Analysis ..................................................................................................... 97 
13.10 Interim Analysis ................................................................................................... 98 
13.10.1 Interim Analysis ......................................................................................... 98 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 22 of 120 
13.10.2 Final  Analysis ......................................................................................... 100 
13.11 Independent Data Monitoring Committee ......................................................... 100 
14 
STUDY MANAGEMENT ................................................................................ 100 
14.1 
Approval and Consent ........................................................................................ 100 
14.1.1 Regulatory Guidelines .............................................................................. 100 
14.1.2 Institutional Review Board/Independent Ethics Committees ................... 101 
14.1.3 Independent Data Monitoring Committee ................................................ 101 
14.1.4 Subject Informed Consent......................................................................... 102 
14.1.5 Discontinuation of the study by the Sponsor ............................................ 103 
14.1.6 Data Handling ........................................................................................... 103 
14.2 
Source Documents .............................................................................................. 104 
14.3 
Record Retention ................................................................................................ 105 
14.4 
Monitoring .......................................................................................................... 105 
14.5 
Quality Control and Quality Assurance .............................................................. 106 
14.6 
Protocol Amendment and Protocol Deviation .................................................... 106 
14.6.1 Protocol Amendment ................................................................................ 106 
14.6.2 Protocol Deviations ................................................................................... 107 
14.7 
Ethical Considerations ........................................................................................ 107 
14.8 
Financing and Insurance ..................................................................................... 107 
14.9 
Publication Policy/Disclosure of Data and Confidentiality ................................ 108 
15 
REFERENCES .................................................................................................. 109 
16 
APPENDICES ................................................................................................... 113 
16.1 
Combined list of drugs that prolong QT and/or cause torsades de Pointes (TDP)
 ............................................................................................................................ 114 
16.2 
Drugs knows to be a substrate of OCT2 transporter ........................................... 118 
16.3 
Drugs known to be P-glycoprotein inhibitors ..................................................... 119 
 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 23 of 120 
IN-TEXT TABLES 
Table 1: Exposure margins for Cmax and AUC:  rat vs. DMD subjects and monkey vs. DMD 
subjects ................................................................................................................... 33 
Table 2: Placebo or Givinostat Starting Dose ....................................................................... 55 
Table 3: Placebo or Givinostat Starting Dose for subjects enrolled under Protocol version 
4.0  ......................................................................................................................... 55 
Table 4: Placebo or Givinostat Dose Modification for subjects randomized under study 
protocol version 6.0 or 7.0 or 8.0. .......................................................................... 56 
Table 5: Placebo or Givinostat Dose Modification for subject randomized under study 
prococol version 4.0 ............................................................................................... 57 
Table 6:    Schedule of Assessments ....................................................................................... 65 
Table 7: Laboratory Assessment Samples ............................................................................ 84 
 
IN-TEXT FIGURES 
Figure 6-1: 
Study Design .................................................................................................... 43 
Figure 12-2:  Five Point Hedonic Scale - Face Descriptions ................................................ 82 
 
 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 24 of 120 
3 
LIST OF ABBREVIATIONS 
Abbreviation 
Definition 
4SC 
4-stairs climb 
6MWT 
Six-minute walking test 
ADR 
Adverse drug reaction 
AE 
Adverse event 
ALP 
Alkaline phosphatase 
ALT 
Alanine aminotransferase 
ANCOVA 
Analysis of covariance  
aPTT 
Activated partial thromboplastin time 
AST 
ATS 
Aspartate Aminotransferase 
American Thoracic Society 
AUC 
Area under the curve  
bid 
twice daily 
BMI 
Body mass index  
BUN 
Blood urea nitrogen 
CBC 
Complete Blood Count 
CFR 
Code of Federal Regulations 
Cmax 
Maximum observed concentration 
CRA 
Clinical research associate  
CRF 
Case Report Form 
CSA 
Cross sectional area  
CSOM 
Clinical Study Operations Manual 
CSR 
Clinical study report 
DAPC 
Dystrophin-associated protein complex 
DMD 
Duchenne muscular dystrophy  
DNA 
Deoxyribonucleic acid 
ECG 
Electrocardiogram 
ECHO 
Echocardiogram 
eCRF 
electronic Case Report Form 
EDC 
Electronic Data Capture 
EOS 
End of study 
EU 
European Union 
FAPs 
Fibro-adipogenic progenitors 
FDA 
Food and Drug Administration 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 25 of 120 
FEV1 
Forced Expiratory Volume at 1 second  
FVC 
Forced Vital Capacity  
GCP 
Good Clinical Practice 
GGT 
Gamma-glutamyl transpeptidase 
GI 
Gastrointestinal  
GSPV 
Global Safety and Pharmacovigilance 
Hct 
Hematocrit 
HDAC 
Histone deacetylase  
HDACi 
Histone deacetylase inhibitors  
HDL 
High-Density Lipoprotein  
HHM 
Hand-held myometry 
HIPPA 
Health C Portability Accountability Act 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonization 
IDMC 
Independent Data Monitoring Committee  
IEC 
Independent Ethics Committee 
IL-1β 
Interleukin-1 beta 
IND 
Investigational New Drug  
IRB 
Institutional Review Board 
IRT 
Interactive response technology  
ITT 
Intention-to-Treat 
LDH 
Lactate dehydrogenase 
LDL 
Low-Density Lipoprotein  
IFN-γ 
Interferon gamma 
IL-6 
Interleukin-12  
IL-12 
Interleukin-6 
LLN 
Lower Limit Normal 
Lsmeans 
Least squares means  
MCH 
Mean corpuscular hemoglobin 
MCHC 
Mean corpuscular hemoglobin concentration 
MCV 
Mean corpuscular volume 
MedDRA 
Medical Dictionary for Competent Activities 
MFAF 
Muscle Fibers Area Fraction  
MFF 
Muscle fat fraction 
MMT 
Manual muscle testing  


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 26 of 120 
MoA 
Mechanism of action 
MRI 
Magnetic resonance imaging  
MRS 
Magnetic resonance spectroscopy 
mRNA 
Messenger ribonucleic acid 
nNOS 
Neuronal nitric oxide synthase 
NO 
Nitric oxide 
NOAEL 
No-Adverse Effect Level 
NSAA 
North Star Ambulatory Assessment  
OCT 
Organic Cation Transporter 2 
PEF 
Peak Expiratory Flow  
PI 
Principal Investigator 
PK 
Pharmacokinetic  
PODCI 
Paediatric Outcomes Data Collection Instrument  
PT 
Prothrombin time 
QT 
QT interval 
QTc 
Corrected QT interval 
QTcF 
QT interval, Fridericia’s correction  
RBC 
Red blood cell 
ROM 
Range of motion 
SAE 
Serious adverse event 
SAP 
Statistical Analysis Plan 
SD 
Standard deviation  
TEAE 
Treatment-emergent adverse event  
TFT 
Timed function test 
TNF-α 
Tumor necrosis factor-alpha 
TSA 
Trichostatin A 
ULN 
Upper Limit Normal 
US 
United States 
VL MFF 
Vastus lateralis muscle fat fraction 
WBC 
White blood cell 
 
 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 27 of 120 
4 
INTRODUCTION 
4.1 
Background on Duchenne Muscular Dystrophy  
Duchenne muscular dystrophy (DMD) is a rare degenerative, X-linked recessive genetic 
disorder with estimated incidence of 1 in 5000 live births (Mendell, J. R., et al.1), caused by 
mutations in the dystrophin gene.  In DMD, mutations in the dystrophin gene disrupt the 
open-reading frame, resulting in an absence of functional dystrophin, a critically important 
part of the protein complex that connects the cytoskeletal actin of a muscle fiber to the 
extracellular matrix.   
Lack of dystrophin causes repetitive muscle damage.  In a normal muscle, the physiological 
repair process removes the damaged muscle fibers and reconstitutes normal muscle fibers.  In 
DMD, on the other hand, the repair process leads to a combination of new muscle fibers, fatty 
replacement and fibrosis, with the two latter components progressively prevailing as a process 
called fibroadipose degeneration.  This detrimental outcome typically compromises muscle 
function, alters the tissue environment, and probably limits the potential effectiveness of 
regenerative approaches.  As described by Peverelli et al.2, fibrosis is already significant at 
one year of age in DMD patients constituting approximately 16% of a muscle biopsy (3% in 
age matched controls) and remains relatively constant until 7 years of age.  At this age, there 
is an important increase in the proportion of fibrosis that reaches approximately 30% of 
muscle biopsy between 7 and 10 years of age.  Similarly MRI studies have shown that fat 
infiltration is already present at 5 years of age and constantly increases (Forbes, et al.3). 
Duchenne muscular dystrophy is characterized by progressive symmetrical muscular 
weakness that affects proximal muscles more than distal muscles, often accompanied by calf 
muscle pseudo hypertrophy.   
Significant motor deficits may be present during the first year of life, but diagnosis is usually 
made between the ages of 3 to 5 years when the affected patients begin to show waddling gait, 
toe walking, and difficulty climbing stairs.  Over time, ambulation becomes increasingly 
abnormal, and by 8 years of age, most patients lose the ability to rise from the floor and climb 
stairs, and often fall while walking.  By 12 to 14 years of age, most lose the ability to walk 
and the heart and respiratory muscles also are affected.  Upper limb, cardiac, and 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 28 of 120 
diaphragmatic muscles progressively weaken during adolescence.  After 18 years all patients 
are affected by cardiomyopathy.  Only few survive beyond the third decade; most patients die 
because of respiratory complications and heart failure due to cardiomyopathy.  There are still 
no curative treatments for such a debilitating disease and the current management of the 
disease is based on prevention and management of complications (Bushby, et al.4). 
Corticosteroids (e.g., prednisone or deflazacort) have been demonstrated to slow the rate of 
muscle weakness when initiated in ambulatory boys,  however, the use of corticosteroids is 
limited by all the potential side effects, including weight gain, cataracts, osteopenia, and 
avascular necrosis (Manzur, A, et al.5).  Recently, the European Medicines Agency has 
granted a conditional approval to Ataluren, which targets nonsense mutations as the cause of 
DMD, which is relevant for only 13% of DMD population, or approximately 2,000 patients in 
the United States (US) and 2,500 patients in the European Union (EU).   
In addition, FDA has granted an accelerated approval to Eteplirsen and Golodirsen, which 
targets DMD gene mutations skippable with exon 51 skipping and exon 53 skipping, 
respectively, which are relevant for only 21% of DMD population, or approximately 3,200 
patients in the United States (US).   
Ataluren, Eteplirsen and Golodirsen are  the first of a number of treatments that are aimed at 
correcting the original genetic defect in the dystrophin gene.   
Genetic Duchenne therapy via AAV Micro-dystrophin  may be promising.  
In light of the above considerations, it becomes evident that an unmet therapeutic need exists 
for the treatment of this disabling and fatal condition. 
4.2 
Background on Givinostat 
Zinc dependent histone deacetylases (HDACs) are a class of 11 isoenzymes associated with 
numerous nuclear repressor complexes that, once recruited to specific sites of euchromatin, 
maintain nucleosome histones in a state of deacetylation so that deoxyribonucleic acid (DNA) 
remains tightly bound and inaccessible to transcription factors for gene expression.  In 
contrast, inhibition of HDAC results in hyperacetylation of these histones and allows the 
unraveling of DNA sufficient for the binding of transcription factors and the synthesis of 
messenger ribonucleic acid (mRNA). 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 29 of 120 
Some HDACs may shuttle between nucleus and cytosol in a stimulus-dependent way or may 
have a predominantly cytosolic localization, where they affect the post-translational 
modification of cytosolic proteins (Choudhary C et al. 20096). 
Givinostat is an orally active hydroxamic acid derivative possessing a potent HDAC (Class I 
and II) inhibitory activity.  As potent and specific inhibitor of the HDAC enzymes, givinostat 
shares the anti-tumor properties of the histone deacetylase inhibitor (HDACi)- class, i.e., 
cell-cycle inhibition, induction of apoptosis and stimulation of cell-differentiation. 
In the clinic, the HDACi doses required to achieve efficacy in cancer patients are generally 
poorly tolerated and dose-limiting toxicities include thrombocytopenia, gastrointestinal (GI) 
tract adverse events (AEs), and fatigue (Guha 20157).  While reactivation of epigenetically 
silenced tumor suppressors apparently requires high concentrations of HDACi, some gene 
promoters may be affected at much lower and better tolerated doses.  It has been suggested 
that regulators of cell fate decisions in stem or progenitor cells are under the control of 
promoters that are in a poised, “bivalent” state, characterized by the simultaneous presence of 
both chromatin activation and silencing marks, within the same regulatory region (Azuara, 
Perry et al. 20068; Bernstein, Mikkelsen et al. 20069).  Exposure to low doses of HDACi may, 
in these cases, tip the balance and redirect differentiation programs.  Dystrophin interacts with 
a group of peripheral membrane and transmembrane proteins through the C-terminal domain 
to form the dystrophin-associated protein complex (DAPC), which provides the molecular 
link between the cytoskeleton and the extracellular matrix of skeletal myofibers that is 
disrupted in dystrophic muscle (Ervasti 200710).  As such, DAPC supports sarcolemmal 
integrity during muscle contraction.  Neuronal nitric oxide synthase (nNOS) is an important 
component of the DAPC.  Nitric oxide (NO) produced by nNOS was shown to specifically 
inactivate HDAC2 via S-nitrosylation of a cysteine residue (Colussi, Mozzetta et al. 200811).  
This mechanism is dysfunctional in dystrophic muscle, leading to aberrantly upregulated 
HDAC activity.  There are at least two distinct mechanisms by which this upregulation 
impinges pathologically on cell fate decisions during muscle regeneration (Consalvi, Saccone 
et al. 201112):  
1. Resident muscle interstitial cells fibro-adipogenic progenitors (FAPs) retain the ability 
to turn into fibroadipocytes in response to signals released by degenerating muscles.  


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 30 of 120 
These cells affect differentiation of muscle satellite cells into muscle fibers through 
secretion of follistatin, the endogenous antagonist of the most potent inhibitor of 
skeletal myogenesis, myostatin.  Direct inhibition of myostatin or delivery of 
follistatin exerted similar beneficial effects in mdx mice, the mouse model of DMD.  
The follistatin gene promoter is controlled by HDAC2 in muscle cells (Minetti, 
Colussi et al. 200613) and direct inhibition of HDAC2 by HDACi, or inactivation by 
either NO donors or by reconstitution of the dystrophin-NO signaling leads to 
derepression of follistatin, which mediates the ability of HDACi and NO signaling to 
stimulate myogenesis in vitro and counters muscle degeneration in mdx mice. 
2. Histone deacetylase inhibitors may directly stimulate the myogenic differentiation of 
FAPs.  The HDAC inhibition induces two core components of the myogenic 
transcriptional machinery, MyoD and BAF60C, and up-regulates the myogenic miRs 
(myomiRs) (miR-1.2, miR-133, and miR-206), which target the alternative BAF60 
variants BAF60A and BAF60B, ultimately promoting promyogenic differentiation 
while suppressing the fibro-adipogenic phenotype (Saccone, Consalvi et al. 201414).  
Histone deacetylase inhibitors, therefore, seem to derepress a ‘‘latent’’ myogenic 
program in FAPs from dystrophic muscles, at least at early stages of disease. 
By inhibiting several pro-inflammatory cytokines (e.g., tumor necrosis factor-alpha [TNF-α], 
interleukin-1 beta [IL-1β], interferon gamma [IFN-γ], Interleukin-6 [IL-6], and Interleukin 12 
[IL-12]), givinostat also reduces the production and activity of pro-inflammatory cytokines 
(Leoni, F et al. 200515 and Joosten, L. A., F. Leoni, et al 201116).  Pro-inflammatory cytokines 
have been shown to inhibit muscle satellite cells differentiation into muscle fibers in DMD, 
thus contributing to the impaired muscle regeneration in this disease (Boldrin et al, 201517, 
Tierney et al. 201418, Doles, Olwin, 201419)  
Experimentally, the preclinical effectiveness of givinostat was demonstrated in mouse models 
with muscular dystrophy, such as the mdx mice.  Givinostat produced beneficial functional 
and morphological effects, such as increased cross-sectional area of myofibers, decreased 
inflammatory infiltrate, and prevention of fibrotic scars, which contribute to counter the 
muscle loss and the functional decline that are typically observed in mdx mice (see Section 
4.2.1). 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 31 of 120 
4.2.1 Nonclinical Studies  
A standard nonclinical program composed of safety pharmacology, pharmacokinetics, single 
and repeat dose toxicity, mutagenicity/genotoxicity, reprotoxicity and juvenile toxicity studies 
has already been carried out to support the oral administration of givinostat to adult and 
paediatric subjects.  Details of each study are available in the current Investigator’s 
Brochure (IB). 
In summary, in rats the predominant toxicities at the highest doses were hematologic, with 
larger decreases in white blood cells (WBC) (-84% males, -78% females) and smaller effects 
on red blood cells (RBC) (-10% males, -5% females) and platelets (-16% males, -11% 
females).  It has to be pointed out, that this toxicity pattern is different from what is observed 
clinically in humans, where thrombocytopenia and not leukopenia is dose-limiting, suggesting 
a different sensitivity of the hematopoietic lineage in rats versus humans. 
Non-hematologic toxicity in rats included changes in blood chemistry: decrease in total 
proteins, alkaline phosphatase (ALP), alanine aminotransferase (ALT) and increase in 
aspartate aminotransferase (AST), bilirubin, urea, creatinine and triglycerides.  All of these 
changes were modest (equal to or less than 50%), their extent overlapped with control animals 
and they were not considered of toxicological significance.  Lower weight of liver, spleen and 
adrenals was also observed.  In all cases the underlying histopathological changes were 
minimal.  All pathologic effects trended toward reversibility or completely reversed following 
the recovery period.   
In contrast to rats, in the 39-week study in monkeys, hematologic toxicities were of minor 
significance, with a minimal decrease in RBC counts seen during and at the end of the 
treatment period at the high dose only.  A dose-related decrease in weight of the thymus was 
observed in both sexes at all doses.  Histologically, an increased incidence of minimal 
involution/atrophy was observed in high-dose animals.  In animals at recovery, the decrease 
of thymus weight was minimal, whilst no histological changes were noted.  The dose of 
12 mg/kg/day was therefore defined as the No-Adverse Effect Level (NOAEL) under the 
conditions used in the present study, even if the compound was well tolerated also at the 
highest dose of 30 mg/kg/day.  Similar effects on thymus weight were reported also for other 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 32 of 120 
HDACi and are likely reflective of the known and well-characterized cytostatic mechanism of 
action of high doses of these compounds (Kerr, Galloway et al. 201020).   
Additional findings of possible toxicological relevance included minimal effects on hepatic 
enzymes (ALT, AST), triglycerides, and bilirubin.  Some of these effects were observed at 
intermediate examination (Week 20) and partially recovered at the end of the treatment 
period.  Treatment-related effects were observed at the high dose also in the bone marrow and 
liver.  The bone marrow showed slightly reduced cellularity in two animals given 
30 mg/kg/day.  Also this effect can be ascribed to the well-characterized cytostatic 
mechanism of action of high doses of the HDACi (Kerr, Galloway et al. 201020). The liver 
showed minimal bile duct hyperplasia in two male animals out of four, receiving 
30mg/kg/day, whilst males from the others dose-groups and females at all doses were 
unaffected.  After recovery, a similar finding was still noted in a single animal. 
Givinostat is eliminated for approximately 50% in faeces after IV administration of 
14C-ITF2357 to rats, highlighting the quantitative importance of the biliary excretion route.  
In addition, a more intensive biotransformation occurs in animal species with respect to 
humans as shown in in vitro metabolic stability tests with hepatocytes of different species 
(Intrinsic Clearance (µL/min*106 cells: humans=4.0; monkey=25.4; dog=32.4; rat=33.8; 
mouse=42.0). 
Thus, the bile duct hyperplasia is likely to be the result of a pronounced metabolism and 
excretion of givinostat in the preclinical species, which is also associated with increased 
plasma bilirubin levels.  Therefore, this finding can be easily monitored in humans.  Of note, 
no increase of hepatic enzyme or bilirubin was recorded in approximately 450 subjects treated 
so far; bilirubin levels are also monitored clinically in DMD subjects with, so far, no evidence 
for significant alterations, providing no confirmation for the occurrence of analogous 
toxicities in humans. 
The maximum observed concentration (Cmax) and area under the curve (AUC) safety margins 
were calculated using the NOAEL of 10 mg/kg/day obtained in rats after 6 months of 
administration, the NOAEL of 12 mg/kg/day obtained after exposing monkeys for 39 
consecutive weeks, and the actual human data obtained in the clinical study in DMD subjects 
(Study DSC/11/2357/43) after 12 month the administration of 37.5 mg twice daily (bid) (i.e., 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 33 of 120 
Cmax approximately 104 ng/mL and AUC approximately 1144 ng*h/mL).  The human 
exposure achieved at this dose level is the exposure to be used in this study 
(DSC/14/2357/48).  Only data from male animals were considered since DMD occurs in male 
subjects. 
Safety ratios calculated using data from both the animal species used in toxicology studies 
differed quite markedly one from the other.  The rat to human exposure margins (Table 1) 
were 0.16 (Cmax) and 0.04 (AUC) at the human exposure considered (i.e., Cmax approximately 
100 ng/mL and AUC approximately 1150 ng*h/mL), while the exposure margins Cmax and 
AUC were larger for monkeys than those seen in rats.  The Cmax ratio was about 2.4 fold and 
the mean AUC ratio was 0.34.  A more intensive biotransformation is observed in rats and 
monkeys as evidenced by the larger intrinsic clearance and the shorter half-life of givinostat 
in rats and monkeys compared to humans.  
Table 1: 
Exposure margins for Cmax and AUC:  rat vs. DMD subjects and monkey vs. DMD 
subjects 
Ratios NOAEL rats/paediatric DMD exposure 
Ratios NOAEL monkey/paediatric DMD exposure 
 
Cmax 
AUC0-t 
 
Cmax 
AUC0-t 
Week 26 
0.16 
0.04 
Week 39 
2.40 
0.34 
NOAEL= no-observed-adverse-effect-level; DMD = Duchenne muscular dystrophy; Cmax= maximum observed 
concentration; AUC0-4 = area under the curve (over the first 4 hours) 
Even though the safety margin between NOAEL in non-clinical studies/paediatric DMD 
exposure, are <1 (except for Cmax monkey), the main findings observed in non-clinical 
toxicology studies (e.g., reduction in white blood cells, cellularity reduction in bone marrow, 
reduced thymus weight, and bile duct hyperplasia) were observed at high doses of givinostat 
(e.g., rats, 90-160-250 mg/kg/day depending on the treatment duration; dogs, 50 mg/kg/day; 
and monkeys, 30-90 mg/kg/day); all of them, as described above, can and will be carefully 
monitored during this clinical study. 
A post-weaning study in young rats treated with givinostat 20 to 180 mg/kg/day for 4 weeks 
was also performed and showed a toxicological profile similar to that seen in adult animals.  
Givinostat did not affect the behavioral and physical development and reproductive 
performance of pups.  The NOAEL in this study was 60 mg/kg/day. 
Concerning the safety pharmacology, givinostat has a favorable profile.  The IC50 of 
givinostat in the in vitro hERG assay was 1.4 µM.  At 3 and 10 µM, givinostat increased the 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 34 of 120 
action potential duration at 50% and 90% repolarization during bradycardia, although not in a 
statistically significant manner.  Givinostat did not induce any marked changes in heart rate, 
electrocardiogram (ECG) intervals, or waveform at any dose in in vivo, in a cardiovascular 
study in dogs.  The combined evidence from these in vitro and in vivo studies plus the lack of 
accumulation of drug in the heart as seen in tissue distribution studies, suggest that the drug is 
unlikely to exert any cardiovascular side effect at therapeutic doses.  The maximal circulating 
concentrations seen in subjects both adults and paediatric subjects receiving the highest doses 
of givinostat were generally below 100-150 ng/mL (200-300 nM) of total givinostat, 
corresponding to 5-7.5 ng/mL (10-15 nM) of free givinostat, approximately 90-140 fold less 
than the IC50 on hERG. 
Finally, givinostat was positive for frameshift mutations in the bacterial mutagenesis assay (2 
out of 5 strains), but givinostat did not display any genotoxicity/mutagenic potential in 
mammalians in both in vitro and in vivo studies.  
Nonclinical evidence supports a potential therapeutic role of givinostat in DMD.   
A dose-finding study using doses of givinostat ranging from 1 to 10 mg/kg/day orally 
delivered daily for 3 months to mdx (i.e., murine model of DMD) mice (2 month old at the 
beginning of the treatment) was performed (Consalvi, et. Al 201212).  The effect of these 
doses was compared to that of vehicle alone (oral delivered) or the HDACi TSA (0.6 mg/kg, 
i.p.) and assessed by monitoring total body weight during the time of exposure, the weight of 
single muscles at the end of the treatment, and by measuring muscle function (with treadmill 
test at specific time points during the treatment) CSA at the end of the treatment.  The results 
showed an increase of the weight of a single muscle analysed, a dose-dependent reduction of 
intramuscular fibrosis and inflammatory infiltrate (by myeloperoxidase activity) and a dose-
related increase of muscle mass and fibers CSA.  All these histological effects translated into 
an improvement in function as assessed by monitoring the performance of mdx mice on a 
treadmill test at defined time points during the treatment.  To further elucidate the relationship 
between givinostat exposure and effects on muscle tissue and on performance, a 
pharmacokinetic/pharmacodynamic (PK/PD) analysis was conducted.  The PK/PD analysis 
showed that at least a blood AUC0-24 of 600 nmol*h/L (i.e., corresponding to 300 ng*h/mL) 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 35 of 120 
was estimated to be needed to exert the beneficial histological and functional effects 
in mouse. 
4.2.2 Clinical Experience with Givinostat Including Risks and Benefits 
Completed and updated data that describe the clinical experience with givinostat are reported 
in Section 6 “Effects in Humans” of the current Investigator Brochure Dossier related 
to ITF2357. 
Givinostat has been tested in a number of clinical studies in adults and paediatric populations.  
Three major indications have been explored with Givinostat, chronic inflammatory diseases, 
neuromuscular disorder and oncology.  The maximum administered dose was a single dose of 
600 mg in healthy volunteers and up to 400 mg once per week in subjects with multiple 
myeloma.  Doses up to approximately 100 mg bid were generally well tolerated in adults.  In 
paediatric subjects, doses up to 0.75 mg/kg bid have been administered for up to 6 months 
(with 1 additional subject having been treated for 2 years and 7 months) in patients with 
Juvenile Idiopathic Arthritis.  In subjects with DMD enrolled in study DSC/11/2357/43 (i.e., 
subjects between 7 and 10 years of age at study start), the maximum dose administered in the 
dose escalation phase was 50 mg bid for up to 2 weeks i.e., while the maximum dose 
administered for up to 1 year in the second part of the study was 37.5 mg bid.  Since, 
clearance increases with increased weight (see Section 8.2.1) doses have been increased in the 
extension phase of study DSC/11/2357/43 due to the increase in weight of the enrolled 
children; as a result the maximum dose administered in this extension phase is  60 mg bid.  
The most common AEs observed were thrombocytopenia, as well as gastrointestinal 
toxicities.  Adverse events were generally mild to moderate and reversible upon 
discontinuation of study drug.  Moreover, dose-dependent asymptomatic and reversible 
platelets count reductions were observed both in healthy volunteers and subjects treated with 
givinostat.  These decreases typically occurred within the first week after treatment initiation, 
reached a nadir after 2 to 3 weeks of treatment, and then remained at a plateau (see the IB, 
Section 7).  The majority of thrombocytopenic events were mild in severity with fewer than 
10% of subjects developing platelets count below 75 x 109/L.  All occurrences resolved 
completely within 2 to 3 weeks of discontinuation of treatment, suggesting a rapidly 
reversible effect. Overall, sixteen haemorrhagic drug-related AEs were reported by 14 patients 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 36 of 120 
in the completed clinical trials with Givinostat. However, only in seven of these cases the 
haemorrhagic drug-related AE occurred in patients with concomitant thrombocytopenia; these 
were all oncology patients and in some of these patients thrombocytopenia up to grade 4 was 
already present before givinostat treatment start. In all the remaining cases (nine 
haemorrhagic drug-related AEs occurred in seven subjects) platelet counts at the time of the 
haemorrhagic AE were either within the normal range or above the upper limit of normal 
range. None of the above summarized drug-related hemorrhagic episodes were observed in 
DMD subjects.  
Therefore, given these known effects of HDAC inhibitors including Givinostat a thorough 
monitoring of haematologic parameters will be implemented in order to avoid the occurrence 
of severe thrombocytopenia (see Section 12.8). 
In addition, during the study particular attention will be paid in monitoring possible effects on 
QTc (see Table 6:    Schedule of Assessments for details), since some episodes (21 episodes in 
15 subjects) of Corrected QT interval (QTc) prolongation have been recorded during the 
clinical studies performed so far.  It is worth noting that 90% of the recorded events were 
reported in oncological studies in subjects treated at highest doses (e.g., ≥100 mg/daily) and 
no events were recorded during the previous study in DMD subjects. 
Concerning the clinical experience in DMD, the aforementioned histological results observed 
in the mdx mouse model were replicated in a Phase 2 study of givinostat (Study 
DSC/11/2357/43, EudraCT n. 2012-002566-12) in 20 ambulant DMD subjects (from 7 to 
10 years of age at study start, on stable steroid treatment) where, after one year of treatment, 
the muscle biopsy analysis showed a significant increase in muscle fibers area fraction 
(MFAF) and a significant reduction of muscle necrosis, fatty replacement and fibrosis.  
Analysis of the effect on CSA of the muscle fibers showed that givinostat significantly 
increases CSA of all type of fibers (small, medium, large) in a similar manner and that such 
effect on CSA predicts the increase in MFAF and the reduction of fibrosis.  In addition, an 
increase in the number of regenerating fibers and satellite cells was observed.  Moreover, 
descriptive analysis conducted on the secondary efficacy endpoints on muscle function (i.e., 
six-minute walking test [6MWT], North Star Ambulatory Assessment [NSAA], time function 
tests and pulmonary function tests) showed an overall stability after 1 year of treatment in this 
population. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 37 of 120 
The risk/benefit ratio of the proposed study is postulated to be favorable for both the results of 
the clinical safety and pre-clinical toxicology studies and for the efficacy results in the 
previous Phase 2 DMD study. 
4.2.3 Rationale of the study 
Nonclinical studies have shown that givinostat has a potent anti-inflammatory effect (see 
(current IB) and that HDACi regulate the transcription of a number of factors that are key in 
muscle regeneration, e.g., follistatin.  The combination of these effects is expected to re-
balance the repair process in DMD muscle towards increased muscle regeneration and 
reduced fatty infiltration and fibrosis.  Indeed, in a study in mdx mice and in a phase 2 study 
in DMD children, givinostat was shown to reduce muscle inflammation, necrosis and fibrosis 
and to increase muscle regeneration. 
These results indicate that the induction of an active regeneration program, the reduction of 
adipose replacement and the enlargement of pre-existing muscle fibers are all key elements of 
givinostat’s putative mechanism of action (MoA), supporting the potential therapeutic role of 
givinostat in counteracting muscle tissue degeneration, which occurs downstream of the 
genetic defect in DMD. 
On the basis of its putative MoA as described above, givinostat is expected to act at all stages 
of the disease and to counter the disease pathogenetic events in all muscular districts.  
However, as the fibers CSA enlarging effect appears key in givinostat’s pharmacological 
effect, the functional benefit obtained will likely depend on the amount of muscle that is still 
present when therapy is started.   
In Study DSC/11/2357/43, in ambulant DMD subjects ≥7 years of age on steroid for more 
than 6 months, only 50% of the muscle biopsy was occupied by muscle fibers at baseline with 
the remainder being represented mainly by fibrotic tissue.  Although after one year of 
treatment with givinostat, the histological results showed a significant increase in muscle 
fibers CSA and a significant improvement in all the histological parameters analyzed, the fact 
that already 50% of muscle was lost in these children suggests that givinostat should be 
started at an earlier age if the objective is to achieve a clinical benefit in terms of ambulation 
within a reasonable timeframe.  Several studies, however, have shown that ambulatory 
function naturally improves in children with DMD up to the age of 7 years (Goemans, 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 38 of 120 
Klingels et al. 201322; McDonald, Henricson et al. 201323) suggesting that studies in DMD 
children <7 years of age may require larger numbers and a longer treatment duration to show 
a significant difference from placebo.  As a result all the pivotal studies in DMD ambulant 
children reported so far (e.g., Ataluren, Drisapersen, Tadalafil phase III trial ) have selected 
children who were expected to have a sufficient decline in ambulatory function after 1 year on 
placebo based on age and 6 Minute Walk Test at baseline.  However, all these studies were 
not able to show a functional benefit of the tested drug versus placebo.   
Although a lack of efficacy cannot be ruled out, the poor therapeutic response observed in 
these studies could be the result of selecting a patient population characterized by a degree of 
functional impairment that may be less likely to benefit from treatment. This is also suggested 
by the fact that while ambulatory function improves up to the age of 7 years and then 
declines, the underlying muscle morphology constantly declines from the age of 5 years 
(Forbes, et al.3). A post-hoc analysis on study DSC/11/2357/43 suggests that children with a 
more preserved Vastus Lateralis (VL) muscle at baseline MRI (score 0 to 2 on a 0 to 5 semi-
quantitative MRI score, modified Mercuri’s score24) have a lesser degree of functional decline 
2 years after start of givinostat treatment.  This is in line with data from the Imaging DMD 
group suggesting that changes from baselite at 1 year in VL Fat Fraction (FF) assessed by 
magnetic resonance spectroscopy (MRS) are correlated with Timed Function Tests  (TFTs) 
and 6MWT (Data on file).   These analyses, however, have also shown that children with a 
baseline MVL MFF <10% show very little change in any parameter (MRI/MRS or function) 
within 1 year. A more recent (i.e. July 2018) and detailed analysis of Imaging DMD data 
showed that patients with a baseline MRS VL FF up to 5% have little change in clinically 
relevant functional parameters such as 4 stairs climb after 1 and 2 years. Based on these data, 
the current protocol will select a population of subjects with a VL MFF >5% but ≤30% 
(corresponding approximately to a score >2 in the aforementioned 0 to 5 semi-quantitative 
MRI score Mercuri, et al. 200224) as this population is expected to still have enough muscle to 
build on and to have enough function decline in 18 months if on placebo.  Since the analyses 
of the Imaging DMD data (Data on file) also suggested that TFTs predict VL MFF, an 
algorhythm has been developed to identify at screening those children with a VL MFF within 
the required range.  However, the screening data colleted up to 18th June 2018 showed that the 
accuracy of the algorithm was less predictive since it did not allow the selection of a 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 39 of 120 
population with the predefined range of VL FF that identified a population most likely to 
benefit from treatment. As a result, the algorhythm is removed and the selection of eligible 
subjects will be based on age and the functional tests at screening (see below). The 
assessment of VL FF at screening (range >5% to ≤30%), on the other end, will be used to 
identify the target population on which to perform the primary and key secondary analyses. 
The inclusion of an additional off-target population (up to 50 subjects) outside of the VL FF 
range of  >5% to ≤30% will provide supportive data. Considering the recent recommendations 
outlined in the EMA “Guideline on the clinical investigation of medicinal products for the 
treatment of Duchenne and Becker muscular dystrophy” (December 2015) and in the Federal 
Drug Administration (FDA) draft guidance for industry “Duchenne Muscular Dystrophy and 
related dystrophinopathies: developing drugs for treatment” (June 2015), the time to climb 4 
standard-sized stairs has been chosen to evaluate the efficacy of givinostat in slow down 
disease progression.  Timed function tests, such as time to climb 4-stairs (4SC), to walk 10 m, 
and to stand up, are reliable and feasible in the majority of the DMD population from age 4 
and older (McDonald, C. M., et al. 201325) and have a documented response to therapeutic 
intervention with steroids (Manzur AY, K. T., 200926).  In particular, time to climb 4 
standard-sized stairs is a TFT that represents stair climbing ability, a clinically meaningful 
function in and of itself.  It has been used as an endpoint in DMD studies for decades and the 
test is reproducible and simple to administer.  It is predictive of loss of stair climbing ability, 
loss of ambulation and time to 10% decline in ambulatory capacity (Bushby, K. 201127).  
Furthermore, climbing stairs requires a greater range of motion (ROM) from the joints of the 
lower limb and greater muscle strength than 6MWT, which is a functional test more related to 
endurance.  Therefore, in light of givinostat MoA (e.g., increase fibers CSA) the time to 4SC 
test is expected to be more appropriate to evaluate the efficacy of givinostat in DMD subjects. 
The key secondary endpoints (cumulative loss of function in the NSAA, change inTime to 
Rise from Floor, in NSAA, in 6MWT and in strength) include those parameters which are 
considered relevant in this population to corroborate the results obtained on the primary 
endpoint.  
Changes in MRS parameters will be also key endpoints.  Previous studies have shown that 
MRI can visualize structural alterations of muscle in muscular dystrophies (Willcocks, 201428, 
201629, Wren 200830, Bonati 201531) and have shown that fat fraction measured by MRI or 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 40 of 120 
magnetic resonance spectroscopy (MRS) highly correlates with lower limb function.  
Although longitudinal data on MRI/MRS particularly from randomised clinical trials are still 
limited, a number of randomized clinical trials currently ongoing include magnetic resonance 
evaluations and both the FDA and EMA guidelines identify MRI/MRS as a potential 
biomarker. 
Finally safety and tolerability and pharmacokinetics will be also assessed in the study for a 
proper risk-benefit evaluation of givinostat. 
5 
STUDY OBJECTIVES AND ENDPOINTS 
5.1 
Study Objectives 
5.1.1 Primary Objective 
To establish the effects of givinostat versus placebo administered chronically over 18 months 
to slow disease progression in ambulant DMD subjects. 
5.1.2 Secondary Objectives 
The secondary objectives of this study are: 
 To assess the safety and tolerability of givinostat versus placebo administered 
chronically in DMD subjects.  
 To evaluate the PK profile of givinostat administered chronically in DMD subjects  
 To evaluate the impact on quality of life and activities of daily living of givinostat 
versus placebo administered chronically. 
5.1.3 Secondary Exploratory Objectives 
 To evaluate the correlation between PK profile of givinostat  and pharmacodynamics 
(PD) data; 
 To explore whether the effects of givinostat versus placebo administered chronically 
may be related to the type of DMD mutation (Pane M et al. 201432) or to the 
biomarkers. 
5.2 
Study Endpoints 
5.2.1 Primary Endpoint  
The primary endpoint of this study is the mean change in 4SC before and after 18 months of 
treatment of givinostat versus placebo. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 41 of 120 
5.2.2 Key Secondary Endpoints 
The key secondary efficacy endpoints for this study are as follows: 
Function : 
 Mean change in time to rise from floor  
 Mean change in 6MWT  
 
Mean change in NSAA  
 Cumulative loss of function on the NSAA 
 Mean change of muscle strength evaluated by knee extension, elbow flexion  as 
measured by hand-held myometry (HHM)  
Imaging: 
 Mean change in vastus lateralis muscles fat fraction   
The above endpoints will be formally assessed after 18 months of treatment. 
 
5.2.3 Safety Endpoints 
The safety endpoints of this study are as follows: 
 Number of subjects experiencing treatment-emergent adverse events (TEAEs) and 
serious adverse events (SAEs) (Baseline through end of study [EOS]); 
 Type, incidence, and severity of TEAEs and SAEs (Baseline through EOS); 
 Changes from baseline to end of study of: 
o Vital signs and clinical laboratory tests (blood chemistry and hematology); 
o Respiratory function evaluated by forced vital capacity (FVC), forced expiratory 
volume at 1 second (FEV1), FVC/FEV1, peak expiratory flow (PEF); 
o Cardiac function evaluated by ECG and echocardiogram (ECHO); 
o Cognitive function evaluated by the Raven coloured progressive matrices; 
o Weight, height, and body mass index (BMI); 
 Evaluation of acceptability/palatability of the oral suspension. 
5.2.4 Pharmacokinetic Endpoints 
The PK endpoints of this study are as follows: 
 Description of the PK of givinostat and its major metabolites: ITF2374 and ITF2375 
in the subject population; 
 Identification of the relevant demographic and pathophysiological covariates 
influencing the PK of givinostat; 
5.2.5 Exploratory Endpoints 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 42 of 120 
The exploratory endpoints of this study are as follows: 
 Mean changes  in:  
o time to walk/run 10 meters; 
o PODCI scores. 
o %-predicted 6MWT (the predicted value is against healthy subjects and is 
calculated using the equation of Geiger [Henricson, et.al.33]); 
o Only in the MR cohort:  MRI parameters (e.g., fat fraction of  thigh muscles, 
CSA of vastus lateralis and other thigh muscles);  
 Time to 10% persistent worsening in 6MWT (Baseline through end of study); 
 Proportion of subjects with ≥10% worsening in 6MWT at end of study; 
 Time to loss of standing (Baseline through end of study); 
 Proportion of subjects who loose ambulation during the study; 
 Evaluation of any correlation between the effect of Givinostat on disease progression 
and the type of DMD mutation, LTBP4 and Osteopontin genotype; 
 Evaluation of any possible DMD serum biomarker; 
 PK-PD analyses: relationships between metrics of exposure and efficacy/safety 
endpoints of givinostat.  
6 
INVESTIGATIONAL PLAN 
6.1 
Description of Overall Study Design and Plan 
This is a Phase 3, randomised, double blind, placebo controlled, multicentre study to evaluate 
the efficacy and safety of givinostat in ambulant subjects with DMD.  This study will include 
ambulant male paediatric subjects aged ≥6 years at baseline affected by DMD.  
A total of  110 subjects in the target population (Group A: subjects with a baseline vastus 
lateralis muscle fat fraction (VL MFF) assessed by MRS  in the range >5% and ≤30%) will be 
randomised.  Up to 50 subjects (about 35% of the overall population) outside of the target 
may also be recruited into the study (Group B: subjects with a baseline vastus lateralis muscle 
fat fraction (VL MFF) assessed by MRS  in the range ≤5% or >30%). Subjects who assent to 
participate in this study (if capable of doing so) and whose parent/legal guardian sign the 
Informed Consent Form (ICF) to participate will undergo pre-study screening assessments up 
to 4 weeks before the first scheduled dose of study drug.  


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 43 of 120 
At the randomisation visit, in addition to the continued standard of care corticosteroids 
regimen, DMD subjects will be randomised (2:1 ratio) to receive givinostat oral suspension 
10 mg/mL or placebo oral suspension bid (in a fed state) as described in Section 8.3. 
At randomisation, subjects will be stratified for their concomitant use of steroids in 4 strata: 
1. Deflazacort Daily regimen 
2. Deflazacort Intermittent regimen 
3. Other steroids Daily regimen 
4. Other steroids Intermittent regimen 
 The study duration is planned for 19 months and comprises 2 phases: 
1. 
Screening period: starting 4 weeks (± 2 weeks) before randomisation 
2. 
Treatment period: 18 months of treatment 
An overview of the study is provided in  
Figure 6-1. 
 
 
Figure 6-1: 
Study Design 
There will be a total of 15 visits, including the Screening and the Randomisation Visits and 
excluding the Follow up Visit.  Subjects may be evaluated more often if necessary for safety 
reasons.  Subjects who discontinue the study drug early will be asked to come in for an  Early 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Double-blind Treatment 
Period  
Randomisation 
Screening
-
 
Period
 
Screening
 
Period
  
1 month  
  
Placebo 
18 months
  
Givinostat
 
 
  
 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 44 of 120 
Withdrawal Visit within 2 weeks after the last dose of study drug.  Subjects who have 
ongoing AEs at discontinuation will be followed until resolution or stabilization.  
In order to guarantee the continuation of treatment with givinostat, the Sponsor has planned a 
long-term study which will start when the first subject enrolled in this study has attended his 
last visit.  As a consequence, at the end of the treatment, parent/ legal guardian will be asked 
to consent and subject will be asked to assent/consent to his participation to the long-term 
study.  In case the subject will not assent/consent and/or the parent/ legal guardian will not 
consent it, a final follow up visit will be performed 4 weeks after last dose administration. 
6.2 
Discussion of Study Design 
This study is designed as a conventional parallel group design.  Since the study will be 
conducted in a paediatric population with a serious and life-threatening disease, the unequal 
randomisation ratio (i.e., 2:1 to givinostat and placebo) will be applied to reduce the exposure 
to placebo to only one third of subjects.    A 2:1 randomisation also provides for an increased 
number of subjects who are exposed to givinostat. 
The sample size was originally calculated to provide 90% power and a 1-sided alpha of 2.5% 
to detect a true difference between givinostat and placebo in the target population in the 4SC 
18 month change from baseline of 3 seconds, assuming a common standard deviation (SD) of 
6 seconds (being based on publicly available phase 3 study data on ataluren and drisapersen in 
DMD subjects in addition to internal Italfarmaco S.p.A data.), giving rise to an estimated 
sample size of N=192 subjects.  However, the planned  interim analysis took place in January 
2020 based upon the first 50 randomised patients reaching 12 months of treatment.  This 
interim provided a revised, blinded within treatment SD estimate of 3.094 seconds, 
approximately half of that assumed in the original power calculation. Based on this revised 
SD estimate, the revised sample size is N=102 which provides 90% power for a 2 second 
difference between givinostat and placebo for the change in 4SC at 18 months.    
In a recent analyses performed by C-Tap (Wong B, et al. Action Duchenne International 
Conference, November 9–11, 2018, Birmingham, UK), the minimally clinically important 
difference (MCID) for timed function tests (TFTs) in DMD was estimated at ~1.0 to 
1.6 seconds. These results were confirmed by additional analyses performed on the CINRG 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 45 of 120 
natural history database (Data on File), which showed that a change of 1 to 1.5 seconds in 
TFTs has clinical meaningfulness based on health-related QoL and participation measures in 
DMD and that a 1.6 to 1.7 second change over 12-months in TFTs translates to a 3-year 
prolongation of ambulation in DMD. Together, these new data suggest that 2 seconds is an 
appropriate conservative estimate of a clinically meaningful effect size for TFTs in DMD, 
which is less than the 3 seconds originally hypothesized in the study protocol(MCID; 
McDonald CM et al. 201322); however, with the blinded SD estimate made at the planned 
interim, the revised total number of subjects, N=102 has 90% power to detect this smaller, yet 
clinically relevant treatment effect.   The treatment duration of 18 months has been chosen 
because DMD children with more preserved muscle mass will be enrolled in this study,  and 
despite the underlying progression of muscle tissue deterioration, a decline of function is 
expected to be slower in the selected patient population compared to DMD subjects in 
“decline phase” (e.g., DMD subjects >7 years with 6MWT < 350 meter, McDonald, 
Henricson et al. 201323);  thus, a longer observation period is needed to demonstrate 
functional benefits compared givinostat to placebo controls. 
At randomisation, the population will be stratified according to steroid type and regimens 
(i.e., daily regimen or intermittent regimen) because some evidence suggests Deflazacort use 
was associated with later loss of ambulation and increased frequency of side effects (Bello et 
al. 201536) and daily administration of steroids to be more eﬀective than treatment on alternate 
days (Bushby, Finkel et al. 201034; Ricotti, Baranello et al. 201335).   Thus, to help to ensure 
balance between the randomised treatment arms stratification by steroid type and regimens 
will be implemented.  
Daily regimen means every daily intake of steroids, while intermittent regimens comprise 
steroids used every other day, high dose weekend and 10 days on alternate to 10 or 20 days 
off.  Different schedule can be discussed with the Medical Monitor before the subject 
randomisation, however the decision remains with the Investigator only or its authorized 
designee. 
An Independent Data Monitoring Committee (IDMC) will review, evaluate, and categorise 
safety findings every three months during the study and will be responsible for oversight of 
the interim analysis (see below) at which futility will be assessed and a blinded sample size 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 46 of 120 
reestimation will be made.  The IDMC will have access to unblinded data, if necessary, and 
will operate according to the rules defined in the IDMC charter. 
A single interim analysis has been planned in this study which will be overseen by the IDMC 
in order to ensure the study integrity: 
 The first interim analysis will be performed when the first N=50 subjects randomised 
in the target population have reached the 12 month time point and the effects of 
givinostat versus placebo on the mean vastus lateralis muscles fat fraction (VL MFF) 
assessed by MRS will be evaluated.  The purpose of this interim is to assess futility. 
There will be no formal assessment of efficacy and no unblinded evaluation of the 
primary endpoint, even by the IDMC.    
Based on prior data, a 5% annual mean increase in VL MFF in the placebo group is 
expected and a corresponding 3.5% annual mean increase in the givinostat group is 
desired.  Futility will be considered if the mean change in VL MFF in the givinostat 
group is equal to or worse than that seen in the placebo group since the biologic 
plausibility of a subsequent treatment effect on 4SC time would be greatly diminished.  
The IDMC will only communicate to the Sponsor, whether the study should proceed 
or be stopped, based on whether the study has met the futility criteria.  If the IDMC 
indicates that the study should proceed, a blinded sample size re-estimation will also 
be conducted for VL MFF and 4SC in the target population.   
More details about the interim analysis are described in Section 13.10. 
7 
SELECTION AND WITHDRAWAL OF SUBJECTS 
The study will enroll male subjects with an established molecular diagnosis of DMD who are 
at least 6 years of age at randomisation. 
Specific entry criteria are detailed in Section 7.1 and in Section 7.2. 
Subjects dropping out before the end of treatment will not be replaced.  
7.1 
Inclusion Criteria 
Subjects must meet all of the following criteria in order to be included in the study: 
1. Are an ambulant male aged ≥6 years at randomisation with DMD characteristic 
clinical symptoms or signs (e.g., proximal muscle weakness, Gowers’ maneuver, 
elevated serum creatinine kinase level) already present at screening; 
2. Have DMD diagnosis confirmed by genetic testing;  
3. Are able to give informed assent and/or consent in writing signed by the subject and/or 
parent/legal guardian (according to local regulations); 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 47 of 120 
4. Are able to complete 2 Four Stairs Climb test (4SC) screening assessments; the results 
of these tests must be within ±1 second  of each other;  
5. Have the mean of 2 screening 4SC assessments ≤8 seconds;  
6. Have time to rise from floor between ≥3 and  <10 seconds at screening; 
7. Have manual muscle testing (MMT) of quadriceps at screening ≥ Grade - 3; 
8. Have used systemic corticosteroids for a minimum of 6 months immediately prior to 
the start of study treatment, with no significant change in corticosteroids type or 
dosage or dosing regimen (excluding changes related to body weight change) for a 
minimum of 6 months immediately prior to start of study treatment and a reasonable 
expectation that dosage and dosing regimen will not change significantly for the 
duration of the study. 
9. Subjects must be willing to use adequate contraception.  
Contraceptive methods must be used from Randomization Visit 3 through 3 months 
after the last dose of study drug, and include the following: 
o True abstinence (absence of any sexual intercourse), when in line with the 
preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, 
ovulation, symptothermal, postovulation methods) and withdrawal are not 
acceptable methods of contraception. 
o Condom with spermicide and the female partner must use an acceptable 
method of contraception, such as an oral, transdermal, injectable or implanted 
steroid-based contraceptive, or a diaphragm or a barrier method of 
contraception in conjunction with spermicidal jelly such as for example 
cervical cap with spermicide jelly. 
7.2 
Exclusion Criteria 
Subjects meeting any of the following criteria are ineligible to participate in this study: 
1. Have exposure to another investigational drug within 3 months prior to the start of 
study treatment  (only exception allowed is use of Deflazacort in US as part of the 
Expanded Access Program and in Canada as part of the Special Access Program;  
2. Have exposure to idebenone within 3 months prior to the start of study treatment;  
3. Have exposure to any dystrophin restoration product (e.g., Ataluren, Exon-skipping) 
within 6 months prior to the start of study treatment; 
4. Use of any pharmacologic treatment, other than corticosteroids, that might have had an 
effect on muscle strength or function within 3 months prior to the start of study 
treatment (e.g., growth hormone); Vitamin D, calcium, and any other supplements will 
be allowed as long as their intake has been stable for 3 months prior to the start of 
study treatment; Testosterone will also be allowed if it is used as a replacement 
therapy for the treatment of delayed puberty, and testosterone dose and regimen have 
been stable for at least 6 months and circulating testosterone levels are within the 
normal ranges for the subject’s age; 
5. Have surgery that might have an effect on muscle strength or function within 3 months 
before study entry or planned surgery at any time during the study; 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 48 of 120 
6. Loss of ≥30 degrees of plantar flexion from the normal range of movement at the 
ankle joint due to contracture (i.e. fixed loss of more than 10 degrees of plantar flexion 
from plantigrade, assuming normal range of dorsiflexion of 20 degrees); 
7. Change in contracture treatment such as serial casting, contracture control devices, 
night splints, stretching exercises (passive, active, self) within 3 months prior to 
enrollment, or expected need for such intervention during the study; 
8. Have presence of other clinically significant disease, which, in the Investigator’s 
opinion, could adversely affect the safety of the subject, making it unlikely that the 
course of treatment or follow-up would be completed, or could impair the assessment 
of study results; 
9. Have a diagnosis of other uncontrolled neurological diseases or presence of relevant 
uncontrolled somatic disorders that are not related to DMD; 
10. Have platelets count, White Blood Cell and Hemoglobin at screening < Lower Limit 
of Normal (LLN) (for abnormal screening laboratory test results (<LLN), the platelets 
count, White Blood Cell and Hemoglobin will be repeated once; if the repeat test 
result is still <LLN, then exclusionary); 
11. Have symptomatic cardiomyopathy or heart failure (New York Heart Association 
Class III or IV) or left ventricular ejection fraction <50% at screening; 
12. Have a current or history of liver disease or impairment, including but not limited to 
an elevated total bilirubin (i.e. > 1.5 x ULN), unless secondary to Gilbert disease or 
pattern consistent with Gilbert's; 
13. Have inadequate renal function, as defined by serum Cystatin C >2 x the upper limit 
of normal (ULN).  If the value is >2 x ULN, the serum Cystatin C will be repeated 
once; if the repeated test result is still >2 x ULN, the subject should be excluded);  
14. Have Triglycerides > 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit; 
15. Have a positive test for hepatitis B surface antigen, hepatitis C antibody, or human 
immunodeficiency virus at screening; 
16. Have a baseline corrected QT interval, Fridericia’s correction (QTcF) >450 msec, (as 
the mean of 3 consecutive readings 5 minutes apart) or history of additional risk 
factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of 
long QT syndrome); 
17. Have a psychiatric illness/social situations rendering the potential subject unable to 
understand and comply with the muscle function tests and/or with the study protocol 
procedures; 
18. Have any hypersensitivity to the components of study medication; 
19. Have a sorbitol intolerance or sorbitol malabsorption, or have the hereditary form of 
fructose intolerance; 
20. Have contraindications to MRI or MRS (e.g., claustrophobia, metal implants, or 
seizure disorder). 
At the discretion of the Investigator, subjects not meeting inclusion/exclusion criteria may be 
re-screened twice with an interval of at least 3 months between assessments. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 49 of 120 
7.3 
Withdrawal, Removal, and Replacement of Subjects  
Withdrawal from study participation and study medication may occur under the following 
circumstances: 
 Withdrawal of consent.  The subject or his parent/guardian desire to withdraw from 
further participation in the study in the absence of the Investigator determining a 
medical need to withdraw.  If the subject or parent/guardian give a reason for 
withdrawing, it should be recorded in the electronic Case Report Form (eCRF). 
 Protocol Violation.  The subject’s findings or conduct failed to meet the protocol entry 
criteria or failed to adhere to the protocol requirements (e.g.,  failure to return for 
defined number of visits). Before withdrawing a subject each case will be discussed 
with the study medical monitor and if the safety of the subject can be reasonably 
assured, the subject will not be discontinued.  
 Lost to Follow-Up.  The subject stopped coming for visits, and study personnel were 
unable to contact the subject. 
 Other reason.  The subject was terminated for a reason other than those listed above, 
such as at the discretion of the Investigator (i.e., any other condition that, in the 
opinion of the Investigator, may jeopardize the study conduct according to the 
protocol, or when the Investigator feels that it is in the best interest of the subject to 
discontinue) or termination of study by the Sponsor. 
Withdrawal from study medication may occur under the following circumstance: 
 Adverse event.  Clinical or laboratory events occur that, in the medical judgment of 
the Investigator for the best interest of the subject, are grounds for discontinuation.  
Moreover, if the subject meets one of the safety stopping criteria described in Section 
7.3.1, he will be withdrawn from the study medication.  In case of withdrawal due to 
AEs/SAEs, the Investigator will follow up with the subject until resolution or 
acceptable stabilization of the event and document all the relevant information, as 
applicable. 
In case of withdrawal from study participation and /or study medication, the following general 
rules apply: 
 If a subject is discontinued from study medication and is withdrawn from the study 
for any reason, the study site must immediately notify the medical monitor. 
 When a subject withdraws from the study, the date and reasons for withdrawal shall 
be recorded by the Investigator on the Subject’s Medical File and on the relevant 
page of the eCRF.  


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 50 of 120 
In case of multiple reasons, AEs should be indicated as the primary reason whenever 
applicable.  All relevant information related to the reason for treatment 
discontinuation including contributory factors must be included on the eCRF. 
 All subjects prematurely discontinuing the study must be seen for a final evaluation 
performed within 2 weeks after the last drug intake.  Final evaluation is defined as 
completion of the assessments scheduled for the Early Termination Visit (as detailed 
in Section 9.1.8).  Data collected during the final evaluation are crucial to the 
integrity of the final study analysis because early withdrawal could be related to the 
safety profile of the study drug.  The Investigator will make every effort to see 
subjects who fail to return for a final visit.   
 In the event that a subject is discontinued prematurely from the study due to a 
treatment-related TEAE or serious TEAE, the TEAE or serious TEAE will be 
followed until it resolves (returns to normal or baseline values) or stabilizes, or until 
it is judged by the Investigator to be no longer clinically significant. 
 Once a subject is withdrawn from the study, he may not re-enter the study. 
7.3.1 Safety Stopping Rules   
Study drug should be permanently interrupted if any of the following occurs: 
 severe drug-related diarrhoea (i.e., increase of  ≥7 stools per day);  
 any drug-related SAE; 
 QTcF >500 msec*; 
 platelets count ≤50 x 109/L (to avoid laboratory errors and anomalous values, platelets 
count ≤50 x 109/L must be confirmed with a repeated test performed on the next 
working day.  The treatment should be stopped until the retest result becomes 
available.  If the repeated platelets count is still ≤50 x 109/L, study drug must be 
permanently discontinued.  If the repeated test is acceptable, the subject can resume 
treatment.);   
 white blood cells  ≤2.0 x 109/L (to avoid laboratory errors and anomalous values, 
white blood cells  ≤2.0 x 109/L must be confirmed with a repeated test performed on 
the next working day.  The treatment should be stopped until the retest result becomes 
available.  If the repeated white blood cells is still ≤2.0 x 109/L, study drug must be 
permanently discontinued.  If the repeated test is acceptable, the subject can resume 
treatment.);   
 hemoglobin  ≤8.0 g/dL (to avoid laboratory errors and anomalous values, hemoglobin  
≤8.0 g/dL must be confirmed with a repeated test performed on the next working day.  
The treatment should be stopped until the retest result becomes available.  If the 
repeated hemoglobin is still ≤8.0 g/dL, study drug must be permanently discontinued.  
If the repeated test is acceptable, the subject can resume treatment.).   


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 51 of 120 
The Investigator will follow up on him until resolution or acceptable stabilization of the event 
occurs and document all the relevant information, as applicable.  After the 
resolution/stabilization of the event, the subject will be withdrawn from the study and the 
EOS Visit (see Section 9.1.8) will be performed. 
* based on average QTc value of triplicate ECGs.  For example, if an ECG demonstrates a prolonged QTcF 
interval >450msec, 2 more ECGs should be obtained over a brief period, and then the averaged QTcF values of 
the 3 ECGs should be used to determine whether the subjects should be discontinued from the study.  If the mean 
QTcF value of the 3 replicates still meets the stopping criteria the subject has to interrupt the study drug, the 
medical monitor has to be informed and the value must be confirmed by the central reading before withdraw the 
subject from the study.  The QTc has to be calculated with the Fridericia formula QTc = QT/RR1/3. 
Study drug should be temporarily stopped if any of the following occur: 
 moderate or severe diarrhoea (i.e., increase more than 4 stools per day).  
 platelets count <75 x 109/L but >50 x 109/L (the treatment should be temporarily 
stopped and platelets count has to be performed by 1 week and re-tested until platelets 
will be normalized); 
 white blood cell  <3.0 x 109/L but >2.0 x 109/L (the treatment should be temporarily 
stopped and white blood cells have to be measured by 1 week and re-tested until white 
blood cells  will be normalized); 
 hemoglobin  <10.0 g/dL but > 8.0 g/dL (the treatment should be temporarily stopped 
and hemoglobin has to be measured by 1 week and re-tested until hemoglobin will be 
normalized); 
 Triglycerides >300 mg/dL (3.42 mmol/L) in fasting condition (the treatment should be 
temporarily stopped and  triglycerides has to be measured every 2 weeks until  
triglycerides return to levels below 300 mg/dL (3.42 mmol/L); 
For subjects randomized under protocol version 6.0, or 7.0 or 8.0: 
Study drug can be reduced by 20% of the current dose at which the AE leading to temporary 
stop occurred, once platelets and/or white blood cell and/or hemoglobin are normalized, 
and/or triglycerides return to levels below 300 mg/dL (3.42 mmol/L), or diarrhoea is mild.  
The subject may have more than the usual number of scheduled visits if needed, until the AE 
resolves, and then will continue the study as per scheduled visits. 
In addition, in case a subject will have a consistent (e.g., at least two consecutive evaluation) 
platelets count ≤150 x 109/L and not meeting the stopping criteria for platelets, the 
Investigator will have to reduce the dose by 20% of the current dose (see Section 8.2.2 for 
more details). 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 52 of 120 
For subjects randomized under protocol version  6.0 or 7.0 or 8.0, only one dose reduction is 
allowed during the treatment period. 
Any decision relevant to the dose interruption and/or modification of the schedule of 
assessments can  be discussed with  the Medical Monitor, but the final decision remains with 
the Investigator only or its authorized designee. 
For subjects randomized under protocol version 4.0: 
Study drug can be reduced by 1/3 of the starting dose at which the AE leading to temporary 
stop occurred, once platelets and/or white blood cell and/or hemoglobin are normalized and/or 
triglycerides return to levels below 300 mg/dL (3.42 mmol/L), or diarrhoea is mild.  The 
subject may have more than the usual number of scheduled visits if needed, until the AE 
resolves, and then will continue the study as per scheduled visits.  
If a subject was randomized with baseline triglycerides above 300 mg/dL (3.42 mmol/L) the 
Investigator can discuss how to manage the case with the medical monitor, however the final 
decision remains with the Investigator only or its authorized designee. 
In addition, in case a subject will have a consistent (e.g., at least two consecutive evaluations) 
platelets count ≤150 x 109/L and not meeting the stopping criteria for platelets, the 
Investigator will have to reduce the dose  by 1/3 vs the starting dose (see Section 8.2.2 for 
more details).  
If a subject has a medical event not necessarily drug related that requires interruption of study 
drug dosing for >4 weeks, the Investigator can discuss the case with the medical monitor if 
the subject may resume study drug treatment, however the final decision remains with the 
Investigator only or its authorized designee.  
Moreover, for subjects who have already reduced the dose of 1/3 an additional reduction of 
20%  is allowed for safety reasons following the inscruction in section “For subjects 
randomized under protocol version 6.0, or 7.0 or 8.0”. 
Any decision relevant to the dose interruption and/or modification of the schedule of 
assessments can  be discussed with  the Medical Monitor, but the final decision remains with 
the Investigator only or its authorized designee. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 53 of 120 
8 
TREATMENTS 
8.1 
Details of Study Treatments 
The investigational study drug to be used in this study is givinostat (ITF2357) and a placebo.  
For the duration of the study, givinostat and placebo will be supplied by Italfarmaco S.p.A. 
 
Investigational Medicinal Drug 
 
Test treatment 
Comparator 
Product name: 
ITF2357/givinostat* 
Placebo 
Dosage form: 
Oral suspension 
Oral suspension 
Unit dose 
strength: 
Bottle containing 140 mL of givinostat 
10 mg/mL  
Bottle containing 140 mL of 
placebo 
Route of 
Administration 
Oral administration under fed 
conditions 
Oral administration under fed 
conditions 
Dosing 
instructions: 
See Table 2 
See Table 2 
Physical 
description: 
White to off-white or faintly pink, 
homogenous suspension when mixed  
White to off-white or faintly 
pink, homogenous suspension 
when mixed 
Device included 
in the packaging: 
Two graduated dosing syringes for 
oral use: 
One 5 mL syringe and 
One 1 mL syringe 
Two graduated dosing syringes 
for oral use: 
One 5 mL syringe and 
One 1 mL syringe 
*Givinostat is used to indicate the whole study drug name givinostat hydrochloride monohydrate.  The 
dosages/concentrations of the study drug are expressed as givinostat hydrochloride monohydrate. 
 
The investigational sites will be supplied initially with a congruous number of suspension 
bottles, in order to have sufficient supply of study drug to treat subjects who are enrolled in 
the study. 
8.2 
Dosage  
8.2.1 Rational for Dose Selection 
The dose for this study has been selected based on: the dose ranging evaluation done in the 
mdx model; the results of the Phase 2 study in DMD paediatric subjects (DSC/11/2357/43), 
and the evaluation of PK and efficacy results obtained in other inflammatory diseases.   
The PK/PD analysis done with the data collected during the non-clinical studies in mdx 
model, showed that a blood AUC0-24 of at least 300 ng*h/mL was estimated to be needed to 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 54 of 120 
exert the beneficial histological and functional effects in mouse and thus was considered the 
target exposure for the exploratory Phase 2 study in the DMD population (DSC/11/2357/43 
study).  
The study DSC/11/2357/43 was designed to first verify that doses of givinostat leading to an 
AUC0-24 of at least 300 ng*h/mL in the majority of DMD subjects were tolerated and then to 
verify that such exposures would translate into a significant histological benefit.  Results have 
confirmed that doses of 25/37.5 mg bid are tolerated, do result in an AUC0-24 of at least 300 
ng*h/mL in the majority of treated DMD subjects, and result in a significant histological 
benefit. 
On the other hand, previous clinical experience in chronic inflammatory diseases in adult and 
paediatric populations (i.e., Crohn’s Disease, Psoriasis, Systemic Onset Juvenile Idiopathic 
Arthritis and Polyarticular Course Juvenile Idiopathic Arthritis) have shown that givinostat 
was overall not efficacious in controlling symptoms and biological features of these diseases 
at exposures (AUC0-24) lower or comparable to those obtained in study DSC/11/2357/43.  
Lack of efficacy of doses lower than those tested in study DSC/11/2357/43 were also 
suggested by the post-hoc analysis of study DSC/11/2357/43 results which showed that a 37.5 
mg bid dose was associated with a larger increase in CSA of fibers compared to 25 mg bid. 
Based on these considerations, the Sponsor believes that doses leading to daily exposures 
lower than those obtained in study DSC/11/2357/43 are very unlikely to be efficacious and 
therefore chose an initial study dose to ensure a mean AUC0-24 similar to that achieved with 
37.5 mg/bid (i.e., approximately 1150 ng*h/mL). As of 18th of June 2018, based on blinded 
safety haematologic data, the Sponsor has evaluated that, a vast majority of randomized 
subjects who had completed at least 8 weeks of treatment (approximately 50 to 60%) had to 
reduce the starting dose due to a decrease in platelet levels. It is, therefore, expected that a 
relevant amount of subjects that will be enrolled into the study will need to require the same 
dose adjustment. Therefore, a new starting dose corresponding to the reduced dose (i.e. 1/3 
lower than the starting dose) of protocol version 4.0 (i.e. 13.3-46.7 mg/bid according to body 
weight) is proposed by the Sponsor in protocol version 6.0. This new starting dose ensures a 
mean AUC0-24 similar to that achieved with 25 mg/bid during the DSC/11/2357/43 study in 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 55 of 120 
DMD patients (i.e., approximately 674 ng*h/mL), which was safe and showed significant 
histological benefit. 
As weight was shown to significantly affect givinostat clearance, and the study will enroll 
paediatric DMD subjects with a broad range of weight, the initial dose will be adjusted to the 
current body weight of the subject (see Table 2). A strict monitoring of platelets count has 
been planned, and it will be followed with dose adjustment instruction as described in the 
safety rules as described in Section 7.3.1 in order to avoid the risk of platelet reduction <75 x 
109/L. 
8.2.2 Dosage Schedule 
The following is a description of the dosage, treatment regimen, and route of administration.  
Givinostat oral suspension (10 mg/mL) and placebo oral suspension have to be administered 
orally as 2 oral doses daily while the subject is in a fed state.  Before its use, the suspension 
must be shaken for at least 30 seconds by rotating the bottle by 180° and the homogeneity of 
the obtained suspension verified.  The suspension will be administered by means of a 
graduated dosing syringe.  The dosage to be administered is based on subject weight and the 
starting doses are described below: 
Table 2: 
Placebo or Givinostat Starting Dose 
Weight (kg) 
≥10 
and 
< 12.5 
≥12.5 
and 
< 20 
≥20 
and 
< 25 
≥25 
and 
< 30 
≥30 
and 
< 40 
≥40 
and 
< 50 
≥50 
and 
< 60 
≥60 
and 
< 70 
≥70 
Dose (mg) bid 
13.3 
16.7 
20 
23.3 
26.7 
33.3 
36.7 
40 
46.7 
Oral suspension 
(mL) bid 
1.3 
1.7 
2.0 
2.3 
2.7 
3.3 
3.7 
4 
4.7 
 
The subjects who were randomized under protocol version 4.0 will continue the current dose 
(see  Table 4). 
Table 3: 
Placebo or Givinostat Starting Dose for subjects enrolled under Protocol version 4.0 
Weight (kg) 
≥10 
and 
<12.5 
≥12.5 
and 
<20 
≥20 
and 
<25 
≥25 
and 
<30 
≥30 
and 
<40 
≥40 
and 
<50 
≥50 
and 
<60 
≥60 
and 
< 70 
≥70 
Dose (mg) bid 
20 
25 
30 
35 
40 
50 
55 
60 
70 
Oral suspension (mL) bid 
2.0 
2.5 
3.0 
3.5 
4.0 
5.0 
5.5 
6.0 
7.0 
Dose Modifications for subjects randomized under protocol version 6.0 or 7.0 or 8.0: 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 56 of 120 
Study drug dose adjustment including safety rules for permanently or temporarily stopping 
study drug are described in Section 7.3.1. 
As mentioned in Section 7.3.1, in case a subject has a consistent (e.g., at least 2 consecutive 
evaluations) platelets count ≤150 x 109/L and but does not meet the stopping criteria due to 
platelet reduction, the Investigator will have to reduce the dose by 20%  of the current dose 
(first example: e.g., starting dose = 20 mg bid  20%  dose reduction  new dose = 16 mg 
bid; second example: starting dose = 26.7 mg bid  20% dose reduction  new dose = 
21.4 mg bid) (see  Table 4). 
 Table 4: Placebo or Givinostat Dose Modification for subjects randomized under study 
protocol version 6.0 or 7.0 or 8.0. 
Weight (kg) 
≥10 
and 
<12.5 
≥12.5 
and 
<20 
≥20 
and 
<25 
≥25 
and 
<30 
≥30 
and 
<40 
≥40 
and 
<50 
≥50 
and 
<60 
≥60 
and 
< 70 
≥70 
Starting Dose 
(mg) bid 
13.3 
16.7 
20 
23.3 
26.7 
33.3 
36.7 
40 
46.7 
Oral suspension 
(mL) bid 
1.3 
1.7 
2.0 
2.3 
2.7 
3.3 
3.7 
4 
4.7 
Reduced Dose 
(mg) bid 
10.6 
13.4 
16 
18.6 
21.4 
26.6 
29.4 
32 
37.4 
Oral suspension 
(mL) bid 
1.1 
1.3 
1.6 
1.9 
2.1 
2.7 
2.9 
3.2 
3.7 
Study drug can be resumed at a level 20% smaller than the dose at which the AE leading to 
temporary stop occurred, once platelets and/or white blood cell and/or hemoglobin are 
normalized  and/or triglycerides return to levels below 300 mg/dL (3.42 mmol/L) or when 
diarrhoea is mild. 
For subjects randomized under protocol version 6.0 or 7.0 or 8.0, only one dose reduction is 
allowed during the treatment period. 
Dose Modifications for subjects randomized under protocol version 4.0: 
The subjects who were randomized under protocol version 4.0, will follow the dose 
modification instruction as per  protocol version 4.0,  as described below in Table 5.  


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 57 of 120 
Table 5: 
Placebo or Givinostat Dose Modification for subject randomized under study 
prococol version 4.0 
Weight (kg) 
≥10 
and 
<12.5 
≥12.5 
and 
<20 
≥20 
and 
<25 
≥25 
and 
<30 
≥30 
and 
<40 
≥40 
and 
<50 
≥50 
and 
<60 
≥60 
and 
< 70 
≥70 
Starting Dose 
(mg) bid 
20 
25 
30 
35 
40 
50 
55 
60 
70 
Oral suspension 
(mL) bid 
2.0 
2.5 
3.0 
3.5 
4.0 
5.0 
5.5 
6.0 
7.0 
Reduced Dose 
(mg) bid 
13.3 
16.7 
20 
23.3 
26.7 
33.3 
36.7 
40 
46.7 
Oral suspension 
(mL) bid 
1.3 
1.7 
2.0 
2.3 
2.7 
3.3 
3.7 
4 
4.7 
Study drug dose adjustment including safety rules for permanently or temporarily stopping 
study drug are described in Section 7.3.1. 
As mentioned in Section 7.3.1, in case a subject has a consistent (e.g., at least 2 consecutive 
evaluations) platelets count ≤150 x 109/L and does not meet the stopping criteria due to 
platelet reduction, the Investigator will have to reduce the dose by 1/3 of the starting dose (see 
Table 5). 
Study drug can be resumed at a level 1/3 smaller than the dose at which the AE leading to 
temporary stop occurred, once platelets and/or white blood cell and/or hemoglobin are 
normalized  and/or triglycerides return to levels below 300 mg/dL (3.42 mmol/L) or when 
diarrhoea is mild. 
If a subject was randomized with baseline triglycerides above 300 mg/dL (3.42 mmol/L), the 
Investigator can discuss how to manage the case with the medical monitor, however the final 
decision remain with the Investigator or its authorized designee only.  
Moreover, for subjects who have already reduced the dose of 1/3 an additional reduction by 
20%  is allowed for safety reasons following the instruction reported in  Table 4.  
Dose Modification (all subjects): 
If subjects (i.e. those already in treatment or those who will be randomized under protocol 
version 6.0 or 7.0 or 8.0) gain weight during the study the drug dose must be kept unchanged.  
If subjects (i.e. those already in treatment or those who will be randomized under protocol 
version 6.0 or 7.0 or 8.0) lose weight during the study, the drug dose should be adjusted 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 58 of 120 
according to Table 2 or Table 3 if the subject is still on treatment at starting dose, or according 
to Table 4 or Table 5 if the subject has already reduced the starting dose. 
All subjects will be asked to have platelets count assessments weekly during the first month of 
treatment and performed every two weeks during the second month of treatment, in order to 
strictly monitor this parameter for safety reasons. 
If the dose is reduced due to platelet count ≤150 x 109/L, and/or white blood cell  <3.0 x 109/L 
and/or hemoglobin <10.0 mg/dL a complete blood count (i.e.CBC) test must be performed 
weekly for 8 consecutive weeks. 
If a dose adjustment and/or modification of schedule of assessments is decided by the 
Investigator or authorized designee, it is advised to discuss this decision with the Medical 
Monitor, however this is not mandatory as the Investigator is the only responsible for the 
medical care of the subject and the Investigator’s decision should not be influenced, deleted 
nor approved by the Medical Monitor. 
8.3 
Study Treatment Assignment 
The Investigator will be responsible for the delivery of study drug to the subject’s parent/legal 
guardian according to the protocol.  Subjects will be administered the study drug on an 
outpatient basis.  All study drug supplies are to be used only for this protocol and for no other 
purpose. 
At Visit 3, subjects fulfilling all inclusion criteria and none of the exclusion criteria will be 
randomised via interactive response technology (IRT). During the randomization procedure, 
the Investigator will be asked to record the type of steroid used by the subject (i.e. Deflazacort 
or other type of steroids) and to record the regimen of intake (i.e. daily regimen or intermittent 
regimen) following the instruction provided in the IRT manual. The IRT will assign the 
subject to one stratum according to the collected information (i.e. Deflazacort Daily regimen, 
Deflazacort Intermittent regimen, Other steroids Daily regimen, Other steroids  Intermittent 
regimen) and them to a treatment arm in a 2:1 ratio to receive givinostat or placebo. 
During the first 3 months, the Investigator will supply the child’s parent/legal guardian with 
the appropriate number of suspension bottles sufficient to cover one month of treatment at 
scheduled visits (i.e., at Visit 3, 7 and 9).  Then, for the remaining part of the study (i.e., at 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 59 of 120 
Visit 10, 11, 12, 13, and 14, the Investigator will supply the child’s parent/legal guardian with 
the appropriate number of suspension bottles sufficient to cover the period between two visits 
(i.e., 3 months of treatment).   
The Investigator is to call using IRT at each dispensing visit in order to obtain the packaging 
number of the study treatment to be dispensed to the subject by the subject’s parent/legal 
guardian.   
Study treatment should be dispensed to each subject’s parent/legal guardian by authorized 
personnel only. 
The Investigator will provide to the subject parent/legal guardian written instruction on the 
dosage and corresponding volume in milliliters of suspension to be taken at each 
administration.  Refer to the relevant Clinical Study Operations Manual (CSOM) for more 
detailed information. 
8.4 
Blinding 
This is a double-blind, placebo controlled study, so subjects receiving givinostat or placebo 
will receive medication indistinguishable in appearance. Personnel involved in the study 
(Investigators, nurses, all other site personnel, clinical research associate (CRA), Medical 
Monitors, Project Managers, and personnel involved in data management) will remain blind at 
all times, unless under exceptional circumstances when knowledge of the study drug is 
essential for treating the subject, such as in case of an AE. If the Investigator or authorized 
designee decides to break the code of a subject, it is suggested that the Monitoring Team 
(Medical Monitor or CRA) would be consulted if possible before breaking the code, however 
this is not mandatory because the decision of the Investigator cannot be influenced, deleted 
nor approved by the Monitoring Team.  
Code breaking can be performed by the Investigator or authorized designee at any time by 
using the proper module of the IRT system. 
If the code is broken, treatment with the study drug must be stopped.  
In any case, after breaking the code, the Investigator must record the date, time, and reason 
for breaking the code in the CRF, and must notify the Monitoring Team as soon as possible. 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 60 of 120 
As platelets count reductions are observed after treatment with givinostat, study site personnel 
who will perform functional tests and MRI/MRS must be different from the personnel who 
will review subjects’ safety results and safety results must not be shared with the personnel 
responsible for the functional tests and MRI/MRS.  
Regarding the PK results, all the personnel involved in the study will remain blind at all times 
and Sponsor may review the PK results only in scrambled format. 
8.5 
Drug Supply 
The investigational site will be supplied initially with a congruous number of suspension 
bottles, in order to have sufficient supply of study drug to treat the children who are enrolled 
in the study. 
8.5.1 Packaging 
The primary packaging will consist of an amber plastic bottle containing the suspension.  
Givinostat/Placebo oral paediatric suspension is supplied in a 150 mL capacity amber PET 
bottle closed by means of a red-white HDPE child-proof screw cap with a LDPE 
shutter/syringe-adapter.  Each bottle contains 140 mL of givinostat 10 mg/mL or placebo.  
The secondary packaging will be a carton box containing one amber bottle and a two syringe 
for oral use as dosing systems for dispensing the suspension. 
8.5.2 Labelling 
The primary and secondary labels will show all the information requested according to the 
Annex 13 of the Good Manufacturing Practice and comply with the legal Investigation use 
requirements of each country.  
Medication labels will be in the local language. 
The labels for European countries will include at least: 
 Name of the medicinal product  
 Pharmaceutical dosage form  
 Route of administration  
 Quantity of dosage units 
 Strength/potency 
 Batch number/Packaging number 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 61 of 120 
 Sponsor’s study code (*) 
 EudraCT number (*) 
 Investigator name (*) 
 Site and subject number (*) 
 Treatment/Randomization number (*) 
 Name, address, and telephone number of the main contact (the sponsor or the 
contract research organization or the investigator)  (*) (**)  
 Period of use (*) 
 Storage conditions (*) 
 Directions for use (*) (**) 
 For clinical trial use only (*) 
 Keep out of reach of children (*)  
Notes:  
(*) According to Annex 13 and EU law in force, when using a centralized electronic 
randomization system, some of the listed information may be omitted from the label.  
(**) According to Annex 13, such information might not need to appear on the label if 
separately provided in a leaflet or card.  
The labels for United State and Canadian sites will include at least: 
 Sponsor’s study code  
 IND number  
 Packaging number  
 Name of the medicinal product  
 Pharmaceutical dosage form  
 Route of administration  
 Quantity of dosage units  
 Strength/potency 
 Batch number  
 Expiry date 
 Administer as per Protocol 
 Caution: Investigational Drug – Limited by Federal (United States) Law to 
Investigational Use  
 Storage conditions  
 Keep out of the reach of children 
 Sponsor. 
8.5.3 Storage 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 62 of 120 
The investigational site will store the study drug under the conditions specified here below, 
ensuring that it is not accessible to unauthorized persons until it is dispensed to the subject’s 
parent/legal guardian. 
Givinostat/Placebo suspension has to be stored in a refrigerated condition at 5°C±3°C.  Once 
the container is firstly opened, the suspension can be administered for a maximum of 30 days. 
8.6 
Treatment Accountability and Compliance 
The study drug packaging will be provided with tear off labels; before treatment dispensation 
the tear-off label should be removed from the subject’s pack by the Investigator and stuck on 
the appropriate drug accountability form. 
At each dispensing visit, the subject’s parent/legal guardian will bring back to the study site 
all bottles previously received (used, partially used and unused) and receive a new supply of 
the study drug.  
Subject compliance will be evaluated through a subject diary indicating how many doses were 
effectively administered by the subject. .  
Compliance will be checked by Italfarmaco S.p.A. or its designee based on the drug 
accountability documented by the site staff and monitored by Italfarmaco S.p.A. or its 
designee.  
The used, partially used, and unused bottles will be collected and sent back to Italfarmaco 
S.p.A. or their designee periodically or at the end of the study.  
Accountability and compliance is detailed in the relevant CSOM. 
8.7 
Prior and Concomitant Illnesses and Medications 
8.7.1 Prior and Concomitant Illnesses 
Investigators should document all prior significant illnesses that the subject has experienced 
within 6 months of screening.  The starting date of corticosteroids use will be also collected. 
Additional illnesses present at the time when informed consent is given and up to the time of 
first dosing (Visit 3) are to be regarded as concomitant illnesses.  


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 63 of 120 
Illnesses first occurring or detected during the study and/or worsening of a concomitant illness 
during the study are to be documented as AEs on the eCRF. 
8.7.2 Prior and Concomitant Medications 
All medications and other treatments taken by the subject during the study, including those 
treatments initiated within 6 months prior to the start of the study, must be recorded on 
the eCRF. 
Subjects should be on systemic corticosteroid therapy for at least 6 months prior to initiation 
of study drug.  That is, there have been no changes in systemic corticosteroid therapy (e.g., 
change in type of drug, dose modification not related to body weight change, schedule 
modification, interruption, discontinuation, or re-initiation) during the previous 6 months. 
As the subjects to be randomised are on stable steroids, the recommended national 
immunisation schedule, including varicella immunity, should be completed (i.e., as 
recommended in the “Diagnosis and Management of Duchenne Muscular Dystrophy” 
guideline4), before the Screening Visit.   
Concomitant treatments are defined as treatments taken after study drug administration.  
Any medication or therapy that is taken by or administered to the subject during the course of 
the study must be recorded in the eCRF.  The entry must include the dose, regimen, route, 
indication, and dates of use. 
After the Screening visit, medication to treat minor treatment-emergent illnesses are generally 
permitted; supportive treatments, such as anti-emetics, anti- diarrhoeals, anti-pyretics, anti-
allergics, analgesics, and antibiotics are allowed. 
Use of Vitamin D, calcium and any other supplements if clinically indicated before 
enrollment and for duration of the study are allowed. 
The following therapies are expressly prohibited throughout the study:  
 Any other investigational drug while on this study,  
 any dystrophin restoration product  
 use of any pharmacologic treatment, other than corticosteroids, that might have an 
effect on muscle strength or function (e.g., growth hormone) 
The following are concomitant therapy requiring caution throughout the study: 


Italfarmaco S.p.A.   
   DSC/14/2357/48 
Givinostat  
               Protocol Version 8.0  
  08 April 2020 
 
Page 64 of 120 
 Drugs known to increase the QT interval (see Appendix 16.1 for a list of such 
compounds).  
 Drugs known to be P-glycoprotein inhibitors (see Appendix 16.3 for a list of such 
compounds). 
 Live or live attenuated vaccines: the subject must be carefully monitored. While the 
decision of the Investigator cannot be influenced, deleted nor approved by the Medical 
Monitor, it is advised but not mandatory that the Investigator discuss the case with the 
Medical Monitor before using these vaccines.  
 Drugs knows to be a substrate of Organic Cation Transporter 2 transporter (see 
Appendix 16.2 for a list of such compounds). 
 Antiplatelets, thrombolytic and anticoaugulants drugs: subject must be carefully 
monitored (i.e. increase the frequency of hematology testing,  evaluate any possible 
sign of bleeding). 
9 
STUDY PROCEDURES 
Table 6 outlines the timing of procedures and assessments to be performed throughout the 
study.  See Section 9.1 for additional details of study procedures. 


Italfarmaco S.p.A.   
DSC/14/2357/48 
Givinostat  
Protocol Version  8.0 
 08 April 2020 
Page 65 of 120 
Table 6:    Schedule of Assessments 
Month 
-1 
0 
1 
2 
3 
6 
9 
12 
15 
18 
19 
Week 
-41 
From 
1 day 
after 
V1 to 
 -2 
0 
1 
2 
3 
4 
6 
8 
12 
24 
36 
48 
60 
72 
76 
Visit window 
± 2 weeks 
+ 3 days 
0 
± 3 
days 
± 3 
days 
± 3 
days 
± 3 
days 
± 3 
days 
± 3 
days 
± 7 
days 
± 7 
days 
± 7 days 
± 7 
days 
± 7 
days 
± 7 days 
± 7 days from 
last dose 
Visit 
V1 
V21 
V3  
V4 
 
 
 
V52 
 
 
 
V62 
 
 
 
V7 
 
 
 
V82 
 
 
 
V9 
 
 
 
V10 
 
 
 
V11 
 
 
 
V12 
 
 
 
V13 
 
 
 
V14 
 
 
 
V15 
V16 
Screening 
Rand 
EOS/Early 
Withdrawal3 
FUV4 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligibility criteria 
X 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history and 
demographic data 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prior and concomitant 
medications 
X 
 
X 
X 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination 
X5 
 
X 
X 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X5 
X 
Vital Signs 
X 
 
X 
X 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
Weight 
X 
 
X 
X 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
Height 
X 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
X 
 
ECG Test6 
X 
 
X 
X 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
ECHO 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Pulmonary function tests7 
X7 
 
 
 
 
 
 
 
 
 
 
 
X7 
 
X7 
 
Serology8 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematology9 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Blood chemistry10 
X 
 
 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
Coagulation tests (PT and 
aPTT) 
X 
 
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Urine analysis11 
X 
 
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
LTBP4 and osteopontin 
genotype 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exploratory serum 
Biomarkers 
 
 
X 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
Quality of life test 
(assessed by PODCI) 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
4 -stairs Climb12 
X 
X 
X 
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
 
NSAA + 6MWT 
X 
 
X 
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
 


Italfarmaco S.p.A.   
DSC/14/2357/48 
Givinostat  
Protocol Version  8.0 
 08 April 2020 
Page 66 of 120 
Month 
-1 
0 
1 
2 
3 
6 
9 
12 
15 
18 
19 
Week 
-41 
From 
1 day 
after 
V1 to 
 -2 
0 
1 
2 
3 
4 
6 
8 
12 
24 
36 
48 
60 
72 
76 
Visit window 
± 2 weeks 
+ 3 days 
0 
± 3 
days 
± 3 
days 
± 3 
days 
± 3 
days 
± 3 
days 
± 3 
days 
± 7 
days 
± 7 
days 
± 7 days 
± 7 
days 
± 7 
days 
± 7 days 
± 7 days from 
last dose 
Visit 
V1 
V21 
V3  
V4 
 
 
 
V52 
 
 
 
V62 
 
 
 
V7 
 
 
 
V82 
 
 
 
V9 
 
 
 
V10 
 
 
 
V11 
 
 
 
V12 
 
 
 
V13 
 
 
 
V14 
 
 
 
V15 
V16 
Screening 
Rand 
EOS/Early 
Withdrawal3 
FUV4 
Muscle strength13 
X 
 
X 
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
 
Cognitive function 
evaluation 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PK blood sample 
collection14 
 
 
 
 
 
 
X 
 
 
X 
X 
 
X 
 
X 
 
Study drug dispensation 
and accountability 
 
 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
 
 
Subject diary dispensation 
and evaluation of drug 
compliance through diary 
 
 
X 
 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
Acceptability/ Palatability 
evaluation 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
AE assessment 
X 
 
X 
X 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
MRI/MRS15 
 
X 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
Genetic Test16 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6MWT=6-minute walking test; AE=adverse event; NSAA= North Star Ambulatory Assessment;  PODCI= Paediatric Outcomes Data Collection Instrument; 
PFTs= pulmonary function tests; PT=Prothrombin time; aPPT= activated partial thromboplastin time; ECG= electrocardiogram; ECHO= echocardiogram; PK= 
pharmacokinetics;  MRI= magnetic resonance imaging; MRS= magnetic resonance spectroscopy; FEV1= forced expiratory volume at 1 second; FVC=forced 
vital capacity; PEF= peak expiratory flow; RBC-red blood cell; WBC=white blood cell; ALT=alanine aminotransferase; AST=aspartate aminotransferase; LDH= 
lactate dehydrogenase; CRP=C-reactive protein; GGT=gamma-glutamyl transpeptidase; BUN=blood urea nitrogen; fT3= free T3 (the active part of 
triiodothyronine); fT4=Free T4 (the active part of thyroxine); TSH=thyroid-stimulating hormone; eGFR=estimate Glomerular Filtration Rate; HHM=hand-held 
myometry; MMT=manual muscle testing 
1. 
During screening visit V2, the second Time to 4-stair climb test (4SC) will be performed. The second 4SC can be performed one day after V1 up to a 
maximum of 2 weeks (+3 days). 
The cognitive function evaluation by Raven coloured progressive matrices could be performed during this visit if not done during the previous one (i.e. 
V1). Test should be performed at the same time at the beginning and at the end of the study 
MRI/MRS could be performed in a different day (i.e. not necessarily during the same day of Time to 4-stair climb test, due to the fact that the MRI site 
can be performed in a different site).  


Italfarmaco S.p.A.   
DSC/14/2357/48 
Givinostat  
Protocol Version  8.0 
 08 April 2020 
Page 67 of 120 
2. 
These visits may be performed by Investigator’s authorized personnel outside the site location (e.g., at the subject’s home or at the subject’s General 
Practitioner’s practice.  See conditions in Section 9.1.4) 
3. 
If the subject is discontinued from the study treatment, the subject will be asked to return for the early withdrawal visit to be performed within 2 weeks 
of the last dose of study drug.  In this case, the cognitive function evaluation and MRI/MRS may not be performed. 
4. 
The subjects who complete the study (i.e. 18 months of treatment) will be asked to return to the centre for the Follow up visit to be performed after 4 
weeks from the last dose of study drug (i.e. 4 weeks ± 7 days). 
5. 
During the screening visit V1 and at the end of study (i.e. V15) assessment for ankle range of motion (ROM) should be performed.  
6. 
12-lead ECG has to be done in triplicate at the screening visit and during the other visits if an ECG demonstrates a prolonged QTcF interval ˃ 450 msec, 
obtain 2 more ECGs over a brief period, and then use the averaged QTcF values of the 3 ECGs to determine whether the subjects should be discontinued 
from the study (see Section 7.3.1). 12-lead ECG should be performed  at 2,5 hours (i.e 150 minutes) ±30 minutes after drug intake.  
7. 
Pulmonary function tests FEV1, FVC, FEV1/FVC and PEF. In case the test does not achieve ATS criteria and the evaluator does not feel a valid attempt 
has been made, the subject should repeat the test at randomization if the test is failed at screening visit. If the test is failed at 12 months and/or  at 18 
months the subject has to be asked to come back to perform the test. 
8. 
Serology: immunoassay methodology for CMV IgM; in-house methodology of chemiluminescence for HBsAg/HCV/HIV; and ECLIA for EBV IgG. 
9. 
Hematology test: CBC:RBC, WBC (including differential count), hemoglobin, MCH, MCHC, MCV, hematocrit, and platelets.  Test will be done 
according to the schedule (i.e., weekly for the first month of treatment, every 2 weeks for the second month of treatment) and are to be performed more 
frequently if clinically indicated.  Note: Repeat visits for the platelets count will be assumed at the request of the Investigator. If the dose is reduced due 
to platelet count ≤150 x 109/L, and/or white blood cell  <3.0 x 109/L and/or hemoglobin <10.0 mg/dL, a complete blood count (i.e.CBC) test must be 
performed weekly for 8 consecutive weeks. 
10. 
The following blood tests will be assessed: total bilirubin, direct bilirubin, alkaline phosphatase, amylase, ALT, AST, LDH, cystatin C, CRP, GGT, 
creatine kinase, total protein, albumin, uric acid, triglycerides, phosphorus, total cholesterol, LDL, HDL, sodium, potassium, chloride, calcium, glucose, 
creatinine, BUN, TSH, fT3, fT4, bicarbonate). Note that TSH, fT3, and fT4 will be taken  at Visits 7, 9, 10, 11, 12, 13, 14, 15 and 16. 
11. 
Urinalysis: appearance, pH, specific gravity, protein, glucose, ketone bodies, blood and WBCs, and urobilinogen. 
12. 
During the screening period (i.e., 4 weeks ±2), time to 4-stair climb test (4SC) should be  performed at V1 and V2. The 4SC at V2 can be performed one 
day after V1 up to a maximum of 2 weeks (+3 days). For this reason the subjects should go to the centre 2 times (i.e., Visit 1 and Visit 2).  The test 
should be video recorded during Visit 1, Visit 3, Visit 13 and Visit 15. 
13. 
Muscle strength tests: at screening: knee extension, elbow flexion by HHM and knee extension by MMT. During the study and at the end:  knee 
extension, elbow flexion by HHM. 
14. 
Pharmacokinetic sample collection: sampling (2 pre-dose during the treatment and 4 post-dose) will be collected as described in the protocol during the 
following visits: 7 (4 weeks), 10 (12 weeks), 11 (24 weeks), 13 (Week 48) and 15 (Week 72).  At these visits, the subject will be asked to take the 
morning dose at site. 
15. 
The baseline MRI/MRS test has to be performed when all inclusion/exclusion criteria have been already evaluated and the subject is eligible.  At 
screening all subjects will perform the MRI of thigh and MRS of vastus lateralis; then the MRI of thigh and MRS of vastus lateralis will be performed 
also at 12 and 18 months in a subgroup of subjects: the first 99 - 150 randomised subjects in the target population (i.e. with MRS VL MFF between> 5% 
and ≤30%).  The MRI evaluation using Dixon technique and the MRS will be performed at specialized sites.   
16. 
Genetic test should be performed only in case it is not already available. 
 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 68 of 120 
9.1 
Procedures by Study Visit 
There will be at least 15 study visits, including the Screening and Randomisation Visits. 
Assessments will be performed as outlined in the following by-visit subsections.  As platelets 
count reductions are observed after treatment with givinostat, study site personnel who will 
perform functional tests and MRI/MRS must be different from the personnel who will review 
subjects’ safety results and safety results must not be shared with the personnel responsible 
for the functional tests and MRI/MRS. 
At the discretion of the Investigator, subjects not meeting inclusion/exclusion criteria may be 
re-screened twice with an interval of at least 3 months between assessments. 
If needed, safety assessments (e.g. blood test, unscheduled visits) may be performed at the 
subject’s home by a local qualified nurse trained in the study protocol. 
9.1.1 Visit 1 and Visit 2 - Screening (Week -4 ± 2 weeks) 
The Screening visits (Visit 1 and Visit 2) will occur within 4 weeks (± 2 weeks) prior to the 
Randomisation Visit.  The following assessments will be performed at Visit 1 unless noted 
otherwise:  
 Obtain written Informed Consent from the subject’s parent/legal guardian and assent 
or consent from the subject, if applicable; 
 Eligibility criteria: review inclusion and exclusion criteria; 
 Genetic test (only if it is not already available); 
 Collect medical history and demographic data; 
 Collect and record prior medications (taken in the past 6 months); 
 Perform a physical examination (at Visit 1 assessment for ankle ROM should be 
done); 
 Measure vital signs (blood pressure, pulse rate, and body temperature); 
 Measure weight; 
 Measure height; 
 Perform a 12-lead ECG (in triplicate);  
 Perform an ECHO; 
 Perform pulmonary function tests: FEV1, FVC, FEV1/FVC, and PEF; 
 Collect blood samples for:  
o serology tests; 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 69 of 120 
o hematology; 
o blood chemistry; 
o coagulation tests (prothrombin time [PT] and activated partial thromboplastin 
time [aPTT]);  
 Obtain a urine sample for urine analysis; 
 Perform Quality of Life tests (using Paediatric Outcomes Data Collection Instrument 
[PODCI] scores); 
 Perform time to 4SC (the test should be performed at Visit 1 and at Visit 2; the 4SC at 
Visit 2 can be performed one day after V1 up to a maximum of 2 weeks +3 days);  
 Perform NSAA and 6MWT; 
 Perform muscle strength test (both by HHM and MMT); 
 Perform cognitive function evaluation: Raven coloured progressive matrices (at Visit 
1 or at Visit 2. Test should be performed at the beginning and at the end of the study 
at the same time of the day); 
 Assess AEs; 
 If all inclusion and exclusion criteria have been met and the subject is eligible, the 
following assessments must be performed at Visit 2 to conclude the screening period 
before the randomisation: 
o MRI/MRS 
At Visit 1, functional tests will be video recorded. 
Subjects will be instructed to avoid physical activity that would exceed their normal activity 
for 3 days before each visit. 
NB:  As the subjects to be randomised are on stable steroids, the recommended national 
immunisation schedule, including varicella immunity, should be completed (i.e., as 
recommended in the “Diagnosis and Management of Duchenne Muscular Dystrophy” 
guideline4), before the Screening Visit.  However, in the case of live or live attenuated 
vaccines to be administered during the study, the Investigator must carefully monitor the 
subject, and while the decision of the Investigator cannot be influenced, deleted nor approved 
by the Medical Monitor, it is advised but not mandatory that the Investigator discuss the case 
with the Medical Monitor before using these vaccines. 
9.1.2 Visit 3 - Randomisation (Week 0) 
At Visit 3, the following assessments will be performed: 
 Review eligibility criteria; 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 70 of 120 
 Record prior medications; 
 Perform a physical examination; 
 Measure vital signs (blood pressure, pulse rate, and body temperature); 
 Measure weight; 
 Perform a 12-lead ECG;  
 Collect blood samples for hematology;  
 Perform LTBP4 and Osteopontin genotype tests and collect DMD serum biomarkers; 
 Perform time to 4SC; 
 Perform NSAA and 6MWT;  
 Perform muscle strength test; 
 Randomise the child and dispense and account for study drug; 
 Subject diary dispensation 
 Assess AEs. 
Functional tests will be video recorded. 
Pulmonary function as assessed by spirometry at screening should be repeated if the test does 
not meet ATS/ERS criteria and/or the evaluator deems that a valid attempt to perform a 
correct maneuver has not been made by the subject. 
9.1.3 Visits 4 (Week 1, ±3 days) 
At Visit 4, after 1 week (± 3 days) of treatment, the following assessments will be performed: 
 Record concomitant medications; 
 Perform a physical examination; 
 Measure vital signs (blood pressure, pulse rate, and body temperature); 
 Measure weight; 
 Perform a 12-lead ECG (at 2,5 hour ±30 minutes  after drug intake);  
 Collect blood samples for hematology;  
 Assess AEs. 
9.1.4 Visits 5, 6 and 8 (Weeks 2, 3 and 6, ±3 days) 
Note: Visits 5, 6, and 8 may be performed by Investigator’s authorized personnel outside the 
site location (e.g., at the subject’s home by a local qualified nurse trained in the study 
protocol or at the subject’s General Practitioner’s practice) if the following conditions are 
met: 
 the Investigator is confident that there is no medical concern to do so; 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 71 of 120 
 all study procedures will be followed as per protocol and as per Good Clinical 
Practices (GCP), and with the same quality standard as if being at the site; 
 all required local regulation, insurance and contracting obligation are respected. 
The Visits 5, 6, and 8 will performed respectively 2, 3 and 6 weeks after the Randomization 
Visit (± 3 days), and the following assessment will be performed: 
 Collect blood samples for hematology (the sample will be shipped to the central 
laboratory); 
 Assess AEs; in case of the visit will be performed by the subject’s General 
Practitioner’s, the Investigator will call the subject’s parent/legal guardian to inquire 
if any AE is occurred. 
9.1.5 Visit 7 (Week 4, ±3 days) 
At Visit 7, after 1 month of treatment (± 3 days), the following assessments will be 
performed unless otherwise noted: 
 Record concomitant medications; 
 Perform a physical examination; 
 Measure vital signs (blood pressure, pulse rate, and body temperature); 
 Measure weight; 
 Perform a 12-lead ECG (at 2,5 hours ±30 minutes after drug intake);  
 Collect blood samples for hematology and biochemistry (only TSH, fT3, fT4);  
 Obtain PK blood sample;   
 Dispense and account for study drug ; 
 Subject diary dispensation and evaluation of drug compliance through diary; 
 Perform acceptability/palatability evaluation; 
 Assess AEs. 
9.1.6 Visits 9 (Week 8, ± 3 days)  
At Visit 9, after 2 months of treatment (± 3 days), the following assessments will be 
performed: 
 Record concomitant medications; 
 Perform a physical examination; 
 Measure vital signs (blood pressure, pulse rate, and body temperature); 
 Measure weight; 
 Perform a 12-lead ECG ( at 2,5 hours ± 30 minutes after drug intake);  
 Collect blood samples for:  


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 72 of 120 
o hematology; 
o blood chemistry; 
o coagulation tests (PT and aPTT); 
 Obtain a urine sample for urine analysis; 
 Dispense and account for study drug;  
 Subject diary dispensation and evaluation of drug compliance through diary;  
 Assess AEs. 
9.1.7 Visits 10 – 14 (Weeks 12-60, ± 7 days)  
The Visits 10, 11, 12, 13 and 14 will respectively happen after 12, 24, 36, 48 and 60 weeks 
after the Randomization Visit, with a visit window of ± 7 days. 
At Visit 10 – 14  (i.e., every 3 months), the following assessments will be performed unless 
otherwise noted: 
 Collect and record concomitant medications; 
 Perform a physical examination; 
 Measure vital signs (blood pressure, pulse rate, and body temperature); 
 Measure weight; 
 Measure height (only at Visits 11 and 13; i.e., after 6 and 12 months of treatment) ; 
 Perform a 12-lead ECG (at 2,5 hours ±30 minutes after drug intake); 
 Perform pulmonary function tests: FEV1, FVC, FEV1/FVC, and PEF (only at 
Visit 13);  
Pulmonary function as assessed by spirometry at visit 13 should be repeated if the test 
does not meet ATS/ERS criteria and/or the evaluator deems that a valid attempt to 
perform a correct maneuver has not been made by the subject. 
 Collect blood samples for:  
o hematology; 
o blood chemistry; 
o coagulation tests (PT and aPTT);  
 Collect DMD serum biomarkers (only at Visit 13); 
 Obtain a urine sample for urine analysis; 
 Perform Quality of Life tests (assessed by PODCI) (only at Visit 13; i.e., after 
12 months of treatment); 
 Perform time to 4SC 
 Perform NSAA and 6MWT; 
 Perform muscle strength tests;  
 Obtain PK blood sample (only at Visits 10, 11, and 13; i.e., after 3, 6, and 12 months 
of treatment, respectively); 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 73 of 120 
 Dispense and account for study drug;  
 Subject diary dispensation and evaluation of drug compliance through diary;  
 Assess AEs; 
 Perform MRI/MRS evaluation  (MR cohort only) (only at Visit 13; i.e., after 12 
months of treatment). 
 
At Visit 13, functional tests will be video recorded. 
9.1.8 Visit 15: End of Study Visit (also named “EOS Visit”, Week 72 ± 7 days), and early 
withdrawal visit  
At the end of the treatment (i.e.,  72 weeks after the Randomization Visit, ± 7 days) the EOS 
Visit (Visit 15) will be scheduled.  At EOS Visit the subject should take the morning dose at 
the site. 
Subjects who prematurely withdraw from the study for any reason will perform an Early 
Withdrawal Visit within two weeks after the last study drug dose intake. The Early 
Withdrawal Visit requirements are the same as the EOS Visit (Visit 15) described in this 
section. 
If the Early Withdrawal Visit or the EOS Visit is not done, the reason will be recorded in the 
CRF.  
At this Visit 15, the following assessments will be performed unless otherwise noted: 
 Collect and record concomitant medications; 
 Perform a physical examination (at V15 assessment for ankle ROM should be done) 
 Measure vital signs (blood pressure, pulse rate, and body temperature); 
 Measure weight; 
 Measure height; 
 Perform a 12-lead ECG (at 2,5 hours  ±30 minutes after drug intake);  
 Perform an ECHO; 
 Perform pulmonary function tests: FEV1, FVC, FEV1/FVC, and PEF; 
 Collect blood samples for:  
o hematology; 
o blood chemistry: 
o coagulation tests (PT and aPTT);  
 
Collect DMD serum biomarkers; 
 Obtain a urine sample for urine analysis; 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 74 of 120 
 Obtain PK blood sample. The remaining PK samples may be drawn during this visit 
in order to obtain all required PK samples; 
 Perform Quality of Life test (assessed by PODCI); 
 Perform time to 4SC 
 Perform NSAA and 6MWT; 
 Perform muscle strength tests  
 Perform cognitive function evaluation (test should be performed at the beginning and 
at the end of the study, at the same time of the day); 
 Perform acceptability/palatability evaluation; 
 Evaluation of drug compliance through diary;  
 Assess AEs; 
 Perform MRI/MRS evaluation (MR cohort only). (If the subject is discontinued from 
the study treatment, the subject will be asked to return for the early withdrawal visit 
to be performed within 2 weeks of the last dose of study drug.  In this case, the 
cognitive function evaluation and MRI/MRS may not be performed). 
 
Functional tests will be video recorded. 
The subject has to be asked to attend an unscheduled visit to repeat measurement of 
pulmonary function as assessed by spirometry if the test performed at visit 15 has not met 
ATS/ERS criteria and/or the evaluator has deemed that a valid attempt to perform a correct 
maneuver was not made by the  subject. 
At visit 15, the subject’s parent/legal guardian will be asked to consent in writing and subject 
to assent and/or consent in writing for his participation in the long-term  study. In case the 
subject or parent/legal guardian do not provide assent/consent, a final Follow-up visit will be 
performed.   
9.1.9 Follow up Visit (Week 76)( ± 7 days) 
The follow up visit will be performed 4 weeks after the last dose is administered (± 7 days) 
and only in case the subject or parent/legal guardian do not provide assent/consent to 
participate in long-term study.  
The following assessments will be performed:  
 Collect and record concomitant medications; 
 Perform a physical examination; 
 Measure vital signs (blood pressure, pulse rate, and body temperature); 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 75 of 120 
 Perform a 12-lead ECG;  
 Collect blood samples for:  
o hematology;  
o blood chemistry;  
o coagulation tests (PT and aPTT); 
 Obtain a urine sample for urine analysis; 
 Assess AEs. 
9.1.10 Unscheduled Visits 
The Investigator may, at his/her discretion, arrange for a subject to have an unscheduled 
assessment, especially in the case of AEs that require follow-up or an AE considered by the 
Investigator to be possibly related to the use of study drug.  The unscheduled visit page in the 
eCRF must be completed. If needed, these assessments may be performed at the subject’s 
home by a local qualified personell trained in the study protocol.  
9.2 
Study Conclusion  
The end of the trial is defined as the date of the last visit of the last subject undergoing the 
trial. 
10 EFFICACY ASSESSMENTS 
10.1 Primary Efficacy Assessment 
The primary efficacy assessment for this study is the time to climb 4 standard stairs (at 
18 months). 
The time to climb 4 standard-sized stairs is a TFT that represents stair climbing ability.  The 
test will be evaluated by qualified functional evaluators (i.e., physiotherapists) who will be 
different from the site personnel who will review subjects’ safety results; safety results must 
not be shared with site personnel.  The test will be performed in a standardized manner 
described in a specific site manual. 
In addition to the time to climb 4 standard-sized stairs recorded in seconds, functional 
adaptation employed by the subject during the test will be evaluated and graded by functional 
evaluators according to standardized scales as follows: 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 76 of 120 
1. Unable to climb up 4 standard stairs; 
2. Climbs 4 standard stairs “marking time” (climbs one foot at a time, with both feet on a 
step before moving to next step), using both arms on one or both handrails; 
3. Climbs 4 standard stairs “marking time” (climbs one foot at a time, with both feet on a 
step before moving to next step), using one arm on one handrail; 
4. Climbs 4 standard stairs “marking time” (climbs one foot at a time, with both feet on a 
step before moving to next step), not needing handrail; 
5. Climbs 4 standard stairs alternating feet, needs handrail for support; 
6. Climbs 4 standard stairs alternating feet, not needing handrail support. 
10.2 Secondary Efficacy Assessments (All Subjects) 
The secondary key efficacy assessments (all subjects) in the target population are: 
 Time to rise from floor; 
 Distance done in 6 walking minutes by 6MWT; 
 Physical function assessed by NSAA; 
 Muscle strength evaluated by knee extension, elbow flexion as measured by HHM. 
 Fat fraction of vastus lateralis muscles evaluated by MRS technique (MR cohort) 
The exploratory efficacy assessments are: 
 Time to walk/run 10 meters; 
 Quality of life (assessed by PODCI);  
 %-predicted  6MWT; 
 MRI parameters (e.g., fat fraction of thigh muscles, CSA of vastus lateralis and other 
thigh muscles, etc) only in the MR cohort; 
 Time to 10% persistent worsening in 6MWT (Baseline through end of study); 
 Proportion of subjects with ≥10% worsening in 6MWT at end of study; 
 Time to loss of standing (Baseline through end of study); 
 Proportion of subjects who loose ambulation during the study; 
 Evaluation of any correlation between the effect of Givinostat on disease progression and 
the type of DMD mutation, LTBP4 and Osteopontin genotype; 
 Evaluation of any possible DMD serum biomarker.  
As for the primary efficacy assessment, all the functional and strength assessments will be 
evaluated by qualified functional evaluators (i.e., physiotherapists) who will be different 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 77 of 120 
from the site personnel who will review subjects’ safety results. The safety results must not 
be shared with physiotherapists.  
To limit variability associated with functional evaluators ‘drift’ in performing trial 
assessment across the course of the study, to ensure compliance with functional evaluator 
manual procedures, and valid conduct of assessments, some screening, baseline, 12 month 
and final study visits will be videoed and reviewed for quality assurance across all subjects. 
The videos: will be uploaded to a central secure repository and reviewed only by an expert 
and independent team engaged to train and qualify the site functional evaluators. 
Time taken to stand from a supine position and time to walk/run 10 meters are TFTs.  Timed 
function tests provide a measure of functional capability in ambulatory subjects, which is 
complementary to the 6MWT. The TFTs will be performed in a standardized manner 
described in a specific site manual. 
Six-minute walking test: a modified version of the 6MWT recommended by American 
Thoracic Society (2002) for use in adults will be performed.  
North Star Ambulatory Assessment:  the 17 items of the NSAA, ranging from standing to 
running 10 meters, will be graded using the standard score card with each assessment rated as 
0 – unable to achieve independently, 1 – modified method but achieves goal independent of 
physical assistance from another, or 2 – normal with no obvious modification of activity. 
Muscle strength: using HHM, the muscle strength of knee extensor and elbow flexor will be 
measured following standardized procedures; bilateral assessments will be done, and 
3 measurements will be recorded from each muscle group on each side.   
Quality of Life (QoL): the QoL will be measured via the American Academy of Orthopaedic 
Surgeons Pediatric Musculoskeletal Function Instrument, also referred to as PODCI.  The 
PODCI will be administered to the parent/legal guardian of subjects.  The PODCI is 
comprised of several dimensions that assess upper extremity function, transfers and mobility, 
physical function and sports, comfort/pain (pain-free), and happiness.  There is also a scale 
for global functioning, which is a combination of the 3 function subscales and comfort.  


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 78 of 120 
MR Cohort 
The MRI and MRS will be centralized in a referred qualified site.  Therefore, some subjects 
will be asked to perform the examination at a site that is different from the study site. 
The MRI/MRS personnel involved will be different from the site personnel.  They will not 
review subjects’ safety results; safety results must not be shared with them.  Moreover, the 
MRI/MRS images will be centrally read by an Independent Central Review team.  A 
qualification process will be implemented in order to improve data quality and decrease 
inter-site variability and the test will be performed in a standardized manner described in a 
specific site manual. 
All subjects will perform the baseline MRI/MRS tests. –All 110 randomised subjects in the 
target population (i.e. Group A: subjects with a baseline vastus lateralis muscle fat fraction 
assessed by MRS  in the range >5 and ≤30%),  will be included in the MR cohort. 
The subjects will perform the Dixon MRI and MRS on the thigh muscles without receiving 
general anesthesia.  The MRI/MRS images will be read to evaluate the fat fraction of each 
muscle.  A cross sectional area of muscles will be evaluated as well. 
11 PHARMACOKINETICS  
11.1 Pharmacokinetic Sampling 
11.1.1 Blood Samples 
Blood samples for PK analysis of givinostat and its metabolites will be collected.    All of the 
PK sampling visits are  indicated in the Schedule of Assessments (Table 4).  There are 5 
visits where the PK samples can be taken: Visits 7 (Week 4), 10 (Week 12), 11 (Week 24), 
13 (Week 48), and 15 (Week 72).  
All subjects will have a total of 6 PK blood specimens drawn during the study: 
 Two samples drawn pre-dose, these 2 specimens must be drawn at 2 different visits; 
 One sample drawn between 0 and 2 hours post-dose; 
 One sample drawn between 2 and 4 hours post-dose; 
 One sample drawn between 4 and 6 hours post-dose; 
 One sample drawn between 6 and 10 hours post-dose. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 79 of 120 
During Visits 7 (week 4), 10 (week 12), 11 (week 24), 13 (week 48) and 15 (week 72) at 
least one PK sample is collected for each subject. After the randomization, the site personnel 
will be informed at which time the PK samples will be drawn during these visits.  
On the day when the pre-dose PK blood is drawn, subjects should be instructed to take the 
morning dose at the site. 
For the PK draws, the parent/legal guardian must be reminded to provide the date and time of 
the last evening dose from the day before the visit, which will be recorded in the source 
documents and eCRF together with the date and time of the blood draws prior to the morning 
intake of the compound.  
For the post-dose blood draws, the date and time of the dose prior to the blood draws and the 
date and time of blood draws will be recorded in the source documents and eCRF.  
The date and time of the first dose will be recorded in the source documents and eCRF for 
each subject. 
In case the subject is withdrawn from the study prematurely, if not all PK samples were 
obtained prior to early withdrawal, the remaining PK samples may be drawn during the Early 
Withdrawal Visit  in order to obtain all required PK samples. 
Specific details regarding collection, handling, processing, storage, and shipment of PK 
samples can be found in a separate laboratory manual (found in the relevant section of the 
Investigator File). 
11.2 Pharmacokinetic Analytical Methodology 
The concentration of givinostat and its main metabolites will be determined from the plasma 
samples using a validated analytical method.  Details of the method validation and sample 
analysis will be included with the final Clinical Study Report (CSR).  
12 SAFETY ASSESSMENTS 
Safety and tolerability will be evaluated by monitoring hematology and blood chemistry, 
coagulation, urinalysis; by measurement of vital signs, physical examinations, weight, height, 
ECHO and ECG recording; and by respiratory function evaluation, cognitive function and 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 80 of 120 
acceptability/palatability evaluation and by AEs recording to be performed at protocol-
specified visits, as specified in the Schedule of Assessments, Table 6. 
12.1 Vital Signs 
Vital signs (body temperature, heart rate, systolic and diastolic blood pressure measurements) 
will be evaluated at the visits indicated in the Schedule of Assessments, Table 6.  All vital 
signs will be measured after the subject has been resting in a sitting position for at least 
5 minutes.  Blood pressure measurements are to be taken in the same arm for the duration of 
the study.  Body weight (without shoes) and height (without shoes) will be recorded at the 
visits indicated in the Schedule of Assessments, Table 6. 
Vital sign measurements will be repeated if clinically significant or machine/equipment 
errors occur.  Out-of-range blood pressure or heart rate measurements will be repeated at the 
Investigator’s discretion.  Any confirmed, clinically significant vital sign measurements must 
be recorded as an AE. 
12.2 Physical Examination 
A complete physical examination (head, eyes, ears, nose, and throat (HEENT), heart, lungs, 
abdomen, skin, lymph nodes, extremities and nervous system) will be performed at 
Screening (Visit 1).  Physical examinations will be performed by a physician.  In addition, 
medical history will be recorded at screening. 
A limited physical examination to verify continued subject eligibility and to follow up on any 
change in medical history will be performed at the visits indicated in the Schedule of 
Assessments, Table 6.  All changes not present at baseline or described in the past medical 
history and identified as clinically noteworthy must be recorded as AEs. 
12.3 Electrocardiogram 
A 12-lead resting ECG will be obtained at the visits indicated in the Schedule of 
Assessments, Table 6. 
At the Screening Visit, the Investigator will examine the 3 ECG traces for signs of cardiac 
disease that could exclude the subject from the study.  An assessment of normal or abnormal 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 81 of 120 
will be recorded.  If the ECG is considered abnormal, the abnormality will be documented on 
the CRF.  If an ECG demonstrates a prolonged QTcF interval (i.e.>450 msec) at the defined 
timepoints (see Schedule of Assessments, Table 6), the Investigator will obtain 2 more ECGs 
over a brief period (5 minutes between recordings), and then use the averaged QTcF value of 
the 3 ECGs.  If the averaged QTcF value meets the stopping criteria, the subject has to 
interrupt the study drug, the Medical Monitor  must be informed and the mean QTcF value 
must be confirmed by central reading.   
During the study, ECG should be performed at 2,5 hours ± 30 minutes after drug intake. 
The QTc has to be calculated with the Fridericia formula QTc = QT/RR1/3. 
Electrocardiograms will be repeated if clinically significant abnormalities are observed or 
artifacts are present. 
12.4 Echocardiogram 
Standard ECHOs will be conducted at the visits indicated in the Schedule of Assessments,  
Table 6, and more often if clinically indicated. 
12.5 Respiratory Function Test 
Forced expiratory volume at 1 second (FEV1), FVC, FEV1/FVC, and PEF, will be collected 
as per the site’s standard process at the visits indicated in the Schedule of Assessments, Table 
6 and more often if clinically indicated.  
At each assessment, three studies with maximal effort will be attempted by each subject, and 
the experienced technician performing the testing will make the determination if the effort 
will be acceptable.  All the study results will be recorded in the eCRF. 
12.6 Cognitive Function Test 
 
A general cognitive function test will be performed at the visits indicated in the Schedule of 
Assessments, Table 6 using the Raven coloured progressive matrices test. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 82 of 120 
12.7 Acceptability/Palatability Evaluation 
At Visit 7 (i.e. at the end of the first month of treatment) and 15 (i.e. at the end of the study), 
the palatability of the oral suspension will be evaluated using the Five-Point Hedonic Scale 
palatability. 
The investigator will explain to the child that he would be asked "how much did you like the 
taste of this medicine?" and encourage to indicate his preference by pointing to the 
appropriate face that depicts five degrees of pleasure: 
5= like very much 
4= like a little 
3= not sure 
2= dislike a little 
1= dislike very much. 
The explanation will be repeated if the child did not understand. 
 
Figure 12-2:  Five Point Hedonic Scale - Face Descriptions 
 
In addition, the acceptability/ palatability will be also indirectly assessed in parents with two 
questions: 
1. "On the basis of reaction / facial expression of your child, do you think that the medication 
is: pleasant= 3; not sure= 2; or unpleasant= 1?" 
2. "Do you sometimes have problems in giving the medication to your child because he 
refuses to take it or throws it up? (Yes / No)" 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 83 of 120 
12.8 Laboratory Assessments 
Laboratory assessment samples, Table 7, will be obtained at designated visits as detailed in 
the Schedule of Assessments, Table 6. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 84 of 120 
Table 7: 
Laboratory Assessment Samples 
Hematology 
Serum chemistry 
Urine analysis 
(dipstick) 
Coagulation 
 Hematocrit (Hct) 
 Hemoglobin (Hb) 
 Mean corpuscular 
hemoglobin (MCH) 
 Mean corpuscular 
hemoglobin 
concentration (MCHC) 
 Mean corpuscular 
volume (MCV) 
 Platelets count 
 Red blood cell (RBC) 
count  
 White blood cell (WBC) 
count  
 with differential  
 
 Albumin 
 Alanine aminotransferase 
(ALT) 
 Alkaline phosphatase (ALP) 
 Amylase 
 Aspartate aminotransferase 
(AST) 
 Bicarbonate 
 Blood Urea Nitrogen (BUN)  
 Calcium 
 Chloride 
 Cystatin C 
 Creatinine 
 Creatine kinase  
 C-reactive protein (CRP) 
 Gamma-glutamyl 
transpeptidase (GGT) 
 Glucose  
 Lactate dehydrogenase 
(LDH) 
 Potassium 
 Phosphorus 
 Sodium 
 Total bilirubin 
 Direct bilirubin 
 Total protein 
 Thyroid-stimulating 
hormone (TSH) 
 Tryglicerides 
 Total cholesterol 
 Low-Density Lipoprotein 
(LDL) 
 High-Density Lipoprotein 
(HDL) 
 fT3 (free T3 – the active part 
of triiodothyronine) 
 fT4 (free T4 – the active part 
of thyroxine) 
 Uric acid 
 Appearance 
 pH 
 Protein 
 Glucose 
 Ketone bodies 
 Indicators of 
blood and WBCs 
 Specific gravity 
 Urobilinogen 
 
 Prothrombin 
time (PT) 
 Activated partial 
thromboplastin 
time (PTT) 
Blood and urine samples will be analysed at a central laboratory facility.  Urine samples will 
be analyzed by dipstick, and a microscopic analysis will be performed if the results of 
dipstick indicate abnormalities to be further investigated.  All laboratory reports must be 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 85 of 120 
reviewed, signed, and dated by the Investigator.  A legible copy of all reports must be filed 
with the medical record (source document) for that visit.  Any laboratory test result 
considered by the Investigator to be clinically significant should be considered an AE.  
Clinically significant abnormal values occurring during the study will be followed until 
repeat test results return to normal, stabilize, or are no longer clinically significant.  
12.9 Adverse Events 
12.9.1 Definitions 
Adverse Events:  
An AE is “any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment (International Conference on Harmonisation [ICH] E2A).”  
Study drug includes both the investigational drug under evaluation and the comparator drug 
or placebo.  Medical conditions that were present before starting study drug are only 
considered AEs if they worsen after the subject has started the study drug.  Abnormal 
laboratory values or test results constitute AEs only if they induce clinical signs or 
symptoms, are considered clinically significant, or require treatment.  All medical and 
psychiatric conditions (except those related to the indication under study) present at 
screening will be documented in the medical history CRF.  Changes in these conditions and 
new symptoms, physical signs, syndromes, or diseases should be noted on the AE CRF page 
during the rest of the study.  Clinically significant laboratory abnormalities should also be 
recorded as AEs.  Surgical procedures that were planned before the subject enrolled in the 
study are not considered AEs if the conditions were known before study inclusion; the 
medical condition should be reported in the subject’s medical history. 
Adverse Drug Reaction: 
In the pre-approval clinical experience with a new medicinal product: “all noxious and 
unintended responses to a medicinal product related to any dose should be considered an 
Adverse Drug Reaction (ADR).”  The phrase “responses to a medical product” means that a 
causal relationship between a medical product and an AE is at least a reasonable possibility, 
i.e., the relations cannot be ruled out. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 86 of 120 
Regarding marketed medicinal products, a well-accepted definition of an adverse drug 
reaction in the post-marketing setting is found in WHO Technical Report 498 [1972] and 
reads as follows:  “A response to a drug which is noxious and unintended and which occurs 
at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for 
modification of physiological function.”  
Unexpected Adverse Drug Reaction - An unexpected ADR is an ADR, the nature or severity 
of which is not consistent with the applicable product information (i.e., Sections 7 and 8 of 
the current IB for ITF2357 Givinostat Hydrochloride Monohydrate). 
Serious Adverse Event: 
An SAE (experience) or reaction is any untoward medical occurrence that at any dose: 
 is fatal (results in the outcome death) 
 is life-threatening* 
 requires in-patient hospitalisation or prolongation of existing hospitalisation 
 results in persistent or significant disability/incapacity 
 is a congenital anomaly/birth defect 
 is medically significant or requires intervention to prevent one or other of the outcomes 
listed above 
*The term “life-threatening” refers to an event in which the subject is at risk of death at the time of the event; it 
does not refer to an event that hypothetically may cause death if it is more severe. 
In addition, any suspect of transmission of infective agents through study drug must be 
reported to the Sponsor as a SAE as medically significant event. 
Other important medical events that may not be immediately life-threatening or result in 
death or hospitalisation, based upon appropriate medical judgment, are considered SAEs if 
they are thought to jeopardize the subject and/or require medical or surgical intervention to 
prevent one of the outcomes defining a SAE.   
A pre-planned hospitalisation should not be considered an SAE. 
A Suspected Unexpected Serious Adverse Reaction (SUSAR) is referred to an ADR that 
complies with both the definitions of “serious” and “unexpected.” 
12.9.2 Adverse Event Reporting 
The Investigators or their designees are requested to collect and assess any spontaneous AE 
reported by the subject or their parent/legal guardian and to question the subject or their 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 87 of 120 
parent/legal guardian about AEs and under current illnesses at each visit during the treatment 
period and any follow-up visit performed to monitor any drug-related AE that is still ongoing 
beyond the last scheduled visit until recovery. The questioning of subject or their parent/legal 
guardian regarding AEs is generalized such as: “How have you been feeling since your last 
visit?”  
Any AE occurring from the Informed Consent signature up to the first study drug intake will 
be recorded on the medical history section of the CRF as baseline condition, while any AE 
occurring after a subject has intake the first study treatment up to the follow-up study visit, 
whether volunteered by the subject/parent/legal guardian, discovered during general 
questioning by the Investigators or detected through physical examination, laboratory test or 
other means will be recorded on the specific section of the CRF.  
Each AE will be described by:  
 seriousness; 
 duration (start and end dates); 
 severity; 
 relationship with the study drug; 
 action taken.  
The severity of AE should be assessed and graded according to the most recently published 
National Cancer Institute Common Terminology Criteria for AE (CTCAE v. 4.03, 
14th June 2010).  
The relationship with the study drug should be assessed as: 
 related to study drug; 
 not related to study drug; 
 unknown.  
The assessment of the relationship of an adverse event with the administration of study drug 
is a clinical decision based on all available information at the time of the completion of the 
CRF. 
An assessment of “Related” indicates that there is a reasonable suspicion that the AE is 
associated with the use of the study drug. 
An assessment of “Not related” would include the existence of a clear alternative 
explanation, or non-plausibility. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 88 of 120 
An assessment “Unknown” indicates there is not a reasonable suspicion that the AE is 
associated with the use of the study drug and at the same time there is not the existence of a 
clear alternative explanation or non-plausibility.  In this case, Investigator has to collect all 
possible information in order to assess the relationship with the study drug, particularly in 
case of SAEs. 
Factors to be considered in assessing the relationship of the AE to study drug include: 
 The temporal sequence from study drug administration; 
 The recovery on discontinuation and recurrence on reintroduction; 
 The concomitant diseases; 
 The evolution of the treated disease; 
 The concomitant medication; 
 The pharmacology and PK of the study drug; 
 The presence of an alternative explanation. 
Abnormal Laboratory Findings and Other Objective Measurements: 
Abnormal laboratory findings and other objective measurements should not be routinely 
captured and reported as AEs as they will be collected and analysed separately in the eCRF.  
However, abnormal laboratory findings and other objective measurements that meet the 
criteria for an SAE, result in discontinuation of the study drug or require medical 
intervention, or are judged by the Investigator to be clinically significant changes from 
baselines values should be captured and reported on the AE pages of the eCRF. 
When reporting an abnormal laboratory finding on the AE pages of the eCRF, a clinical 
diagnosis should be recorded in addition to the abnormal value itself, if this is available (for 
example “anaemia” in addition to “haemoglobin = 10.5 g/dl”). 
Baseline Medical Condition: 
Medical conditions present at the screening visit, that do not worsen in severity or frequency 
during the study are defined as baseline medical conditions and are not AEs.  These medical 
conditions should be adequately documented on the appropriate page of the eCRF, i.e., the 
medical history page.  However, medical conditions present at the initial study visits that 
worsen in severity or frequency during the study should be recorded and reported as AEs. 
 
 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 89 of 120 
12.9.3 Serious Adverse Event Reporting 
Any SAE, including death from any cause that occurs after subject/parent/legal guardian 
have signed the Informed Consent and up to the follow-up visit (regardless of relationship to 
study drug/comparator) must be reported by the Investigators to the Sponsor within 24 hours 
of learning of its occurrence. 
Serious adverse event reports must be made whether or not the Investigator considers the 
event to be related to the investigational drug. 
Related SAEs must be collected and reported regardless of the time elapsed from the last 
study drug administration, even if the study has been closed.  
As soon as an AE becomes serious, it will be recorded in the AE section of the eCRF and in 
the SAE form that will be automatically opened if the answer to the question “Was adverse 
event serious?” in the AE section is “yes.” A paper SAE Form will be also available as 
backup. 
Initial completion and follow-up reporting updates of the SAE eCRF page within the 
Electronic Data Capture (EDC) system will automatically send the SAE report directly to the  
Syneos Health Global Safety and Pharmacovigilance (GSPV) via secure email.  
This automated e-mail alert process supports the Investigator in the notification of SAEs to 
the Syneos Health GSPV.  Sufficient details must be provided to allow for a complete 
medical assessment of the AE and independent determination of possible causality.  The 
Investigators are obliged to pursue and provide additional information as requested by 
Italfarmaco S.p.A.  Corporate Drug Safety, or its designee or the Medical Monitor of the 
study or Clinical Research and Development Director, or his designee.  
The Investigator must notify the Sponsor and his designee of the SAE by completing the 
SAE reporting form available within the eCRF or, as a backup ONLY in case of technical 
issues, by faxing the SAE reporting form at the number specified below, within 24 hours of a 
SAE; then, only in case of SAE notification by fax (backup system) the Investigator must 
confirm any SAE notifications by mailing to the mail address or phoning to the phone 
number specified below: 
Syneos Health Pharmacovigilance Email: SafetyPV@syneoshealth.com 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 90 of 120 
Syneos Health Pharmacovigilance Fax Numbers:   
North America:  866-880-9343 
All other countries:  +44-1628-461184 
If notification cannot be made via these means due to technical delivery problems, initial 
notification may be made by telephone, using the SAE Hotline number: 
888-750-8020 
The same procedure must be applied to the SAE follow-up information.  Preliminary reports 
of SAEs must be followed by detailed descriptions later on, including clear and anonymized 
photocopies of hospital case reports, consultant reports, autopsy reports, and other documents 
when requested and applicable.   
Appropriate remedial measures should be taken to treat the SAE and the response should be 
recorded.  Clinical, laboratory and diagnostic measures should be employed as needed in 
order to determine the etiology of the problem.  All SAEs will be followed until the 
Investigator and Sponsor agree the event is satisfactorily resolved. 
Any SAE that is not resolved by the end of the study or upon discontinuation of the subject’s 
participation in the study is to be followed until it either resolves, stabilizes, returns to 
baseline values (if a baseline value is available), or is shown to not be attributable to the 
study drug or procedures. 
All serious and unexpected AEs that are associated with the use of the study drug (SUSARs) 
will be notified by the Drug Safety Manager to the Ethic Committees or Institutional Review 
Board and competent authority within the required time and following procedures required 
by applicable laws.  It is imperative that the Sponsor be informed as soon as possible, so that 
reporting can be done within the required time frame.  
12.9.4 Overdose 
In general, a drug overdose in a clinical study is defined as the accidental or intentional use 
of a drug or medicine in an amount exceeding the protocol defined dose.  The Investigator 
must immediately notify the Sponsor of any occurrence of overdose with study drug.  In this 
study, if an AE is associated with (“results from”) the overdose of givinostat/placebo, the AE 
is reported as a SAE, even if no other criteria for seriousness are met. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 91 of 120 
If a dose of givinostat/placebo meeting the protocol definition of overdose is taken without 
any associated clinical symptoms or abnormal laboratory results, the overdose is reported as 
a non-serious Event of Clinical Interest, using the terminology “accidental or intentional 
overdose without adverse effect.” 
Any instance of overdose (suspected or confirmed, with and without an AE) must be reported 
to the Sponsor within 24 hours and, only in case of AEs, it must be fully documented as a 
SAE.  Details of any signs or symptoms and their management should be recorded in the 
SAE Form including details of any antidote or systematic treatment administered.  Any signs 
or symptoms of over-dosage will be treated symptomatically.  
Any other situations putting the subject at risk of an adverse reaction, such as misuse and 
abuse, medication errors, suspect of transmission of infective agents must be reported to the 
Sponsor within 24 hours and be fully documented as a SAE. 
12.9.5 Pregnancy reporting 
Since it is possible to randomize adolescent fertile trial male subjects in this trial, the subject 
must be informed by the investigator that if it is suspected that his partner becomes pregnant 
during the study treatment or within 3 months days after the study treatment, he should 
inform the site personnel immediately of this pregnancy. 
If the Investigator is made aware that the partner of a subject who is participating to the study 
become pregnant, he/she is required to report within 24 hours the pregnancy, using the 
Pregnancy Notification Form available in the Investigator Study File, to Syneos Health 
Pharmacovigilance by mailing to the mail address or faxing numbers specified below:  
 Syneos Health Pharmacovigilance Email:  
SafetyPV@syneoshealth.com 
 Syneos Health Pharmacovigilance Fax Numbers:   
North America:  866-880-9343 
All other countries:  +44-1628-461184 
If notification cannot be made via these means due to technical delivery problems, initial 
notification may be made by telephone, using the SAE Hotline number: 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 92 of 120 
 888-750-8020 
Whenever possible, such pregnancy should be followed until termination, any premature 
termination should be reported, and the status of the mother and child should be reported to 
the sponsor after delivery. 
13 STATISTICAL ANALYSIS 
A Statistical Analysis Plan (SAP) will be prepared prior to the first planned interim analysis 
to provide full details on the methods described here and provide a complete description of 
the data presentations required for this study.  Changes to the statistical analysis planned in 
this protocol will be described in the SAP along with the rationale for the changes.  
The statistical evaluation will be performed using the latest available version of the Statistical 
Analysis Software (SAS®) (SAS Institute, Cary, NC).   
All data will be listed, and summary tables will be provided.  Summary statistics will be 
presented by dose group.  For continuous variables, data will be summarized with the number 
of subjects (N), mean, SD, median, minimum, and maximum by treatment group.  For 
categorical variables, data will be tabulated with the number and proportion of subjects for 
each category by treatment group. 
13.1 Overall Statistical Strategy 
This trial design a single planned interim analysis.  The interim will be governed by an 
IDMC. The interim analysis will be performed when the first N=50 subjects randomised in 
the target population have reached the 12 month time point.  The purpose of this interim is to 
solely assess futility on VL MFF and execute a blinded sample size re-estimation procedure, 
there will be no formal analyses for efficacy and no early stopping for efficacy and 
hence no alpha spend. 
13.2 Determination of Sample Size 
The sample size was originally calculated to provide 90% power and a 1-sided alpha of 2.5% 
to detect a true difference between givinostat and placebo in the target population in 4SC 18 
month change from baseline of 3 seconds, assuming a common SD of 6 seconds.  The 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 93 of 120 
estimated SD is based on publicly available Phase 3 study data on ataluren and drisapersen in 
subjects with DMD in addition to internal Italfarmaco data.    
The pre-planned interim analysis was performed in January 2020; it was concluded by the 
IDMC that futility on VLFF was not met and the trial should continue; hence the pre-planned 
blinded sample size re-assessment was performed.  The blinded within treatment SD for the 
change in 4CS from baseline to 18 months was estimated to be 3.094 seconds, approximately 
half of that assumed in the original power calculation. Based on this SD estimate, the revised 
sample size (utilizing a 2:1 randomisation scheme) N= 102 was calculated to provide 90% 
power and a 1-sided alpha of 2.5% to detect a true difference between givinostat and placebo 
in the target population, in 4SC 18 month change from baseline, of 2 seconds. With an 
estimated drop-out rate of 8%, a total of 110 subjects in the target population (Group A) will 
be randomized. 
For the MR cohort, the blinded SD estimate was 5.941%, being in line with the 6% SD 
assumed in the original power calculation, hence all the subjects in the target population will 
be included in the MR cohort.  
A total of 110 male ambulant subjects will be randomised in the target population (Group A). 
Up to 50 subjects (about 35% of the overall population) outside of the target may also be 
recruited into the study (Group B). The overall subjects population (Group A + Group B) will 
provide supportive data. 
13.3 Analysis Population 
13.3.1 Intent-To-Treat Population 
The Intent-to-Treat (ITT) target population will include all subjects in the target population 
who are randomised, irrespective of any deviation from the protocol or premature 
discontinuation.  The treatment group assignment will be designated according to initial 
randomisation.  The ITT target population will serve as the basis for the formal analysis of 
efficacy.  The overall ITT population will include all subjects in both the target and off-traget 
populations (Group A + Group B) who are randomised, irrespective of any deviation from 
the protocol or premature discontinuation.  The overall ITT population will be used for 
supportive efficacy analyses.  


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 94 of 120 
13.3.2 Safety Population 
The target Safety Population will include all randomised subjects in the target population 
who receive at least one dose of study drug.  The treatment group assignment in this 
population will be defined by the treatment actually received.  This population will be used 
for the evaluation of safety in the target population.   The overall Safety Population will 
include all randomised subjects in both the target and off-target population who receive at 
least one dose of study drug. The overall Safety Population will be used for supportive 
evaluations of safety.  
13.4 Demographic and Baseline Characteristics 
Demographic data and other baseline characteristics including medical history will be 
analysed based on the target safety population.  Summary statistics will be provided for all 
collected variables.  Continuous variables will be summarized by descriptive statistics, 
including mean, SD, median, minimum, and maximum.  Details of endpoint analyses will be 
described in the SAP. 
13.5 Investigational Medicinal Products 
The duration (days) of exposure of givinostat/placebo will be calculated for each subject in 
the target and overall populations, and will be summarized descriptively including the mean, 
SD, median, minimum, and maximum by treatment group and overall. 
In addition, the daily dosage (mg) of givinostat will be summarized for each subject in the 
target and overall populations, and will be summarized descriptively including the mean, SD, 
median, minimum and maximum. 
Reason for treatment discontinuation and number of subjects treated beyond 
protocol-specified discontinuation criteria will also be summarized in the target and overall 
populations.  Summaries will be based on the respective safety population. 
13.6 Prior and Concomitant Therapy 
Prior treatments, defined as those taken within 6 months prior to screening, should be 
recorded in the source documents as prior medications.  


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 95 of 120 
Concomitant treatments are defined as treatments taken after study drug administration.  
Prior and concomitant medications will be classified using the WHO-DRL drug dictionary 
(using the most recent version) and summarised in the target and overall populations.  
Summaries will be based on the respective safety population. 
13.7 Efficacy Analysis 
All formal efficacy analyses will be performed on the ITT target population; efficacy 
analyses in the overall population will be supportive and informal.  Descriptive statistics for 
qualitative data will include frequency tabulation and presentation of percentages.  
Descriptive statistics for quantitative data will include mean and SD or geometric mean, 
coefficient of variation, median and interquartile range.  
13.7.1 Analysis of the Primary Efficacy Endpoint 
The change in 4SC from baseline to 18 months will be evaluated in the target population.  
The data will be analyzed using an Analysis of Covariance (ANCOVA) model with the 
change in 4SC from baseline to 18 months as the dependent variable and with terms for 
baseline 4SC value as a covariate and randomised treatment, concomitant steroid use and age 
at baseline as independent class variables. Least squares means will be estimated for 
givinostat and placebo. The treatment effect, being the difference in Lsmeans, will be 
presented along with the associated 95% confidence interval and the p-value. Significance 
will be achieved if the 1-sided p-value is ≤0.025.   
13.7.2 Analysis of Key Secondary Efficacy Endpoints 
Analysis of Key Secondary Endpoints  
Formal analyses of functional key secondary endpoints (i.e., cumulative loss of function in 
the NSAA, change in 6MWT, NSAA, time to rise from floor and muscle strength by knee 
extension and elbow flexion) and Vastus lateralis MFF will take place in the target 
population at 18 months and will be achieved using the same approach as described for the 
primary /endpoint. Possible need for log transformation of these variables will be assessed 
prior to unblinding by assessment of ANCOVA model residuals without a treatment effect 
term.  


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 96 of 120 
13.7.3 Analysis of Exploratory Efficacy Endpoints 
Exploratory efficacy endpoints will be supportive only and not subject to alpha control; 
therefore nominal p-values will be presented. 
The mean change from baseline to 18 months will be compared between givinostat and 
placebo in the target population for: 
 Time to walk/run 10 meters; 
 Quality of life assessed by Paediatric Outcomes Data Collection Instrument (PODCI);  
 %-predicted 6MWT; 
These endpoints will be analyzed using methods in line with those described for the primary 
and key secondary endpoints.   
The fraction of subjects achieving the following endpoints at 18 months will be compared 
between givinostat and placebo in the target population: 
 Proportion of subjects with ≥10% worsening in 6MWT at end of study; 
 Proportion of subjects who loose ambulation during the study. 
These endpoints will be analysed using a logistic regression model with terms for 
randomised treatment, concomitant steroid use and age at baseline.  The odds for each 
treatment group will be extracted along with the odds ratio, associated 95% confidence 
interval and p-value.  
The following endpoints will be compared between givinostat and placebo in the target 
population using Cox proportional hazards modelling: 
 Time to 10% persistent worsening in 6MWT (Baseline through end of study); 
 Time to loss of standing (Baseline through end of study); 
The model will include terms for randomised treatment, concomitant steroid use and age at 
baseline.The hazard ratio will be extracted, along with the associated 95% confidence 
interval and p-value.  
Moreover, exploratory analyses will be done in the target population to explore whether the 
effects of givinostat versus placebo administered chronically may be related to the type of 
DMD mutation, LTBP4 and Osteopontin genotype or to the biomarkers.   


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 97 of 120 
13.8 Pharmacokinetic Analysis 
Nonlinear mixed effect models will be used for the evaluation of the population PK profile.  
The population PK analysis will be performed using NONMEM software (Version VI 
or later).   
The evaluation will be performed for describing the PK of givinostat and its major 
metabolites (ITF2374 and ITF2375) in the subject population and for identifying the relevant 
demographic and pathophysiological covariates. Separate PK models for givinostat and its 
metabolite will be developed.  
Additionally, the relationship of givinostat PK exposure to efficacy and safety endpoints in 
the target population will be explored as exploratory analyses.  
The Population PK approach will be based on the development of the following 3 models: 
1. Identification of the structural model that best describes the PK data in absence of 
covariates;  
2. Random Effect Models: defining the inter-individual variability and the residual 
error.  Different forms of residual error (additive, multiplicative or both) will be 
explored; 
3. Covariate Model: identifying the relevant demographic and pathophysiological 
covariates affecting the PK profile of the compound.  The selection of the covariates 
will be performed using an appropriate statistical methodology.  
Population PK procedures and analyses will be detailed in a separate “Population PK data 
analysis plan.” 
13.9 Safety Analysis 
Safety data will be evaluated descriptively in both the target and overall patient populations.  
The following parameters will be summarized: rates of discontinuation, AEs, and laboratory 
abnormalities. Adverse event data will be coded using the most updated version of Medical 
Dictionary for Competent Activities (MedDRA) dictionary. Adverse events will be 
summarized by treatment group for the number of subjects reporting the AE and the number 
of AEs reported.  Summaries will be performed for treatment-related AEs (TEAEs), SAEs, 
AEs that lead to withdrawal, severity of TEAEs, and relationship of TEAEs to study drug.  


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 98 of 120 
They will be presented by MedDRA System Organ Class (SOC) MedDRA Preferred Term 
and treatment group.  
Serious adverse events and AEs leading to discontinuation will be listed separately. 
A by-subject AE data listing including verbatim term, coded term, treatment group, severity, 
and relationship to treatment will be provided. 
Summary statistics will be presented for changes in vital signs, weight, height and BMI, in 
ECG parameters, in ECHO parameters, in respiratory function parameters, and cognitive 
function parameters.  Laboratory test values will be summarised similarly but will also 
include tabulation of the number of subjects shifting from within the reference range at 
baseline to outside of the reference range on randomised treatment. 
13.10  Interim Analysis  
A single interim analysis is planned and will be performed by the IDMC in the target 
population.  An IDMC charter will be prepared to describe the role, function and operations 
of the IDMC and the rules to be used when reviewing interim data.  
13.10.1 
Interim Analysis 
The interim analysis will be performed when the first N=50 subjects randomised in the target 
population have reached the 12 month time point.  In this interim analysis, the IDMC will 
evaluate the effects of givinostat versus placebo on the vastus lateralis MFF (VL MFF) in 
terms of futility.  Futility will be considered if the mean change from baseline to 12 months 
in VLMFF in the givinostat group is equal to or worse than that seen in the placebo group 
since the biologic plausibility of a subsequent treatment effect on 4SC time would be greatly 
diminished.  The IDMC will only communicate to the Sponsor whether the study should 
proceed or it should be stopped having met the futility criteria.  
If the IDMC indicates that the study should proceed, a blinded sample size re-estimation will 
be conducted for MFF and 4SC in the target population as follows:    
 To maintain the blind on the primary endpoint, the within treatment SD for the 
change from baseline will be estimated as  𝝈̂𝒘𝒊𝒕𝒉𝒊𝒏= √𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍
𝟐
−(
𝜟
𝟐)
𝟐
 where 𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍  
is the overall SD for the change from baseline in 4SC based on the n=50 subjects in 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 99 of 120 
the interim and 𝛥 is the originally hypothesized treatment effect, i.e., 𝛥= 3 seconds.  
Dependent upon the blinded SD estimate, the sample size may be decreased or 
increased to maintain 90% power. Any increase in sample size for 4SC will be 
limited to 1.5 times maximum of the initial target population sample size, i.e., to a 
maximum of 1.5 × 192 = 288 subjects.  For a 20% increase in the SD, this degree of 
increase in sample size will maintain 90% power, and for a 40% increase in SD 
power will be maintained at 80%. 
 
 With respect to VL MFF, a similar approach will be applied; the within treatment SD 
for the change from baseline will be estimated as  𝝈̂𝒘𝒊𝒕𝒉𝒊𝒏= √𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍
𝟐
−(
𝜟
𝟐)
𝟐
 where 
𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍  is the overall SD for the change from baseline in VL MFF and 𝛥 is the 
originally hypothesized treatment effect, i.e. 𝛥= 3.63% (i.e., 55% of 6.6%).  Dependent 
upon the blinded SD estimate, the sample size may be decreased or increased to 
maintain 90% power. Any increase in sample size required to assess MFF will also be 
limited to 1.5 times the required target population sample size stated in the preceding 
power calculation, to a maximum of 1.5 × 99 = 150 subjects.  
 
At the interim futility analysis, there will be no efficacy assessment, no unblinded analysis of 
the primary endpoint and, hence, no alpha spend nor early stopping of the study for efficacy.  
As noted above in Section 13.2, the interim analysis took place in January 2020; futility was 
passed and the blinded sample size reassessment followed.  The estimated SD for 4SC was 
approximately half of that assumed in the original power calculation.  Consequently, it was 
determined that a total of N=102 patients would be sufficient to test the hypothesis that 4SC 
was improved by at least 2 seconds with givinostat compared placebo. With allowance for a 
small dropout rate, a total of 110 male ambulant subjects will be randomised in the target 
population (Group A). Up to 50 subjects (about 35% of the overall population) outside of the 
target may also be recruited into the study (Group B). The overall subjects population (Group 
A + Group B) will provide supportive data. 
For the MR cohort, the blinded SD estimate was 5.941%, being in line with SD assumed in 
the original power calculation for VL MFF, hence all the subjects in the target population 
will be included in the analysis of the MR cohort. 
 
 
 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 100 of 120 
13.10.2 
Final  Analysis 
The final analysis will be performed when N=110 patients in the target population subjects 
have achieved 18 months follow-up.  The p-value applicable to the final analysis of 4SC will 
be p≤0.025 1-sided.    
13.11 Independent Data Monitoring Committee  
The IDMC will be established by the Sponsor to review accumulating safety data at regular 
intervals throughout the study and monitor overall study conduct.  The IDMC will review, 
evaluate, and categorise safety findings every 3 months during the study and will be 
responsible for oversight of the planned interim analysis as described in Section 13.10.  
Members will include at least 3 person, but are not limited to, a chairman, a clinician experts 
in DMD and a biostatistician, who are not participating in this study and do not have 
affiliation with the Investigators or the Sponsor.  The IDMC can recommend in writing to the 
Sponsor whether to continue, modify, or stop the clinical study on the basis of safety 
considerations.   
An IDMC charter will be prepared to describe the role, function and operations of the IDMC 
and the rules to be used when reviewing interim data. 
14 STUDY MANAGEMENT 
14.1 Approval and Consent 
14.1.1 Regulatory Guidelines 
The Investigator will ensure that this study is conducted in full conformity with the principles 
of the “Declaration of Helsinki” or with the laws and regulations of the country in which the 
research is conducted, whichever affords the greater protection to the individual.  
The study must fully adhere to the principles outlined in “Guideline for Good Clinical 
Practice” ICH Tripartite Guideline or with local law if it affords greater protection to the 
subject.  
For EU/EEA countries this study will be performed in accordance with EU and country 
regulation in force. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 101 of 120 
Moreover, this study will be performed in accordance to all relevant federal regulations, as 
set forth in Parts 50 “Protection of Human Subjects”, 56 “Institutional Review Boards”, 312 
“Responsibilities of Sponsors and Investigators”, Subpart D “GCP”, of Title 21 of the Code 
of Federal Regulations (CFR), and in compliance with Good Clinical Practice (GCP) 
guidelines. 
This study will also be carried out in accordance with SOPs of Italfarmaco S.p.A. and/or its 
designee. 
The Investigator agrees, when signing the protocol, to adhere to the instructions and 
procedures described therein and thereby to adhere to the principles of GCP to which it 
conforms. 
14.1.2 Institutional Review Board/Independent Ethics Committees 
The protocol, informed consent form, assent form, recruitment materials, and all participant 
materials will be submitted to the Independent Ethics Committee (IEC) or Institutional 
review Board (IRB) for review and approval.  This study will be undertaken only after 
approval of the protocol, informed consent form, assent form and all other materials 
described above, have been obtained from the appropriate IEC or IRB and a copy of the 
signed and dated approval has been received by Italfarmaco S.p.A.  The name and 
occupation of the chairman and the members of the IRB/IEC must be supplied to Italfarmaco 
S.p.A. or its designee.  The IRB/IEC must be informed of all subsequent protocol 
amendments and should be asked whether a re-evaluation of the ethical aspects of the study 
is necessary. 
If applicable, interim reports on the study and reviews of its progress will be submitted to the 
IRB/IEC by the Investigator at intervals stipulated in their guidelines.  At the completion or 
termination of the study, the Investigator must submit a close-out letter to the IRB/IEC and to 
Italfarmaco S.p.A. 
14.1.3 Independent Data Monitoring Committee 
An IDMC will be utilized in this study to ensure external objective medical and/or statistical 
review of safety issues in order to protect the ethical and safety interests of subjects and to 
protect the scientific validity of the study.  The IDMC also has the responsibility to monitor 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 102 of 120 
risk versus benefit considering factors external to the study when relevant information 
becomes available. 
The members of the IDMC act as advisors to the Sponsor to monitor subject safety and study 
progress. The IDMC will have the responsibility to provide the Sponsor with 
recommendations related to the protection of the subject’s safety, including stopping or 
amending the study protocol, the consent/assent forms, and the IB. 
During the study, the IDMC will review, evaluate and categorise safety findings every three 
months and will be responsible for the interim analyses (see section 13.10.10), which could 
result in recommendations to the Sponsor.  The IDMC will meet at predefined times and 
more frequently as needed. 
The IDMC will be also responsible to review any protocol amendments. 
The IDMC will operate under a written charter that includes a well-defined standard 
operating procedure.  The charter will be prepared to describe the role, function, and 
operations of the IDMC and the rules to be used when reviewing interim data. 
All members should have no financial, scientific, or other conflicts of interest with the study. 
IDMC meeting/phone call will include both an open and closed session, while the 
meeting/phone call with the Sponsor and Investigators will always be blinded session. 
14.1.4 Subject Informed Consent  
Prior to the beginning of the study, the Principal Investigator (PI) must have the IRB/IEC 
written approval/favourable opinion of the written Informed Consent/ Assent Form and any 
other written information to be provided to subject and legally accepted representative. The 
approved subject information letter/Informed Consent/Assent Form must be filed in the study 
files (clinical Trial Master File [TMF] and Investigator File [IF]).  For each study subject, a 
written Informed Consent Form the legally accepted representative will be obtained prior to 
any protocol related activities.  Informed assent or consent, if applicable, may be obtained 
from subjects who are capable of providing assent/consent.  As part of this procedure, the PI 
or a designated representative must explain orally and in writing the nature, duration, and 
purpose of the study, and the action of the drug in such a manner that the subject, the parent 
and, if applicable, appointed guardian are aware of the potential risks, inconveniences, or 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 103 of 120 
adverse effects that may occur.  Subjects and their legally accepted representatives should be 
given ample time and opportunity to inquire about the details of the study prior to deciding 
whether to participate in the study.  It is the responsibility of the Investigator to ensure that 
all questions about the study are answered to the satisfaction of the subjects and their legally 
accepted representatives.  
Subjects and their legally accepted representatives should be informed that subjects may 
withdraw from the study at any time.  They will receive all information that is required by 
local regulations and ICH guidelines.  The PI or a designated representative will provide the 
sponsor or its representative with a copy of the IRB/IEC approved ICF prior to the start of 
the study. 
The ICF should be signed and dated by the subject’s legally accepted representative and the 
Investigator on the same day.  If the subject and/or legally accepted representative are not 
able to read, an impartial witness should be present during the informed consent discussion, 
and the witness must co-sign and date the informed consent form.  The subject’s legally 
accepted representative and/or impartial witness should receive a copy of the signed 
documents.  
For details of the information provided, refer to the ICF. 
14.1.5 Discontinuation of the study by the Sponsor 
The Sponsor has the right to terminate this study at any time.  Reasons for terminating the 
study may include the following: 
 unsatisfactory subject enrolment;   
 inaccurate or incomplete quality or quantity of data recording; 
 incidence or severity of adverse drug reactions in this or other studies with study drug 
indicating a potential health hazard to subjects; 
 poor adherence to protocol and regulatory requirements; 
 plans to modify or discontinue the development of the study drug. 
14.1.6 Data Handling  
 
Data on subjects collected on eCRFs during the trial will be documented in an anonymous 
fashion and the subject will only be identified by the subject number. All the information 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 104 of 120 
required by the protocol should be provided and any omissions require explanation.  All 
eCRFs must be completed expeditiously after the subject’s visit. 
Any data to be recorded directly on the eCRFs (to be considered as source data) will be 
identified at the start of the study.  The Investigator must maintain source documents for each 
subject in the study.  Data reported on the eCRF that are derived from source documents 
should be consistent with the source documents, or the discrepancies must be explained. 
Clinical data will be entered on eCRFs, a 21 CRF Part 11 compliant, for transmission to the 
Sponsor.  Data on eCRFs transmitted via the web-based data system must correspond to and 
be supported by source documentation maintained at the study site, unless the study site 
makes direct data entry to the databases for which no other original or source documentation 
is maintained.  In such cases, the study site should document which eCRFs are subject to 
direct data entry and should have in place procedures to obtain and retain copies of the 
information submitted by direct data entry.  All study forms and records transmitted to the 
Sponsor must carry only coded identifiers such that personally identifying information is not 
transmitted.  The primary method of data transmittal is via the secure, internet-based EDC 
system.  Access to the EDC system is available to authorized users via the study’s Internet 
web site, where an assigned username and password are required for access.  
Any changes made to data after collection will be made through the use of Data Clarification 
Forms.  Case Report Forms will be considered complete when all missing and/or incorrect 
data have been resolved.  
14.2 Source Documents 
Source documents contain all information in original records and certified copies of original 
records of clinical findings, observations, data or other activities in a clinical study necessary 
for the reconstruction and evaluation of the study. All source documents should be completed 
in a neat, legible manner to ensure accurate interpretation of data. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 105 of 120 
14.3 Record Retention 
The Investigator must arrange for retention of study records at the site. The nature of the 
records and the duration of the retention period must meet the requirements of the relevant 
regulatory authority.   
In addition, because this is an international study, the retention period must meet the 
requirements of the most stringent authority.   
 The Sponsor and the Investigator shall archive the content of the clinical trial master file for 
at least 25 years after the end of the clinical study.  However, the medical files of subjects 
shall be archived in accordance with national law. 
The content of the clinical trial master file shall be archived in a way that ensures that it is 
readily available and accessible, upon request, to the competent authorities. 
Any transfer of ownership of the content of the clinical trial master file shall be documented. 
Any alteration to the content of the Investigator file shall be traceable and the Investigator 
should take measures to prevent accidental or premature destruction of these documents.  
14.4 Monitoring 
The study will be monitored to ensure that it is conducted and documented properly 
according to the protocol, GCP, and all applicable regulatory requirements.  
A site visit will be held prior to initiation of subject enrolment.  The protocol, eCRFs, study 
drug supplies and relevant procedures will be explained to the Investigators and his/her staff 
in detail at the site visit.  On-site monitoring visits will be made at appropriate times during 
the study. 
Clinical monitors must have direct access to source documentation in order to check the 
completeness, clarity, consistency of the data recorded in the eCRFs/CRFs for each subject 
and the adherence to the protocol and to GCP.  The clinical monitors will also check the 
progress of enrolment and the handling of study medication to ensure that study medication 
is being stored, dispensed, and accounted for according to specifications. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 106 of 120 
The Investigator will make available to the clinical monitor source documents and medical 
records necessary to complete eCRFs/CRFs.  No information in these records about the 
identity of the subjects will leave the study centre.  In addition, the Investigator and key trial 
personnel will work closely with the clinical monitor and, as needed, provide them 
appropriate evidence that the conduct of the study is being done in accordance with 
applicable regulations and GCP guidelines.  
Monitoring standard procedures require full verification for the presence of informed 
consent/assent, adherence to the inclusion/exclusion criteria, documentation of SAEs and the 
recording of primary efficacy and safety variables.  The Investigator is responsible for 
completing the CRFs expeditiously to capture all the relevant information, while the monitor 
is responsible for reviewing them and clarifying any data queries. 
14.5 Quality Control and Quality Assurance 
The Sponsor or its designee will perform the quality assurance and quality control activities 
of this study; however, responsibility for the accuracy, completeness, and reliability of the 
study data presented to the Sponsor lies with the Investigator generating the data. 
The Sponsor will arrange audits as part of the implementation of quality assurance to ensure 
that the study is being conducted in compliance with the protocol, Standard Operating 
Procedures, GCP, and all applicable regulatory requirements.  Audits will be independent of 
and separate from the routine monitoring and quality control functions.  Quality assurance 
procedures will be performed at study sites and during data management to assure that safety 
and efficacy data are adequate and well documented.  
A Regulatory Authority may also wish to conduct an inspection (during the study or even 
after its completion).  If an inspection is requested by a Regulatory Authority, the 
Investigator must inform Italfarmaco S.p.A. immediately that this request has been made. 
14.6 Protocol Amendment and Protocol Deviation  
14.6.1 Protocol Amendment 
Any change or addition to this protocol requires a written protocol amendment that must be 
approved by Italfarmaco S.p.A. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 107 of 120 
Amendments can be classified as substantial when impact one of the following criteria:  
 The safety or physical or mental integrity of the subject; 
 The scientific value of the study; 
 The conduct or management of the study; 
 The quality or safety of any IMP used in the study. 
Substantial amendments require the authorization to the Competent Authority and the 
positive opinion of the relevant IRB/IEC before implementation. 
In case of urgent safety measures to protect the subject against any immediate hazard, these 
measures may be taken without prior authorization from the Competent Authority or 
favourable opinion of the IRB/IEC.  In this case, the Competent Authority and IRB/IEC will 
be informed as soon as possible using the fastest means of communication followed by a 
written report. 
Amendments classified as non-substantial require only notification to the IRB/IECs involved. 
14.6.2 Protocol Deviations 
Should a protocol deviation occur, the Sponsor must be informed as soon as possible.  
Protocol deviations and/or violations and the reasons they occurred will be included in the 
CSR.  Reporting of protocol deviations to the IRB/IEC and in accordance with applicable 
Regulatory Authority mandates is an Investigator responsibility. 
14.7 Ethical Considerations 
This study will be conducted in accordance with the accepted version of the Declaration of 
Helsinki and/or all relevant federal regulations, as set forth in Parts 50, 56, 312, Subpart D, of 
Title 21 of the CFR, in accordance with European and country regulations in force and in 
compliance with GCP guidelines. 
The IRB/IEC will review and approve this protocol, the informed consent form, the assent 
form, the recruitment materials, and all participant materials.    
14.8 Financing and Insurance 
Prior to the study commencing, the Sponsor (or its designee) and the Investigator (or the 
institution, as applicable) will agree on costs necessary to perform the study.  This agreement 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 108 of 120 
will be documented in a financial agreement that will be signed by the Investigator (or the 
institution signatory) and the Sponsor (or its designee).  
The Investigator is required to have adequate current insurance to cover claims for 
negligence and/or malpractice.  The Sponsor will provide insurance coverage for the clinical 
study as required by national regulations. 
14.9 Publication Policy/Disclosure of Data and Confidentiality  
The Investigator must assure that subjects’ anonymity will be maintained and that their 
identities will be protected from unauthorized parties.  On eCRFs or other documents 
submitted to the Sponsor, subjects should not be identified by their names, but by an 
identification code.  The Investigator should keep an enrolment log showing codes, names 
and addresses. 
By signing the protocol, the Investigator agrees to keep all information provided by 
Italfarmaco S.p.A. in strict confidence and to request similar confidentiality from his/her staff 
and the IRB/IECs.  Study documents provided by Italfarmaco S.p.A. (protocols, IBs, eCRFs, 
and other material) will be stored appropriately to ensure their confidentiality.  The 
information provided by Italfarmaco S.p.A. to the Investigator may not be disclosed to others 
without direct written authorization from Italfarmaco S.p.A., except to the extent necessary to 
obtain informed consent from subjects who wish to participate in the study.  For USA sites, 
the Investigator agrees to comply with all applicable federal, state, and local laws and 
regulations relating to the privacy of subject health information, including, but not limited to, 
the Standards for Individually Identifiable Health Information, 45 CFR, Parts 160 and 164 
(the Health Insurance Portability Accountability Act of 1996 [HIPAA] Privacy Regulation).  
The Investigator shall ensure that study subjects authorize the use and disclosure of protected 
health information in accordance with HIPAA Privacy Regulation and in a form satisfactory 
to the Sponsor.  
Both the use of data and the publication policy are detailed within the clinical study 
agreement.  Intellectual property rights (and related matters) generated by the Investigator 
and others performing the clinical study will be subject to the terms of a clinical study 
agreement that will be agreed upon between the Institution and the Sponsor or their designee.  


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 109 of 120 
With respect to such rights, the Sponsor or its designee will solely own all rights and interests 
in any materials, data, and intellectual property rights developed by Investigators and others 
performing the clinical study described in this protocol, subject to the terms of any such 
agreement.  In order to facilitate such ownership, Investigators will be required to assign all 
such inventions either to their Institution or directly to the Sponsor or its designee, as will be 
set forth in the clinical study agreement. 
Italfarmaco S.p.A assures that the key design items of the Protocol will be published in a 
publicly accessible database such as “Clinicaltrials.gov.”  Moreover, upon completion of the 
study and finalization of the study report, the results of this study will be submitted for 
publication or posted in a publicly accessible data base.   
15 REFERENCES 
1. 
Mendell, J. R., C. Shilling, et al. (2012). “Evidence-based path to newborn screening 
for Duchenne muscular dystrophy.” AnNeurol 71(3): 304-313. 
2. 
Peverelli, L., et al. (2015). “Histologic muscular history in steroid-treated and 
untreated patients with Duchenne dystrophy.” Neurology. 
3. 
Forbes, S. C., R. J. Willcocks, et al. (2014). “Magnetic resonance imaging and 
spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne 
muscular dystrophy: a multicentre cross sectional study.” PLoS One 9(9): e106435. 
4. 
Bushby, K., R. Finkel, et al. (2010). “Diagnosis and management of Duchenne 
muscular dystrophy, part 2: implementation of multidisciplinary care.” Lancet Neurol 
9(2): 177-189). 
5. 
Manzur, A. and M. Pike (2009). “Glucocorticoid corticosteroids for Duchenne 
muscular dystrophy.” Cochrane Database Syst Rev. 
6. 
Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther T, Olsen JV, 
Mann M. Lysine acetylation targets protein complexes and co-regulates major 
cellular functions. Science. (2009); 325:834-40. 
7. 
Guha, M. (2015). “HDAC inhibitors still need a home run, despite recent approval.” 
Nat Rev Drug Discov 14(4): 225-226. 
8. 
Azuara, V., P. Perry, et al. (2006). “Chromatin signatures of pluripotent cell lines.” 
Nat Cell Biol 8(5): 532-538. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 110 of 120 
9. 
Bernstein, B. E., T. S. Mikkelsen, et al. (2006). “A bivalent chromatin structure marks 
key developmental genes in embryonic stem cells.” Cell 125(2): 315-326. 
10. 
Ervasti, J. M. (2007). "Dystrophin, its interactions with other proteins, and 
implications for muscular dystrophy." Biochim Biophys Acta 1772(2): 108-117. 
11. 
Colussi, C., et al. (2008). “HDAC2 blockade by nitric oxide and histone deacetylase 
inhibitors reveals a common target in Duchenne muscular dystrophy treatment.” Proc 
Natl Acad Sci U S A 105(49): 19183-19187. 
12. 
Consalvi, S., et al. (2011). “Histone deacetylase inhibitors in the treatment of 
muscular dystrophies: epigenetic drugs for genetic diseases.” Mol Med 17(5-6): 457-
465. 
13. 
Minetti, G. C., et al. (2006). “Functional and morphological recovery of dystrophic 
muscles in mice treated with deacetylase inhibitors.” Nat Med 12(10): 1147-1150. 
14. 
Saccone, V., et al. (2014). “HDAC-regulated myomiRs control BAF60 variant 
exchange and direct the functional phenotype of fibro-adipogenic progenitors in 
dystrophic muscles.” Genes Dev 28(8): 841-857. 
15. 
Leoni, F., Fossati, G., Lewis, E., Lee, J., Porro, G., Pagani, P., Modena, D., Moras, 
M., Pozzi, P., Reznikov, L., et al. 2005. The histone deacetylase inhibitor ITF2357 
reduces production of pro-inflammatory cytokines in vitro and systemic inflammation 
in vivo. Mol Med 11:1-15. 
16. 
Joosten, L. A., F. Leoni, et al. (2011). “Inhibition of HDAC activity by ITF2357 
ameliorates joint inflammation and prevents cartilage and bone destruction in 
experimental arthritis.” Mol Med 17(5-6): 391-396.) 
17. 
Boldrin L, Zammit PS, Morgan JE. Satellite cells from dystrophic muscle retain 
regenerative capacity. Stem cell research. 2015;14(1):20-9. 
18. 
Tierney MT, Aydogdu T, Sala D, Malecova B, Gatto S, Puri PL, et al. STAT3 
signaling controls satellite cell expansion and skeletal muscle repair. Nature 
medicine. 2014;20(10):1182-6. 
19. 
Doles JD, Olwin BB. The impact of JAK-STAT signaling on muscle regeneration. 
Nature medicine. 2014;20(10):1094-5. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 111 of 120 
20. 
Kerr, J. S., S. Galloway, et al. (2010). “Nonclinical safety assessment of the histone 
deacetylase inhibitor vorinostat.” Int J Toxicol 29(1): 3-19. 
21. 
Population PK/PD analysis to assess Thrombocytopenia of Givinostat (ITF2357) in 
Clinical studies (Report 0428-2012-R1).   
22. 
Goemans, N., et al. (2013). “Ambulatory capacity and disease progression as 
measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects 
on daily corticosteroids.” Neuromuscul Disord 23(8): 618-623. 
23. 
McDonald, C. M., et al. (2013). “The 6-minute walk test and other endpoints in 
Duchenne muscular dystrophy: longitudinal natural history observations over 48 
weeks from a multicenter study.” Muscle Nerve 48(3): 343-356. 
24. 
Mercuri E, Pichiecchio A, Counsell S, Allsop J, Cini C, Jungbluth H, Uggetti C, 
Bydder G. A short protocol for muscle MRI in children with muscular dystrophies. 
Eur J Paediatr Neurol. 2002;6(6):305-7. 
25. 
McDonald CM et al., “The 6-minute walk test and other clinical endpoints in 
duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically 
important differences from a multicenter study.” Muscle Nerve 48(3): 357-368. 
26. 
Manzur AY, K. T., Pike M, Swan A (2009). “Glucocorticoid corticosteroids for 
Duchenne muscular dystrophy.” Cochrane Database Syst Rev. Jan 23. 
27. 
Bushby, K. and E. Connor (2011). “Clinical outcome measures for trials in Duchenne 
muscular dystrophy: report from International Working Group meetings.” Clin 
Investig (Lond) 1(9): 1217-1235. 
28. 
Willcocks RJ, Arpan IA, Forbes SC, et al. Longitudinal measurements of MRI-T2 in 
boys with Duchenne muscular dystrophy: effects of age and disease progression. 
Neuromuscular disorders : NMD 2014;24:393-401 
29. 
Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR, Daniels 
MJ, Wang DJ, Harrington AT, Tennekoon GI, Russman BS, Finanger EL, Byrne BJ, 
Finkel RS, Walter GA, Sweeney HL, Vandenborne K. Multicenter prospective 
longitudinal study of magnetic resonance biomarkers in a large duchenne muscular 
dystrophy cohort. Ann Neurol. 2016 Feb 19. doi: 10.1002/ana.24599. [Epub ahead of 
print] PubMed PMID: 26891991 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 112 of 120 
30. 
Wren TA, Bluml S, Tseng-Ong L, Gilsanz V. Three-point technique of fat 
quantification of muscle tissue as a marker of disease progression in Duchenne 
muscular dystrophy: preliminary study. AJR American journal of roentgenology. 
2008;190(1):W8-12 
31. 
Bonati U, Hafner P, Schadelin S, Schmid M, Naduvilekoot Devasia A, Schroeder J, et 
al. Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne 
muscular dystrophy. Neuromuscular disorders: NMD. 2015;25(9):679-85 
32. 
Pane M, Mazzone ES, Sormani MP, Messina S, Vita GL, et al. (2014) 6 Minute Walk 
Test in Duchenne MD Patients with Different Mutations: 12 Month, Changes. PLoS 
ONE 9(1): e83400. doi:10.1371/journal.pone.0083400. 
33. 
Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, Elfring G, Reha A, 
Barth J, McDonald CM. Percent-predicted 6-minute walk distance in duchenne 
muscular dystrophy to account for maturational influences. Version 2. PLoS Curr. 
2012 Jan 25 [revised 2012 Feb 2];4:RRN1297. PubMed PMID: 22306689 
34. 
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett 
K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD 
Care Considerations Working Group. Diagnosis and management of Duchenne 
muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial 
management. 
Lancet 
Neurol. 
2010 
Jan;9(1):77-93. 
doi: 
10.1016/S1474-
4422(09)70271-6. Epub 2009 Nov 27. Review. PubMed PMID: 19945913. 
35. 
Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, Muntoni F; 
NorthStar Clinical Network. Long-term benefits and adverse effects of intermittent 
versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol 
Neurosurg Psychiatry. 2013 Jun;84(6):698-705. doi: 10.1136/jnnp-2012-303902. 
Epub 2012 Dec 18. PubMed PMID: 23250964. 
36. 
Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman 
EP, Cnaan A, McDonald CM; CINRG Investigators. Prednisone/prednisolone and 
deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 
2015 Sep 22;85(12):1048-55. 


Italfarmaco S.p.A.  
  DSC/14/2357/48 
Givinostat   
  Protocol Version8.0  
08 April 2020 
Page 113 of 120 
16 APPENDICES 
 


Italfarmaco S.p.A. 
DSC/14/2357/48 
Givinostat 
Protocol Version8.0 
 
 08 April 2020 
 
Page 114 of 120 
16.1  Combined list of drugs that prolong QT and/or cause torsades de Pointes (TDP)  
Source:  Arizona Center for Education and Research on Therapeutics.  Link: http://www.crediblemeds.org/everyone/composite-list-
all-qtdrugs/. List last revised: 12 September 2018.  Accessed 9 October 2018. 
CredibleMeds® has reviewed available evidence for the drugs on the following list and placed them in one of three designated 
categories: Known Risk of TdP (KR), Possible Risk of TdP (PR) or have a Conditional Risk of TdP (CR). The full description of these 
categories can be found on the CredibleMeds.org website. 
 
 
 
 
 
 


Italfarmaco S.p.A. 
DSC/14/2357/48 
Givinostat 
Protocol Version8.0 
 
 08 April 2020 
 
Page 115 of 120 
 


Italfarmaco S.p.A. 
DSC/14/2357/48 
Givinostat 
Protocol Version8.0 
 
 08 April 2020 
 
Page 116 of 120 
 


Italfarmaco S.p.A. 
DSC/14/2357/48 
Givinostat 
Protocol Version8.0 
 
 08 April 2020 
 
Page 117 of 120 
 
 


Italfarmaco S.p.A. 
DSC/14/2357/48 
Givinostat 
Protocol Version8.0 
 
 08 April 2020 
Page 118 of 120 
16.2 Drugs knows to be a substrate of OCT2 transporter  
OCT2 transporter = Organic Cation Transporter 2 
Source: http://www.straighthealthcare.com/organic-cation-transporter-2.html 
Accessed October 9th, 2018. 
 
Generic Name 
Brand 
Names 
(Partial 
List) 
OCT2 interaction 
Amantadine 
 
Substrate 
Amiloride 
Midamor® 
Substrate 
Cimetidine 
Tagamet® 
Substrate 
Creatinine 
 
Substrate 
Dofetilide 
Tikosyn® 
Substrate 
Dopamine 
 
Substrate 
Famotidine 
Pepcid® 
Substrate 
Memantine 
Namenda® 
Substrate 
Metformin 
Glucophage® 
Substrate 
Oxaliplatin 
Eloxatin® 
Substrate 
Pindolol 
Visken® 
Substrate 
Procainamide 
 
Substrate 
Ranitidine 
Zantac® 
Substrate 
Trimethoprim 
Bactrim® 
Substrate 
Varenicline  
Chantix® 
Substrate 
 
 
 
 
 
 


Italfarmaco S.p.A. 
DSC/14/2357/48 
Givinostat 
Protocol Version8.0 
 
 08 April 2020 
Page 119 of 120 
16.3 Drugs known to be P-glycoprotein inhibitors 
Source: https://www.straighthealthcare.com/p-glycoprotein.html 
Accessed July 26th, 2019. 
 
 P-glycoprotein inhibitors 
o Amiodarone (Cordarone®)  
o Atorvastatin (Lipitor®)  
o Azithromycin (Zithromax®)  
o Boceprevir (Victrelis®) - Drug PI states possible inhibitor  
o Bromocriptine (Cycloset®, Parlodel®, etc.) 
o Captopril (Capoten®)  
o Carvedilol (Coreg®)  
o Clarithromycin (Biaxin®)  
o Cobicistat (part of Stribild®)  
o Conivaptan (Vaprisol®)  
o Cyclosporine (Neoral®, Gengraf®, Sandimmune®)  
o Daclatasvir (Daklinza™)  
o Diltiazem (Cardizem®, Cartia®, Dilacor®, Diltia®)  
o Doxazosin (Cardura®)  
o Dronedarone (Multaq®)  
o Erythromycin (E.E.S®, Ery-tab®)  
o Felodipine (Plendil®)  
o Fluvastatin (Lescol®)  
o Glecaprevir (Mavyret™)  
o Indinavir (Crixivan®)  
o Itraconazole (Sporanox®)  
o Ketoconazole (Nizoral®)  
o Ledipasvir (Harvoni™)  
o Linagliptin (Tradjenta®)  
o Lopinavir and ritonavir (Kaletra®)  
o Lovastatin (Mevacor®)  
o Meperidine (Demerol®)  
o Methadone  
o Nelfinavir (Viracept®)  


Italfarmaco S.p.A. 
DSC/14/2357/48 
Givinostat 
Protocol Version8.0 
 
 08 April 2020 
Page 120 of 120 
o Nicardipine (Cardene®)  
o Paritaprevir (Viekira Pak™, Technivie™)  
o Pentazocine (Talwin®)  
o Pibrentasvir (Mavyret™)  
o Progesterone  
o Quercetin (supplement)  
o Quinidine  
o Ranolazine (Ranexa®)  
o Reserpine  
o Ritonavir (Norvir®)  
o Saquinavir (Invirase®)  
o Sarecycline (Seysara™) 
o Simeprevir (Olysio®)  
o Simvastatin (Zocor®)  
o Suvorexant (Belsomra®) - in vitro data  
o Tacrolimus (Prograf®)  
o Tamoxifen   
o Telaprevir (Incivek®)  
o Ticagrelor (Brilinta®)  
o Velpatasvir (Epclusa®)  
o Verapamil (Calan®,Covera-HS®, Isoptin®, Verelan®)  
o Vorapaxar (Zontivity®) (weak inhibitor)  
o Voxilaprevir (Vosevi™)  
 

SAP_001.pdf: 
16.1.9 
Documentation of Statistical Methods 
The document listed below is provided in this section. 
Statistical Analysis Plan (DSC/14/2357/48) dated 13-April-2022 
Statistical Analysis Plan (DSC/14/2357/48) Addendum 1 dated 14-July-2022 


 
Date: 13APR2022 
Page 1 of 64 
Version: Final 6.0 
ST/form/010/6 
Randomised, Double Blind, Placebo Controlled, Multicentre Study 
to Evaluate the Efficacy and Safety of Givinostat in Ambulant 
Patients with Duchenne Muscular Dystrophy 
 
Italfarmaco Study No: DSC/14/2357/48 
Veristat Study No: ICO16001 
EudraCT No: 2016-000401-36 
IND No: 126598 
 
Statistical Analysis Plan  
 
Version: Final 6.0 
Date: 13th April 2022 
 
 
For Veristat 
Author 
 
 
 
 
 
 
For Italfarmaco 
Approved by 
 
 
 
 
 
 
Maurizio Caserini  
Position: Clinical Research & Development Director 
 
For KJC Statistics Ltd 
Approved by 
 
Dr Kevin Carroll 
 
Position: Consultant Statistician 
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 2 of 64 
Version: Final 6.0 
ST/form/010/6 
Contents 
 
1 
INTRODUCTION ............................................................................................................................. 7 
2 
STUDY OBJECTIVES AND DESIGN ............................................................................................. 7 
2.1 
Study Objectives ......................................................................................................................... 7 
2.2 
Study Endpoints .......................................................................................................................... 7 
2.3 
Study Design ............................................................................................................................... 7 
2.4 
Visit Structure .............................................................................................................................. 9 
2.5 
Sample Size ................................................................................................................................ 9 
2.6 
Interim Analyses ....................................................................................................................... 10 
2.7 
Changes from the Protocol Planned Analysis .......................................................................... 11 
2.8 
Data presentations .................................................................................................................... 12 
2.9 
COVID-19 ................................................................................................................................. 13 
2.10 
Blinded Data Review Meeting ................................................................................................... 14 
3 
STUDY SUBJECTS ...................................................................................................................... 14 
3.1 
Disposition of Subjects ............................................................................................................. 15 
3.1.1 
Analysis Sets ......................................................................................................................... 15 
3.2 
Protocol Deviations ................................................................................................................... 16 
3.3 
Background and Demographic Characteristics ........................................................................ 16 
3.3.1 
Demography .......................................................................................................................... 17 
3.3.2 
Diagnosis ............................................................................................................................... 17 
3.3.3 
Medical History ...................................................................................................................... 17 
3.4 
Administration of Investigational Medicinal Products ............................................................... 17 
3.5 
Investigational Medicinal Product Modifications ....................................................................... 19 
3.6 
Ankle Range of Motion ............................................................................................................. 19 
3.7 
Muscle Strength Test Modified MRC Grade ............................................................................. 19 
3.8 
Blood Collection for Genotypes ................................................................................................ 19 
4 
EFFICACY EVALUATION ............................................................................................................. 20 
4.1 
Primary Efficacy Variable .......................................................................................................... 20 
4.2 
Key Secondary Efficacy Variables ............................................................................................ 21 
4.2.1 
Functional Key Secondary Efficacy Variables ....................................................................... 21 
4.2.1.1 
Time to Rise from Floor............................................................................................................................ 21 
4.2.1.2 
Distance Walked in 6 Minutes .................................................................................................................. 21 
4.2.1.3 
Physical Function as Measured by NSAA ................................................................................................ 21 
4.2.1.4 
Muscle Strength Evaluated by Knee Extension and Elbow Flexion as Measured by Hand-held Myometry . 
  ............................................................................................................................................................. 22 
4.2.2 
Imaging Key Secondary Efficacy Variable (MR Cohort) ........................................................ 23 
4.2.2.1 
Fat Fraction of Vastus Lateralis Muscles assessed by MRS.................................................................... 23 
4.3 
Exploratory Efficacy Variables for All Subjects ......................................................................... 23 
4.3.1 
Time to Run/Walk 10 Metres ................................................................................................. 23 
4.3.2 
Paediatric Outcomes Data Collection Instrument (PODCI) Scores ...................................... 24 
4.3.3 
Percent Predicted 6MWT....................................................................................................... 24 
4.3.4 
MRI Parameters (MR Cohort Only) ....................................................................................... 24 
4.3.5 
Time to 10% Persistent Worsening in 6MWT ........................................................................ 25 
4.3.6 
Proportion of Subjects with ≥10% Persistent Worsening in 6MWT ....................................... 26 
4.3.7 
Time to Persistent Loss of Standing (Baseline Through End of Study) ................................ 26 
4.3.8 
Proportion of Subjects Who Lose Ambulation ....................................................................... 26 
4.3.9 
Correlation between the effect of Givinostat on disease progression and the type of DMD 
mutation, LTBP4 and Osteopontin genotype......................................................................... 27 
4.3.10 
DMD serum biomarker ........................................................................................................... 27 
4.4 
Statistical Analysis .................................................................................................................... 27 
4.4.1 
Hypothesis to be Tested ........................................................................................................ 27 
4.4.2 
Modelling Methods ................................................................................................................. 27 
4.4.3 
Adjustment for Covariates ..................................................................................................... 29 
4.4.4 
Handling of Missing Data ....................................................................................................... 30 
4.4.4.1 
Classification and Imputation ................................................................................................................... 30 
4.4.4.2 
Analysis .................................................................................................................................................... 31 
4.4.4.3 
Tipping Point Sensitivity Analysis ............................................................................................................. 33 
4.4.4.4 
Imputation of Date of Birth ....................................................................................................................... 34 
4.4.4.5 
Imputation of Dates for Calculations or Classification .............................................................................. 34 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 3 of 64 
Version: Final 6.0 
ST/form/010/6 
4.4.5 
Adjustment for Multiple Comparisons .................................................................................... 34 
4.4.6 
Examination of Subgroups .................................................................................................... 35 
4.4.6.1 
Presentation of Efficacy Data by Subgroup .............................................................................................. 35 
4.4.6.2 
Impact of Age and Baseline Functional Status on Treatment Effect ........................................................ 37 
4.4.6.3 
Presentation of Safety Data by Subgroup ................................................................................................ 38 
4.4.7 
Supplementary Analyses ....................................................................................................... 38 
4.4.7.1 
Impact of 18 Month Visits Performed Outside of Expected Assessment Windows .................................. 38 
4.4.7.2 
Impact of MRS VL MFF on Functional Treatment Effect Over Time ........................................................ 38 
4.5 
Pharmacokinetics...................................................................................................................... 39 
5 
SAFETY EVALUATION ................................................................................................................ 40 
5.1 
Adverse Events ......................................................................................................................... 40 
5.2 
Clinical Laboratory Evaluation .................................................................................................. 42 
5.2.1 
Hematology ............................................................................................................................ 42 
5.2.2 
Clinical Chemistry .................................................................................................................. 43 
5.2.3 
Urinalysis ............................................................................................................................... 43 
5.2.4 
Coagulation ............................................................................................................................ 43 
5.2.5 
Serology ................................................................................................................................. 44 
5.3 
Vital Signs ................................................................................................................................. 44 
5.4 
Physical Exams ......................................................................................................................... 44 
5.5 
Electrocardiography .................................................................................................................. 44 
5.6 
Echocardiography ..................................................................................................................... 45 
5.7 
Pulmonary Function Test .......................................................................................................... 45 
5.8 
Concomitant Medications ......................................................................................................... 45 
5.9 
Concomitant Steroid Treatments .............................................................................................. 46 
5.10 
Raven Coloured Progressive Matrices ..................................................................................... 47 
5.11 
Acceptability and Palatability of the Oral Suspension .............................................................. 47 
6 
References .................................................................................................................................... 48 
7 
Appendices ................................................................................................................................... 50 
7.1 
Functional Evaluation Scale: 4SC ............................................................................................ 50 
7.2 
Functional Evaluation Scale: Time to Rise from the Floor........................................................ 50 
7.3 
Functional Evaluation Scale: Time to Walk/Run 10 Metres ..................................................... 50 
7.4 
PODCI Questionnaire Subscales ............................................................................................. 51 
7.4.1 
PODCI Completed by Parent ................................................................................................ 51 
7.4.1.1 
Upper Extremity Function ......................................................................................................................... 51 
7.4.1.2 
Transfer and Basic Mobility ...................................................................................................................... 51 
7.4.1.3 
Sports and Physical Function ................................................................................................................... 52 
7.4.1.4 
Pain/Comfort ............................................................................................................................................ 53 
7.4.1.5 
Happiness ................................................................................................................................................ 53 
7.4.1.6 
Global Function Scale .............................................................................................................................. 54 
7.4.2 
PODCI Completed by Subject ............................................................................................... 54 
7.4.2.1 
Upper Extremity Function ......................................................................................................................... 54 
7.4.2.2 
Transfer and Basic Mobility ...................................................................................................................... 54 
7.4.2.3 
Sports and Physical Function ................................................................................................................... 55 
7.4.2.4 
Pain/Comfort ............................................................................................................................................ 56 
7.4.2.5 
Happiness ................................................................................................................................................ 56 
7.4.2.6 
Global Function Scale .............................................................................................................................. 57 
7.5 
Missing Data Classification and Imputation Rules .................................................................... 57 
7.5.1 
Time to Climb 4 Standard Stairs (4SC) ................................................................................. 57 
7.5.2 
Time to Rise from Floor ......................................................................................................... 57 
7.5.3 
Distance Walked in 6 Minutes (6MWT) ................................................................................. 57 
7.5.4 
Physical Function as Measured by NSAA ............................................................................. 57 
7.5.5 
Muscle Strength Evaluated by Knee Extension and Elbow Flexion as Measured by Hand-
held Myometry ....................................................................................................................... 58 
7.5.6 
Fat Fraction of Vastus Lateralis Muscles as assessed by MRS............................................ 58 
7.5.7 
Time to Run/Walk 10 Metres ................................................................................................. 58 
7.5.8 
Paediatric Outcomes Data Collection Instrument (PODCI) Scores ...................................... 59 
7.5.9 
Percent Predicted 6MWT....................................................................................................... 59 
7.5.10 
Fat Fraction and Cross-Sectional Area of 5 Thigh Muscles as Assessed by MRI ................ 59 
7.5.11 
Time to 10% Persistent Worsening in 6MWT ........................................................................ 59 
7.5.12 
Proportion of Subjects with ≥10% Persistent Worsening in 6MWT ....................................... 59 
7.5.13 
Time to Persistent Loss of Standing (Baseline Through End of Study) ................................ 59 
7.5.14 
Proportion of Subjects Who Lose Ambulation ....................................................................... 59 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 4 of 64 
Version: Final 6.0 
ST/form/010/6 
7.5.15 
Type of DMD Mutation, LTBP4 and Osteopontin Genotype ................................................. 60 
7.5.16 
DMD Serum Biomarker .......................................................................................................... 60 
7.6 
Outputs to be Reviewed at the Safety Review Meetings.......................................................... 60 
7.7 
Outputs to be Reviewed at the Interim Analysis ....................................................................... 64 
 
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 5 of 64 
Version: Final 6.0 
ST/form/010/6 
LIST OF ABBREVIATIONS 
 
4SC 
4-stairs climb 
6MWT 
6-minute walking test 
AE 
Adverse Event 
ANCOVA 
BDRM             
Analysis of covariance 
Blinded Data Review Meeting  
BMI 
Body mass index 
CI 
Confidence interval 
DMD 
Duchenne muscular dystrophy 
ECG 
Electrocardiogram 
ECHO 
Echocardiogram 
eCRF 
electronic Case Report Form 
EMA 
European Medicines Agency 
EU 
European Union 
FDA 
Food and Drug Administration 
HHM 
Hand-held myometry 
IDMC 
Independent data monitoring committee 
IMP 
Investigational Medicinal Product 
ITT 
Intent-to-treat analysis set 
LLOQ 
Lower Limit of Quantification 
MCID 
Minimal Clinically Important Difference 
MedDRA 
Medical Dictionary for Regulatory Activities 
MFF 
Muscle fat fraction 
MR 
Magnetic Resonance 
MRI 
Magnetic resonance imaging 
MRS 
Magnetic resonance spectroscopy 
NSAA 
North Star Ambulatory Assessment 
PD 
Pharmacodynamic 
PK 
Pharmacokinetic 
PODCI 
Paediatric Outcomes Data Collection Instrument 
PT 
Preferred Term 
SAE 
Serious adverse event 
SAF 
Safety Analysis Set 
SAP 
Statistical Analysis Plan 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 6 of 64 
Version: Final 6.0 
ST/form/010/6 
SD 
Standard Deviation 
SE 
Standard Error 
SOC 
System Organ Class 
TEAE 
Treatment Emergent Adverse Event 
US 
United States 
VL MFF 
Vastus lateralis muscle fat fraction 
 
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 7 of 64 
Version: Final 6.0 
ST/form/010/6 
1 INTRODUCTION 
This statistical analysis plan (SAP) is based on protocol version 8.0 (and 8.1 for France 
use only) dated 8th April 2020 and Version 8.1 for Germany use only dated 25th June 
2020 and will be finalised prior to full study unblinding.  Any additional details or 
amendments will be discussed with Italfarmaco and included in a revised version of 
the SAP.   
The table, figure and listing shells will be supplied in a separate document. 
The analysis and statistical reporting will be conducted at Veristat using SAS version 
9.2 or higher.  
Summary statistics will consist of number of subjects (n), mean, standard deviation 
(SD), minimum, first quartile, median, third quartile and maximum, unless specified 
otherwise.  The precision of these variables is defined in the table, figure and listing 
shells document. 
Unless stated otherwise, for example in Section 4.4.4, missing data will be considered 
missing at random and there will be no imputation of missing data. 
2 STUDY OBJECTIVES AND DESIGN 
2.1 Study Objectives 
The primary objective of the study is to establish the effects of givinostat versus 
placebo administered chronically over 18 months to slow disease progression in 
ambulant Duchenne muscular dystrophy (DMD) subjects. 
The secondary objectives of this study are: 
i. 
To assess the safety and tolerability of givinostat versus placebo administered 
chronically in DMD subjects 
ii. 
To evaluate the pharmacokinetic (PK) profile of givinostat administered 
chronically in DMD subjects 
iii. 
To evaluate the impact on quality of life and activities of daily living of givinostat 
versus placebo administered chronically. 
The secondary exploratory objectives of this study are: 
iv. 
To evaluate the correlation between PK profile of givinostat and 
pharmacodynamics (PD) data 
v. 
To explore whether the effects of givinostat versus placebo administered 
chronically may be related to the type of DMD mutation or to the biomarkers. 
2.2 Study Endpoints 
The study endpoints are detailed in Section 5.2 of the protocol. 
2.3 Study Design 
This is a Phase 3, randomised, double blind, placebo controlled, multicentre study to 
evaluate the efficacy and safety of givinostat in ambulant subjects with DMD.  This 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 8 of 64 
Version: Final 6.0 
ST/form/010/6 
study will include ambulant male paediatric subjects aged ≥ 6 years at baseline 
affected by DMD. 
A target population (Group A) will consist of subjects with a baseline vastus lateralis 
muscle fat fraction (VL MFF) assessed by Magnetic Resonance Spectroscopy (MRS) 
in the range > 5% and ≤ 30%.  An off-target population (Group B) will consist of 
subjects with a baseline VL MFF assessed by MRS in the range ≤ 5% or > 30%.  The 
target and off-target population assignments will be derived from the actual VL MFF 
values entered onto the electronic Case Report Form (eCRF) at baseline.  If for any 
reason this information is missing or it is not possible to determine the assignment 
from the VL MFF results recorded, the subject will be classified as off-target. Following 
collection of MRS VL MFF data, a blinded central review of the data will be conducted 
by University of Florida Imaging DMD network, which may lead to adjustment of some 
VL MFF results. The final VL MFF results following blinded review (external to the 
eCRF) will be used for analyses of MRS data (see Section 4.2.2).  However, the 
assignment to target and off-target populations based on the initial values entered onto 
the eCRF will not be adjusted for any changes in baseline MRS VL MFF results from 
blinded review.    
All subjects in the target population will undergo the magnetic resonance assessment 
at baseline, 12 and 18 months and will be eligible for inclusion in the Magnetic 
Resonance (MR) Cohort defined in Section 3.1.1.  
A total of 110 male ambulant subjects in the target population are planned to be 
randomised (Group A).  In addition, it is planned that up to 50 subjects (about 35% of 
the overall population) outside of the target population may also be recruited into the 
study (Group B).  The overall subject population (Group A + Group B) will provide 
supportive data.   
At the randomisation visit, in addition to the continued standard of care corticosteroids 
regimen, DMD subjects will be randomised in a 2:1 ratio to receive givinostat oral 
suspension 10mg/mL or placebo oral suspension b.i.d. in a fed state. 
At randomisation, subjects will be stratified for their concomitant use of steroids in 4 
strata: 
1. Deflazacort daily regimen 
2. Deflazacort intermittent regimen 
3. Other steroids daily regimen 
4. Other steroids intermittent regimen 
Details regarding concomitant steroid use at randomisation will be collected on the 
diagnosis page of the eCRF and these data will be used to derive the appropriate 
stratum for each subject for the purposes of summary and analyses.  
The study is planned for 19 months and comprises 2 phases: 
1. Screening period: starting 4 weeks (± 2 weeks) before randomisation 
2. Treatment period: 18 months of treatment 
There will be a total of 15 visits, including the screening and randomisation visits and 
excluding the follow up visit.  Subjects may be evaluated more often if necessary for 
safety reasons.   
A final follow up visit will be performed 4 weeks after the last administration of 
givinostat or placebo.  However, in order to guarantee continuation of treatment with 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 9 of 64 
Version: Final 6.0 
ST/form/010/6 
givinostat, the Sponsor has planned a long-term study which will start when the first 
subject randomised in this study has attended his last visit.  Therefore, the final follow 
up visit will only be performed if the subject does not assent/consent and/or the 
parent/legal guardian does not consent to participation in the long-term study. 
A single interim analysis has been planned and will be conducted by the independent 
data monitoring committee (IDMC) in order to ensure study integrity.  The interim 
analysis will be performed when the first 50 subjects randomised in the target 
population have reached the 12-month visit, where the effects of givinostat versus 
placebo on the mean VL MFF will be assessed in terms of futility.  If the IDMC 
recommends that the study should proceed as planned, a blinded sample size re-
estimation will be conducted for VL MFF and the time taken to climb 4 stairs (4SC) in 
the target population. 
Further details regarding the interim analysis are given in Section 2.6. 
2.4 Visit Structure 
The visit structure and scheduled assessments are detailed in Section 9.1 of the 
protocol. 
2.5 Sample Size 
The sample size was originally calculated to provide 90% power and a 1-sided alpha 
of 2.5% to detect a true difference of 3 seconds between givinostat and placebo in the 
target population 4SC change from baseline to 18 months, assuming a common 
standard deviation (SD) of 6 seconds.  The estimated SD was based on publicly 
available Phase 3 study data on ataluren and drisapersen in subjects with DMD in 
addition to internal Italfarmaco data. This gave rise to an estimated sample size of 
N=192 subjects in the target population.  
Based on internal Italfarmaco data, a total of N=99 subjects was originally calculated 
as sufficient to provide 80% power to detect a 55% reduction in the annual mean 
increase in VL MFF (of 6.6%) with givinostat as compared to placebo with a 1-sided 
alpha of 2.5% and assuming an SD for the change from baseline in VL MFF of 6%.   
The pre-planned interim analysis took place in January 2020 based upon the first 50 
randomised subjects reaching 12 months of treatment. It was concluded by the IDMC 
that futility on VL MFF was not met and the trial should continue. Therefore, the pre-
planned blinded sample size re-assessment was performed. This provided a revised, 
blinded within treatment SD estimate for the change in 4CS from baseline to 18 months 
of 3.094 seconds, approximately half of that assumed in the original power calculation. 
Based on this revised SD estimate, the revised sample size (utilising a 2:1 
randomisation scheme) is N=102. This provides 90% power and a 1-sided alpha of 
2.5% to detect a true difference of 2 seconds between givinostat and placebo in the 
target population, for the change from baseline in 4SC at 18 months.  
With an estimated drop-out rate of 8%, a total of 110 male ambulant subjects will be 
randomized in the target population (Group A). Up to 50 subjects (about 35% of the 
overall population) outside of the target population may also be recruited into the study 
(Group B). The overall subjects population (Group A + Group B) will provide supportive 
data. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 10 of 64 
Version: Final 6.0 
ST/form/010/6 
For the MR cohort, the blinded SD estimate was 5.941%, being in line with the 6% SD 
assumed in the original power calculation, hence all the subjects in the target 
population will be included in the MR cohort.  
2.6 Interim Analyses 
An IDMC will review and oversee one planned formal interim analysis in the target 
population. Full details regarding the role, function and operations of the IDMC and 
the rules to be used when reviewing interim data are given in the IDMC charter. 
The interim analysis will be a performed when the first 50 subjects randomised in the 
target population have reached the 12-month visit.  In this interim analysis, the IDMC 
will evaluate the effects of givinostat versus placebo on the VL MFF in terms of futility, 
via a review of the treatment difference on the mean change in VL MFF as assessed 
by MRS before and after 12 months of treatment.  Note that the primary endpoint data 
will not be unblinded at this interim and no subject level unblinding will occur except 
for the VL MFF endpoint only if required.  Futility will be mandated if the mean change 
from baseline to month 12 in VL MFF as assessed by MRS in the givinostat group is 
equal to or worse than that seen in the placebo group since the biologic plausibility of 
a subsequent treatment effect on 4SC would be greatly diminished. The IDMC will only 
communicate to the Sponsor whether the study should proceed or it should be stopped 
having met the futility criteria. 
If the IDMC indicates that the study should proceed, a blinded sample size re-
estimation will be conducted for VL MFF and 4SC in the target population as follows: 
i. 
To maintain the blind on the primary endpoint, the within treatment SD for the 
change from baseline will be estimated as  𝝈̂𝒘𝒊𝒕𝒉𝒊𝒏= √𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍
𝟐
−(
𝜟
𝟐)
𝟐
 where 
𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍  is the overall SD for the change from baseline in 4SC based on the 
n=50 subjects in the interim and 𝛥 is the originally hypothesized treatment 
effect, i.e., 𝛥= 3 seconds.  Dependent upon the blinded SD estimate, the 
sample size may be decreased or increased to maintain 90% power.  Any 
increase in sample size for 4SC will be limited to 1.5 times maximum of the 
initial target population sample size, i.e., to a maximum of 1.5 × 192 = 288 
subjects.  For a 20% increase in the SD, this degree of increase in sample size 
will maintain 90% power, and for a 40% increase in SD power will be maintained 
at 80%. 
ii. 
With respect to VL MFF, a similar approach will be applied; the within treatment 
SD for the change from baseline will be estimated as  𝝈̂𝒘𝒊𝒕𝒉𝒊𝒏= √𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍
𝟐
−(
𝜟
𝟐)
𝟐
 
where 𝝈̂𝒐𝒗𝒆𝒓𝒂𝒍𝒍  is the overall SD for the change from baseline in VL MFF and 𝛥 
is the originally hypothesized treatment effect, i.e. 𝛥= 3.63% (i.e., 55% of 
6.6%).  Dependent upon the blinded SD estimate, the sample size may be 
decreased or increased to maintain 90% power.  Any increase in sample size 
required to assess VL MFF will also be limited to 1.5 times the required target 
population sample size stated in the preceding power calculation, to a 
maximum of 1.5 × 99 ≈150 subjects.  
To ensure that the blind is maintained for the sample size re-estimation, this will be 
completed by a blinded statistician at Veristat.  The IDMC will then formally 
communicate the outcome of the sample size re-estimation. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 11 of 64 
Version: Final 6.0 
ST/form/010/6 
At this interim futility analysis, there will be no efficacy assessment and no unblinded 
analysis of the primary endpoint and, hence, no alpha spend nor early stopping of the 
study for efficacy. 
Details of the outputs to be produced at the interim analysis are given in Appendix 7.7.  
Shells for the outputs to be produced at this interim analysis are included in a separate 
‘Interim Analysis 1 Table, Figure and Listing Shells’ document.  
As noted above in Section 2.5, the interim analysis took place in January 2020; futility 
was passed and the blinded sample size reassessment followed. The estimated SD 
for 4SC was approximately half of that assumed in the original power calculation. 
Consequently, it was determined that a total of N=102 patients would be sufficient to 
test the hypothesis that 4SC was improved by at least 2 seconds with givinostat 
compared with placebo after 18 months of treatment. With allowance for a small 
dropout rate, a total of 110 male ambulant subjects will be randomised in the target 
population (Group A). Up to 50 subjects (about 35% of the overall population) outside 
of the target may also be recruited into the study (Group B). The overall subjects 
population (Group A + Group B) will provide supportive data.  
For the MR cohort, the blinded SD estimate was 5.941%, being in line with the SD 
assumed in the original power calculation for VL MFF.  Therefore, all the subjects in 
the target population will be included in the analysis of the MR cohort. 
Following this interim analysis, the study will continue subject follow-up and 
recruitment and a final analysis will be performed once all randomised subjects have 
achieved 18 months of follow-up. The p-value applicable to the final analysis of 4SC 
in the target population will be p ≤ 0.025 1-sided. See Section 4.4.5 for further details 
regarding all adjustments for multiple comparisons where analyses are formal, and the 
presentation of nominal p-values for supportive analyses. Note that references to 1-
sided p-values are to indicate significance in either direction (i.e. a 2-sided test) per 
Section 4.4.1.   
In addition to the formal interim analysis described above, the IDMC will review, 
evaluate and categorise unblinded safety findings every three months during the 
study.  
An unblinded team at Veristat will be responsible for the ongoing safety summaries 
that are to be produced every 3 months as well as any unblinded aspects of the formal 
interim analysis.  
The outputs to be produced for the safety reviews are listed in Appendix 7.6. 
All details regarding reviews performed by the IDMC at the interim analysis and safety 
reviews are documented in the IDMC charter. 
2.7 Changes from the Protocol Planned Analysis 
The pharmacokinetic analysis set has been introduced.     
The exploratory endpoint “Time to loss of standing (Baseline through end of study)” 
has been updated to clarify that this is the time to persistent loss of standing in order 
to allow time for recovery due to trauma.  Additional clarity has also been added 
regarding how this endpoint is derived. 
The exploratory endpoint “Proportion of subjects with ≥10% worsening in 6MWT at the 
end of the study” has been updated to clarify that this is the proportion of subjects with 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 12 of 64 
Version: Final 6.0 
ST/form/010/6 
≥10% persistent worsening in 6MWT at the end of the study.  Additional clarity has 
also been added regarding the definition for inclusion of subjects in this proportion.  
In addition, exploratory subgroup and supplementary analyses have been included in 
this SAP.   
Summary and analysis of results of the DMD serum biomarker assessment and any 
relationship with treatment effect will not be included as part of this SAP but in a 
separate dedicated SAP. 
The presentation of data on the target and/or overall subject populations has been 
streamlined to ensure the most appropriate population is used for each data type, with 
the option to include additional repeats post hoc if required. 
Additional criteria have been added to the definition of the Intent-To-Treat (ITT) 
analysis set to ensure that subjects included in this population have received at least 
one dose of study drug and have at least one post-baseline 4SC measure, or 
alternatively a missing 4SC measure due to being either non-ambulatory or otherwise 
physically unable to perform the assessment (as this still provides useful information 
regarding disease progression).  This was felt appropriate to ensure a suitable 
population for the primary analysis. 
The text for the analysis set definitions has been updated slightly to clarify the 
difference between the analysis sets themselves (defined by the analysis set criteria) 
and the subdivision into target/overall populations (defined by baseline MRS VL MFF 
results). 
The definition for the MR cohort has been updated to clarify that subjects must 
complete at least one post-baseline MRI/MRS assessment to be included as this 
cohort is to be used for presentation of MRI and MRS data. 
2.8 Data presentations 
The data will be summarised in tabular form by treatment group apart from disposition 
of subjects, protocol deviations, background and demographic data, administration of 
investigational medicinal product (IMP), plasma concentrations of givinostat and its 
major metabolites, prior and concomitant medications, which will be summarised by 
treatment group and overall subjects. 
Only scheduled post-baseline laboratory, vital signs and electrocardiogram (ECG) 
values will be tabulated, post-baseline repeat/unscheduled assessments will be listed.  
Listings will be sorted by treatment group, subject number and date/time of 
assessment.   
Treatment groups will be presented in the following order: Givinostat, Placebo. 
Graphical presentations of the data will also be provided where appropriate. 
All efficacy analyses and data summaries will be presented for the target population 
only.  Safety data will only be summarised for the overall subject population.  Data 
summaries for disposition of subjects, protocol deviations, background and 
demographic data, administration of IMP, ankle range of motion, modified MRC grade 
and genotype data will be presented for both the target and overall subject 
populations.  Presentation of analyses and summaries of PK data will be discussed in 
a separate Population PK data analysis plan (see Section 4.5). 


Veristat study no: ICO16001 
Italfarmaco study no: DSC/14/2357/48 
Date: 13APR2022 
Page 13 of 64 
Version: Final 6.0 
ST/form/010/6 
Listings will be presented for the overall subject population.  Inclusion of each subject 
in the target or off-target population will be indicated in the listing of analysis set 
assignments for reference. Listings for efficacy and PK data will also present patients 
sorted by target or off-target population for each treatment group. 
The target population will serve as the basis for any formal analysis of efficacy.  
Any further repeats of the data summaries and analyses for target, off-target or overall 
subject populations may be considered at a later date and included post hoc.  Details 
of any such repeats will be included in a SAP addendum as appropriate. 
Where data are imputed according to the rules defined in Section 4.4.4, the imputed 
data will be used in all data presentations and analyses. Imputed values for efficacy 
data will be flagged in the listings with an indication of the missing data classification 
as applicable.  
Data collected at the ‘EOS/Early Withdrawal’ visit (Week 72) will be mapped to either 
‘EOS’ for subjects who complete the study, or ‘Early Withdrawal’ for subjects who 
withdraw early.  The mapped visits will be used for all data presentations and analyses. 
Data presentations by visit will present ‘EOS’ followed by ‘Early Withdrawal’.  Data 
collected for the ‘Follow Up Visit’ (Week 76) will be presented and analysed without 
any mapping for completers versus early withdrawal subjects. 
2.9 COVID-19 
It is noted that particular attention may need to be given to the impact on key efficacy 
or safety assessments as a result of the COVID-19 pandemic. Consideration of the 
different areas of impact has been made as described below. 
Protocol deviations related to COVID-19 will be recorded under separate categories 
indicating the type of deviation and that this was due to COVID-19.  The assigned 
categories will be presented in the protocol deviation listing and table summary 
of major deviations as described in Section 3.2. 
Subjects who prematurely discontinue the study due to COVID-19 will record this as 
their reason for withdrawal and this will be included in the summary of reasons for 
withdrawal as described in Section 3.1. 
Subjects with a modification, interruption or who permanently stop IMP due to COVID-
19 will record this as the reason for modification and this will be presented in the 
summary and listing of IMP modifications as described in Section 3.5. 
Missing efficacy data will be subject to the imputation and analysis methods 
described in Sections 4.4.4.1 and 4.4.4.2. Missing data due to COVID-19 will be 
assumed to be Class 1 missing data (due to reasons other than being non-
ambulatory or physically unable to perform the test / assessment) and handled 
accordingly. The tipping point analysis described in Section 4.4.4.3 will assess the 
impact of the missing data on the primary analysis. 
In order to provide supportive information for interpretation of the key efficacy and 
safety analyses, a summary of the number and percentage of subjects with missing 
assessments at each scheduled visit will be presented by treatment group and overall 
for the following selected data on the ITT analysis set in the target population (efficacy 
data) or safety analysis set in the overall population (safety data) as appropriate: 

All primary and key secondary efficacy assessments


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 14 of 64 
Version: Final 6.0 
ST/form/010/6 
 Clinical laboratory  
 Vital signs   
 Electrocardiogram 
 Echocardiography 
 Pulmonary function test 
In addition, these summaries will be repeated to present the number and percentage 
of subjects with assessments completed outside of the expected protocol defined 
assessment window, at each scheduled visit by treatment group and overall. This 
summary will also include the number and percentage of subjects with assessments 
completed outside of the extended window for the 18 month assessment (+/-60 days) 
which was applied due to impact of the COVID-19 pandemic.     
The COVID-19 pandemic has resulted in some subjects completing the EOS (18 
month) assessment outside of the expected protocol defined assessment window or, 
additionally, outside of the extended +/-60 day window, which may have an impact in 
progressive disease.  Therefore, a sensitivity analysis will be conducted on the ITT 
analysis set in the target population.  The analysis described in Section 4.4.2 for each 
of the primary and key secondary endpoints will be repeated, excluding any subjects 
whose respective 18 month assessment was completed outside of the expected 
assessment window. In each case, the analysis will first exclude subjects where the 
18 month assessment was outside of the protocol defined window and then will be 
repeated only excluding subjects where the 18 month assessment was outside of the 
+/-60 day window.   
If these summaries and analyses suggest that further investigation is beneficial, 
additional summaries and/or analyses may be added post hoc to address missing data 
or assessments outside of protocol defined windows. This may include but is not 
limited to: additional sensitivity analyses of the efficacy endpoints, additional 
summaries of selected safety data for overall worst case post-baseline values, 
application of visit windows to group post-baseline data across multiple visits as 
appropriate.   
2.10 Blinded Data Review Meeting 
Italfarmaco will convene a blinded data review meeting (BDRM) after the data have 
been cleaned and before the study is locked and unblinded.  
The BDRM will make decisions that will include, but not be limited to, the determination 
of whether protocol deviations are 'major' or 'minor', or not a protocol deviation at all.  
The definitions used to classify deviations as ‘major’ will be documented in the BDRM 
minutes. 
3 STUDY SUBJECTS 
All study subject data summaries and listings will be based on all enrolled subjects 
unless specified otherwise.  Additionally, see Section 2.8 regarding use of the target 
versus overall population.  Baseline is defined as the last non-missing value recorded 
prior to or on the date of first study treatment. Where the value is recorded on the 
same date as first study treatment and there is no further information to confirm 
whether this was prior to start of treatment, the value will be considered prior to 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 15 of 64 
Version: Final 6.0 
ST/form/010/6 
treatment if this was a screening or randomisation assessment and otherwise will be 
considered post treatment.  
3.1 Disposition of Subjects 
The number and percentage of all subjects enrolled, included in the intent-to-treat 
analysis set, safety analysis set, PK analysis set and MR cohort who completed the 
study and prematurely discontinued the study will be presented by treatment group 
and overall.  The number and percentage of subjects will be summarised by their 
reasons for withdrawal. In addition, the summary of subjects included in analysis sets, 
completed, discontinued and reasons for withdrawal will be repeated by country.  
Individual reasons for withdrawal will be presented in a listing. 
A table will also present the number and percentage of subjects screened, randomised 
and who failed screening overall for all subjects screened.  The number and 
percentage of subjects who passed screening but were not randomised will also be 
presented.  This table will also present the number and percentage of screen failed 
subjects by inclusion/exclusion criteria failed. 
Details of eligibility, including whether all eligibility criteria were met and the criteria 
that were failed (screen failures) or reason for withdrawal (subjects who passed 
screening but were not randomised), will be listed for all screened subjects, including 
the protocol version that the subjects were screened under.  
3.1.1 
Analysis Sets 
The All enrolled subjects set for the target population will include all subjects in the 
target population who were randomised to study treatment.  The all enrolled subjects 
overall set will include all subjects in both the target and off-target populations (Group 
A + Group B) who were randomised to study treatment. 
The Intent-To-Treat (ITT) analysis set for the target population will include all subjects 
in the target population who are randomised, who receive at least one dose of study 
drug and who have at least one non-missing post-baseline 4SC measure or missing 
post-baseline 4SC measure due to being either non-ambulatory or otherwise 
physically unable to perform the assessment, irrespective of any deviation from the 
protocol or premature discontinuation.  The treatment group assignment will be 
designated according to initial randomisation.  The ITT analysis set in the target 
population will serve as the basis for the formal analysis of efficacy.  The ITT analysis 
set for the overall population will include all subjects in both the target and off-target 
populations who are randomised, who receive at least one dose of study drug and 
who have at least one post-baseline 4SC measure or missing post-baseline 4SC 
measure due to being either non-ambulatory or otherwise physically unable to perform 
the assessment, irrespective of any deviation from the protocol or premature 
discontinuation.  The ITT analysis set in the overall population may be used for any 
supportive efficacy analyses. 
The Safety (SAF) analysis set for the target population will include all randomised 
subjects in the target population who receive at least one dose of the study drug.  The 
treatment group assignment in this analysis set will be defined by the treatment 
actually received.  This will be used for any evaluation of safety in the target population.  
The SAF analysis set for the overall population will include all randomised subjects in 
both the target and off-target populations who receive at least one dose of study drug. 
This will be used for evaluation of safety in the overall population. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 16 of 64 
Version: Final 6.0 
ST/form/010/6 
The Pharmacokinetic (PK) analysis set for the target population will include all 
subjects in the target population who have received at least one dose of treatment with 
givinostat and who have at least one post-dose concentration of study drug.  The PK 
analysis set in the target population will be used for all formal PK summaries and 
analyses. The PK analysis set for the overall population will include all subjects in both 
the target and off-target population who have received at least one dose of treatment 
with givinostat and who have at least one post-dose concentration of study drug.  The 
PK analysis set in the overall population may be used for any supportive PK 
evaluations.  Final membership of the PK analysis set in both the target and overall 
populations will be confirmed after unblinding.  
The Magnetic resonance (MR) cohort includes all subjects in the target population 
who were randomised to study treatment and completed at least one post-baseline 
MRI/MRS assessment.  These subjects will be expected to perform the magnetic 
resonance assessment at baseline, 12 and 18 months.  Therefore, this cohort will form 
the basis for analysis of all MRI/MRS parameters.  
 
The definitions for all the above analysis sets are sufficient to determine the subjects 
included and there will be no requirement for formal review and approval of population 
membership by Italfarmaco. 
Membership to each of the above analysis sets will be determined programmatically 
based on the data collected and in line with the defined criteria above.  The assignment 
of subjects to each of the analysis sets, except for the PK analysis set, will be 
determined prior to unblinding, once all study data are available for the respective 
analysis.  For the PK analysis set, final membership to this set will be confirmed 
following unblinding and will again use programmatic derivations without the 
requirement for manual review.    
All enrolled subjects will be listed indicating their membership to each analysis set 
along with the reason for exclusion. A listing will also present details of any 
randomisation code breaks. 
3.2 Protocol Deviations 
Subject level protocol deviations will be recorded in the eCRF.  Prior to database lock 
(interim and final analyses) or data extract for safety reviews, Italfarmaco will review 
the individual deviations recorded in the eCRF and classify them as major or minor.  
The review prior to the final analyses will be conducted at the BDRM and documented 
as described in Section 2.10.  
All protocol deviations will be listed and major protocol deviations will be summarised 
by treatment group and deviation category. 
In addition, site level deviations will be captured and provided to Veristat as a separate 
report for provision to the IDMC members at safety reviews.  This report will not 
otherwise be included in the formal data presentations covered by this SAP. 
3.3 Background and Demographic Characteristics 
Demographic characteristics and other baseline characteristics will be listed based on 
all enrolled subjects and analysed based on the safety analysis set unless specified 


Veristat study no: ICO16001 
Italfarmaco study no: DSC/14/2357/48 
Date: 13APR2022 
Page 17 of 64 
Version: Final 6.0 
ST/form/010/6 
otherwise.  Additionally, see Section 2.8 regarding use of the target versus overall 
population. 
3.3.1 
Demography 
Summary statistics will be calculated for continuous variables and the number and 
percentage of subjects in each category will be presented for categorical variables for 
each treatment group and overall. Individual subject demographic and baseline data 
will be listed. 
Demographic characteristics (age, ethnic origin and race) and body measurements 
(height, weight and body mass index) collected at baseline will be summarised by 
treatment group and overall. 
Age at first dose with study treatment will be collected in years and months.  
However, this will be re-derived in years and months from the subject date of birth 
and date of first IMP intake. The re-derived age will be used for presentation of 
demography data and any further data presentations or calculations using age at first 
dose throughout. Note that the date of birth used in the age calculation will, in all 
cases, be subject to the rules given in Section 4.4.4.4 prior to the calculation. 
BMI will be calculated as follows: 
BMI = weight at baseline (kg) / [height at baseline* height at baseline (m²)] 
Individual subject demographic and body measurement data recorded at baseline 
will be listed. 
3.3.2 
Diagnosis 
A table summarising the time since diagnosis (years) and DMD mutation (deletion, 
duplication, point mutation) will be presented.  This table will also include a summary 
of the time since steroid initiation (years), type of steroid (Prednisone, Deflazacort, 
other) and schedule of steroid use. 
Time since diagnosis will be calculated in years as the date of informed consent - 
date of diagnosis + 1. 
Time since steroid initiation will be calculated in years as the date of informed 
consent - start date of initial steroid usage + 1. 
Where only a partial date of diagnosis or date of initial steroid usage is available, this 
will be imputed to the first of the month or 1st January as needed. 
All details of DMD diagnosis will be listed in full. 
3.3.3 
Medical History 
Medical history events will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) Version 24.1. The number and percentage of subjects will be 
presented for ongoing conditions and previous conditions separately by system organ 
class (SOC) and preferred term (PT) for each treatment group and overall.  
All events will be listed. 
3.4 Administration of Investigational Medicinal Products 
The duration (days) of exposure to the study treatment will be calculated as date of 
last exposure to study drug – date of first dose + 1.  Where these data are analysed 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 18 of 64 
Version: Final 6.0 
ST/form/010/6 
prior to study completion, the duration of exposure will be calculated as follows for 
subjects who have not yet completed the study: date of data cut for analysis – date of 
first dose + 1.  The actual duration of treatment will be calculated as the exposure 
period – number of days on which treatment was temporarily withdrawn (calculated 
from the start and end dates of any modification recorded as ‘Dose temporarily 
stopped’ or ‘Dose skipped’). Where only the morning or evening dose is recorded as 
skipped, this will be counted as 0.5 days of withdrawn treatment.   
At each visit, the ‘Subject Compliance’ page of the eCRF will be completed with details 
of the last IMP dose taken, any doses missed and the date and timing of the first IMP 
dose at the visit.  For subjects who were enrolled after the introduction of this eCRF 
page, total percent compliance for the study will be calculated as follows: 
Total number of expected doses = Duration of exposure (days) x 2 
Total number of missed doses = Sum of number of missed doses at all visits 
Total number of doses taken = Total expected doses – Total missed doses 
Total percent compliance = Total doses taken / Total expected doses x 100 
For subjects who were enrolled prior to the introduction of the ‘Subject Compliance’ 
eCRF page, total percent compliance will be calculated using the information collected 
on the ‘Investigational Medicinal Product Administration’ page as follows: 
Total number of expected doses = Duration of exposure (days) x 2 
Total number of missed doses = Number of days on which treatment was 
temporarily withdrawn or skipped x 2* 
Total number of doses taken = Total expected doses – Total missed doses 
Total percent compliance = Total doses taken / Total expected doses x 100 
* Number of days on which treatment was temporarily withdrawn will be calculated 
from the start and end dates of any modification recorded as ‘Dose temporarily 
stopped’ or ‘Dose skipped’. Where only the morning or evening dose is recorded as 
skipped, this will be counted as 0.5 days of withdrawn treatment equating to one dose 
missed for the respective day. 
Subjects will be categorised as ‘compliant’ or ‘not compliant’, where compliant subjects 
are those who achieve >80% overall compliance according to the above calculation.   
A table will be presented to summarise the duration of exposure to study treatment, 
actual duration, percent compliance and number and percentage of subjects 
categorised as compliant, by treatment group and overall for the safety analysis set.  
This table will also summarise the total daily dose of treatment administered by visit, 
allowing for any dose modifications.  This will be presented both for total daily dose 
measured in mg, as well as for total daily dose measured in mg per kg.  Total daily 
dose (mg per kg) will be calculated as: total daily dose (mg) at the time of the visit / 
most recent non-missing subject weight (kg) at the time of the visit.  In addition, the 
table will summarise total weight adjusted exposure (mg/kg), calculated as: 
∑(duration of dosing period (days) ∗total daily dose for dosing period (mg per kg)) 
where the duration of dosing period refers to the duration each different dose was 
taken, excluding interruptions and skipped doses. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 19 of 64 
Version: Final 6.0 
ST/form/010/6 
Details about medication bottles dispensed and returned, study drug administration 
and modifications, compliance and derived variables will be listed for the safety 
analysis set. 
3.5 Investigational Medicinal Product Modifications 
The number and percentage of subjects in the safety analysis set with and without 
any IMP modification, as well as the number and percentage of subjects with each 
type of IMP modification (dose increased, dose reduced, dose permanently stopped, 
dose temporarily stopped or dose skipped) and the reason for the modification 
(adverse event or other) will be summarised by treatment group and overall for each 
visit and overall for the study.  For each visit in this table, the summaries will be 
presented both in relation to the number of subjects recording modifications in the 
time from the previous visit up to and including the time of the respective visit and 
also the cumulative number of subjects who have recorded a modification at any visit 
up to and including the respective visit.  The overall cumulative summary will 
additionally include the number and percentage of subjects who recorded more than 
one occurrence of each type of IMP modification during the study.   A separate table 
will summarise the duration of first temporary dose interruption (for subjects with 
temporary dose interruption) and time from first IMP administration to the first dose 
modification of each type, presented by treatment and overall for the safety analysis 
set.  Finally, a further table will present descriptive statistics for the number of times 
dose was temporarily stopped for each patient both in total and by visit. 
All details about IMP modifications will be listed for the safety analysis set, including 
flags to indicate any subject who recorded more than one occurrence of a dose 
reduction and those who recorded more than one occurrence of a temporary stop 
(with an indication of the number of temporary stops where this is the case). 
3.6 Ankle Range of Motion 
Summary statistics of ankle dorsiflexion flexed (left and right) and ankle dorsiflexion 
straight (left and right) will be presented by treatment group and overall for the all 
enrolled subjects set. 
All ankle range of motion data will be listed in full for the all enrolled subjects set. 
3.7 Muscle Strength Test Modified MRC Grade 
Muscle strength test modified MRC grade will be evaluated for each knee at 
baseline.  The number and percentage of subjects with each modified MRC grade 
will be presented by treatment group and overall for each knee for the safety 
analysis set.  All baseline data for muscle strength test modified MRC grade will be 
listed for the all enrolled subjects set. 
3.8 Blood Collection for Genotypes 
Haplotypes of LTBP4 (VTTT, IAAM and other), SPP1 (TT, GT and GG) and the 
number of samples collected will be summarised by treatment group and overall for 
the all enrolled subjects set. 
All genotype data will be listed in full for the all enrolled subjects set. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 20 of 64 
Version: Final 6.0 
ST/form/010/6 
Only overall haplotype results will be summarised and listed.  Any further results for 
sub-parameters (e.g. relating to different positions on the gene and nucleotide 
substitutions) will not be presented but will be kept within the data for reference.   
4 EFFICACY EVALUATION 
Unless specified otherwise, all listings will be based on the all enrolled subjects set.  
All efficacy analyses and summaries will be performed on the ITT analysis set with the 
exception of analyses and summaries presenting MRI/MRS data  which will be on the 
MR cohort.  Additionally, see Section 2.8 regarding use of the target versus overall 
population. 
Baseline is defined as the last non-missing value recorded prior to or on the date of 
first study treatment. Where the value is recorded on the same date as first study 
treatment and there is no further information to confirm whether this was prior to start 
of treatment, the value will be considered prior to treatment if this was a screening or 
randomisation assessment and will be considered post treatment otherwise. 
4.1 Primary Efficacy Variable 
The primary efficacy assessment for this study is based on the time to climb 4 standard 
stairs (4SC) at 18 months.  The primary endpoint is the mean change in time to climb 
4 standard stairs before and after 18 months of treatment of givinostat versus placebo. 
Baseline 4SC will be the measurement taken at the randomisation assessment unless 
this is missing in which case baseline will be taken as the last non-missing value 
recorded prior to or on the date of first study treatment. 
In addition to the 4SC recorded in seconds, functional adaptation employed by the 
subject during the test will be evaluated and graded by functional evaluators according 
to standardised scales (See Appendix 7.1).  
Summary statistics of 4SC observed values and change from baseline will be 
presented by visit and treatment.  In addition, a plot of the average 4SC at each visit 
will be produced by treatment group. 
A shift table showing the movement of subjects with respect to functional adaptation 
options for the 4SC from baseline to 18 months after treatment will be presented by 
treatment.   
Furthermore, in order to additionally assess the 4SC data in terms of velocity rather 
than time, a reciprocal transformation will be applied to convert the timed results to 
appropriate units of velocity, according to the following conversion: 
Velocity (stairs/second) = 4 / Completion time (seconds) 
where this conversion is applied following any imputation of missing data as 
described in Section 4.4.4.  The summary statistics and plot described above will be 
repeated for these transformed values.  Analysis of this endpoint (described in 
Section 4.4.2) will also be repeated on the transformed scale.  
All 4SC and functional adaptation data will be listed. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 21 of 64 
Version: Final 6.0 
ST/form/010/6 
4.2 Key Secondary Efficacy Variables 
All key secondary efficacy data will be listed. All key secondary efficacy variables will 
be formally assessed after 18 months of treatment.   
4.2.1 
Functional Key Secondary Efficacy Variables 
4.2.1.1 Time to Rise from Floor 
The mean change from baseline in time to rise from the floor after 18 months of 
treatment with givinostat versus placebo will be assessed.  Time to rise from the floor 
will also be graded by functional evaluators according to standardised scales (see 
Appendix 7.2).  
Summary statistics of time to rise from floor observed values and change from 
baseline will be presented by visit and treatment group.  A plot of the average time to 
rise from the floor over time by treatment group will be produced. 
A shift table showing the movement of subjects with respect to functional adaptation 
options employed for rising from the floor from baseline to 18 months after treatment 
will be presented by treatment group.   
Note that where subjects have stopped the test prematurely, this is equivalent to not 
completing the test and therefore the missing time to rise from floor will be imputed 
according to the rules in Section 4.4.4 for summaries, plots and analyses. 
Furthermore, in order to additionally assess the time to rise from floor data in terms 
of velocity rather than time, a reciprocal transformation will be applied to convert the 
timed results to appropriate units of velocity, according to the following conversion: 
Velocity (1/second) = 1 / Completion time (seconds) 
where this conversion is applied following any imputation of missing data as 
described in Section 4.4.4.  The summary statistics and plot described above will be 
repeated for these transformed values.  Analysis of this endpoint (described in 
Section 4.4.2) will also be repeated on the transformed scale.  
4.2.1.2 Distance Walked in 6 Minutes 
The mean change from baseline in 6MWT after 18 months of treatment with givinostat 
versus placebo will be assessed.   
The number and percentage of subjects who completed the assessment and who 
stopped the assessment prematurely will be presented by visit and treatment group.  
Summary statistics of 6MWT observed values and change from baseline will be 
presented by treatment group.  In addition, a plot of the mean 6MWT over time will 
be produced by treatment group.  Summary statistics of observed values and 
change from baseline in the number of falls will also be presented.  Note that 
subjects who stopped the test prematurely will still be included in the summaries, 
plots and analyses of the total distance walked by the end of the test and the number 
of falls. 
4.2.1.3 Physical Function as Measured by NSAA 
The 17 items of the NSAA, ranging from ability to stand to ability to run 10 metres, 
will be graded using a standard score card with each assessment rated as 0 – 
unable to achieve independently, 1 – modified method but achieves goal 
independent of physical assistance from another, or 2 – normal with no obvious 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 22 of 64 
Version: Final 6.0 
ST/form/010/6 
modification of activity.  The total NSAA score will be calculated as the sum of the 
scores for each of the items. Where one or more scores for the 17 items are missing 
at a visit, the relevant rules described in  Section 4.4.4 and Appendix 7.5.4 will be 
followed.  
The first key secondary endpoint associated with NSAA is the change from baseline 
in the total NSAA score to after 18 months of treatment with givinostat or placebo.  
The second key secondary endpoint associated with NSAA is the cumulative loss of 
function on the NSAA over 18 months of treatment with givinostat or placebo.  For 
each subject at each post-baseline visit, failure to perform each of the 17 items of the 
NSAA will be assessed, where ‘failure’ is defined as a score transition from 2 or 1 at 
baseline to 0 at the respective visit. The total number of failed items for the visit will 
be calculated (maximum of 17 failed items per visit per subject).  The subject’s 
cumulative number of failures across all visits will be the sum of the total failures at 
each post-baseline visit.  Subject cumulative number of failures across all post-
baseline visits will be the endpoint of interest for analysis. In addition, total failed 
items at baseline will be calculated for each subject as the number of items with a 
score of 0 at the baseline NSAA assessment. Where one or more scores for the 17 
items are missing, the relevant rules described in Section 4.4.4 and Appendix 7.5.4 
will be followed. Note that as a result of the rule to impute any scheduled visits after 
early withdrawal, early withdrawal subjects will be included in the analysis using both 
collected and imputed assessments to calculate the cumulative number of failures 
post-baseline. The early withdrawal visit itself will be excluded from the cumulative 
number of failures across all post-baseline visits since this is an additional visit for 
these subjects outside of the expected scheduled post-baseline visits and would 
result in an inflated cumulative count. Where a subject scores zero at baseline on all 
items of the test, they will be excluded from the summaries and analyses of 
cumulative loss of function. 
Summary statistics for the observed responses and change from baseline for each 
item included in the NSAA assessment, as well as for the total NSAA score will be 
presented by visit and treatment group. 
Summary statistics will also be presented for baseline total items failed and for 
subject cumulative number of failed items across all post-baseline visits by treatment 
group. In addition the number and percentage of subjects meeting the above criteria 
for failure will be presented by visit for each of the NSAA items. 
4.2.1.4 Muscle Strength Evaluated by Knee Extension and Elbow Flexion as 
Measured by Hand-held Myometry 
The key secondary efficacy endpoint related to muscle strength is the mean change 
from baseline to 18 months after treatment with givinostat versus placebo in muscle 
strength evaluated by knee extension and elbow flexion.  These muscle strength 
variables will be measured by hand-held myometry (HHM). 
Summary statistics of the observed muscle strength measured in N (left knee 
extension, right knee extension, left elbow flexion and right elbow flexion) and change 
from baseline will be presented by visit and treatment group.  If more than one 
measurement is taken, the arithmetic mean of the measurements will be used for that 
visit for that particular subject.  These summaries will be repeated for muscle strength 
assessments normalised by subject weight (i.e. measured in N/Kg).  A plot of the mean 
muscle strength (measured in N/Kg) over time will be produced by treatment group.  


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 23 of 64 
Version: Final 6.0 
ST/form/010/6 
The endpoint values of interest for analysis will be the normalised muscle strength 
values (N/Kg).  
4.2.2 
Imaging Key Secondary Efficacy Variable (MR Cohort) 
4.2.2.1 Fat Fraction of Vastus Lateralis Muscles assessed by MRS 
The key secondary efficacy endpoint relating to imaging data will be the mean 
change in VL MFF as assessed by MRS before and after 18 months of treatment 
with givinostat versus placebo.  Analysis of this endpoint will only apply to the MR 
cohort (who will complete magnetic resonance assessment at baseline, 12 and 18 
months).   
Observed values and change from baseline in VL MFF will be summarised by visit 
and treatment group for the MR cohort.  The listing of MRS data for the final analysis 
will include the baseline data for all subjects, as well as the post-baseline data for the 
MR cohort, with a flag to indicate subjects in the MR cohort. 
For all analyses of MRS VL MFF, the final results from the blinded review of these 
data by University of Florida Imaging DMD network (see Section 2.3) will be used 
(external to the eCRF). The baseline VL MFF value initially entered onto the eCRF, 
prior to any adjustment from blinded review, will not be used in the analyses and will 
only be used for the purposes of assignment to target or off-target populations. It is 
acknowledged that there may be differences between the initial eCRF baseline result 
and the final baseline result following blinded review. This could mean that the 
adjusted result indicates the subject is in a different target/off-target population to 
that assigned from the initial eCRF result. Population assignment will not be adjusted 
for this. However, the listing of MRS data will include the baseline results from both 
the eCRF and final blinded data with an indication of the target/off-target outcome in 
each case. 
4.3 Exploratory Efficacy Variables for All Subjects 
All exploratory efficacy endpoint data will be listed.  The exploratory efficacy 
variables will be analysed at the final analysis after 18 months of treatment and will 
be supportive only and not subject to alpha control.  Therefore, nominal p-values will 
be presented with no adjustment. 
4.3.1 
Time to Run/Walk 10 Metres 
Mean change before and after 18 months of treatment with givinostat and placebo in 
the time to run or walk 10 metres will be assessed.  Summary statistics of observed 
values and change from baseline in the time to run or walk 10 metres will be 
presented by visit and treatment group.  A plot of the average time to run/walk 10 
metres at each visit will also be produced by treatment group.  A shift table showing 
the movement of subjects with respect to functional adaptation options (see 
Appendix 7.3) from baseline to 18 months after treatment will also be presented by 
treatment group. 
Note that where subjects have stopped the test prematurely, this is equivalent to not 
completing the test and therefore the missing time to run or walk 10 metres will be 
imputed according to the rules in Section 4.4.4 for summaries, plots and analyses.  
Furthermore, in order to additionally assess the time to run or walk 10 metres data in 
terms of velocity rather than time, a reciprocal transformation will be applied to 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 24 of 64 
Version: Final 6.0 
ST/form/010/6 
convert the timed results to appropriate units of velocity, according to the following 
conversion: 
Velocity (metres/second) = 10 / Completion time (seconds) 
where this conversion is applied following any imputation of missing data as 
described in Section 4.4.4.  The summary statistics and plot described above will be 
repeated for these transformed values.  Analysis of this endpoint (described in 
Section 4.4.2) will also be repeated on the transformed scale.  
4.3.2 
Paediatric Outcomes Data Collection Instrument (PODCI) Scores 
The PODCI quality of life questionnaire can either be completed by the subject’s 
parent or the subject themselves.  A total of five subscales (upper extremity function; 
transfer and basic mobility; sports and physical functioning; pain/comfort and 
happiness) and one global function scale can be calculated from the questionnaire.   
Summary statistics for the raw scores and standardised scores, together with the 
change from baseline over time for each subscale included in the PODCI 
assessment, as well as for the standardised scores of the global function scale will 
be presented by treatment group.  These tables will be produced separately for 
assessments completed by parents and for assessments completed by the subjects 
themselves. The endpoints of interest will be the change from baseline to 18 months 
in the standardised scores for each subscale and the global function scale, as 
completed by the parent and the subject. 
Details of the items included in each of the subscales, as well as the calculations to 
be applied in order to derive the raw and standardised scores, are included in 
Appendix 7.4. 
4.3.3 
Percent Predicted 6MWT 
The endpoint associated with the % predicted 6MWT is the mean change from 
baseline to after 18 months of treatment with givinostat or placebo in % predicted 
6MWT.  The predicted 6MWT at baseline is against healthy male subjects and is 
calculated using the Geiger formula (Geiger R, 2007) which is given as: 
♂: 6MWT = 196.72 + (39.81*age) – (1.36*age2) + (132.28*height) 
where age is the re-derived age in years and months at first study drug intake and 
height is in metres at baseline. The % predicted 6MWT at each visit for a subject is 
then found as: measurement for 6MWT at the visit / predicted 6MWT at baseline * 
100.  
Summary statistics of the % predicted 6MWT observed values and change from 
baseline will be presented by visit and treatment group.  In addition, subjects will be 
assigned to one of two subgroups based on their baseline % predicted 6MWT value 
(<80% versus ≥80%).  A summary table will present the observed values and 
changes from baseline over time for actual 6MWT values by treatment group and 
baseline % predicted 6MWT subgroup.  
4.3.4 
MRI Parameters (MR Cohort Only) 
The quantitative analysis of the acquired MRI imaging and QC reviewing will be 
performed by blinded personnel from University of Florida Imaging DMD. Two QC 
reviewers will cross-reference the event; in case of disagreement in grading, a third 
reader will provide independent grading as a tiebreaker.  


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 25 of 64 
Version: Final 6.0 
ST/form/010/6 
The following MRI observed values and change from baseline will be summarised by 
visit and treatment group for the MR cohort.  The endpoints of interest will be the 
mean change from baseline to 18 months in: 
 Fat fraction in 5 thigh muscles or muscle groups 
o Vastus lateralis 
o Biceps femoris long head  
o Semitendinosus 
o Quadriceps, encompassing the vastus lateralis, vastus intermedius, 
vastus medialis, rectus femoris 
o Hamstrings, encompassing the biceps femoris, semitendinosus, 
semimembranosus.  
 Cross-sectional area of 5 thigh muscles or muscle groups  
o Vastus lateralis 
o Biceps femoris long head  
o Semitendinosus 
o Quadriceps, encompassing the vastus lateralis, vastus intermedius, 
vastus medialis, rectus femoris. 
o Hamstrings, encompassing the biceps femoris, semitendinosus, 
semimembranosus.  
 Fat-corrected cross-sectional area (i.e. contractile CSA) of 5 thigh muscles or 
muscle groups 
o Vastus lateralis 
o Biceps femoris long head 
o Semitendinosus 
o Quadriceps, encompassing the vastus lateralis, vastus intermedius, 
vastus medialis, rectus femoris. 
o Hamstrings, encompassing the biceps femoris, semitendinosus, 
semimembranosus.  
The listing of MRI data for the final analysis will include the baseline data for all 
subjects, as well as the post-baseline data for the MR cohort, with a flag to indicate 
subjects in the MR cohort. 
4.3.5 
Time to 10% Persistent Worsening in 6MWT 
Time to 10% persistent worsening in 6MWT will be defined as the time from the date 
of first study treatment to the last time the 6MWT was not ≥10% worse than the 
baseline 6MWT (McDonald, et al., 2013).  If a subject has not achieved ≥10% 
persistent worsening in 6MWT, then time to 10% persistent worsening in 6MWT will 
be censored at the date of the last 6MWT assessment (including imputed 
assessments per Section 4.4.4.1), i.e. the 18 month assessment. 
The number and percentage of subjects who achieved ≥10% persistent worsening in 
6MWT and of those censored will be summarised by treatment group.  The Kaplan-


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 26 of 64 
Version: Final 6.0 
ST/form/010/6 
Meier estimates of the median, 25th percentile and 75th percentile for time to ≥10% 
persistent worsening in 6MWT, together with the associated 2-sided 95% confidence 
intervals (CI) will also be presented by treatment group.  Time to 10% persistent 
worsening in 6MWT will also be presented graphically by treatment group using a 
Kaplan-Meier plot.   
4.3.6 
Proportion of Subjects with ≥10% Persistent Worsening in 6MWT 
The proportion of subjects with ≥10% persistent worsening in 6MWT at the end of 
the study (compared to baseline) will be summarised by treatment group.  Subjects 
with ≥10% persistent worsening in 6MWT at the end of the study will be defined as 
those who record a 6MWT value which is ≥10% worse than the baseline 6MWT at 
any visit before or at the end of the study and this remains ≥10% worse than 
baseline until the end of the study.  
4.3.7 
Time to Persistent Loss of Standing (Baseline Through End of Study) 
Functional assessments are scheduled to take place every 3 months.  In order to 
allow time for recovery due to trauma, a subject will be considered to have persistent 
loss of standing if they are unable to stand for at least 2 consecutive assessments 
(i.e. at least 6 months).  Start of a persistent loss of standing will be the first 
assessment where this is observed.  A subject is unable to stand if their score for 
“Rise from floor” on the NSAA assessment is 0b (“Unable”) and if their rising from 
floor grading is 1 on the Rise from floor assessment.  If a subject has not met the 
criteria for persistent loss of standing by the end of the study, the time to persistent 
loss of standing will be censored at the date of the last NSAA or Rise from floor 
assessment (including imputed assessments per Section 4.4.4.1), i.e. the 18 month 
assessment.     
The number and percentage of subjects who have persistent loss of standing at any 
point post-baseline, as well as those censored, will be summarised by treatment 
group.  Time to persistent loss of standing will be calculated as the time from the 
date of first study treatment to the start of the first occurrence of persistent loss of 
standing.  The Kaplan-Meier estimates of the median, 25th percentile and 75th 
percentile for time to persistent loss of standing, together with the associated 2-sided 
95% CIs will also be presented by treatment group.  Time to persistent loss of 
standing will also be presented graphically by treatment group using a Kaplan-Meier 
plot. 
4.3.8 
Proportion of Subjects Who Lose Ambulation 
The proportion of subjects who lose ambulation during the study will be summarised 
by treatment group.  Loss of ambulation is defined as any subject who satisfies both 
of the following criteria at the same visit at any point prior to or at the end of the 
study and continues to satisfy the criteria at all subsequent visits to the end of the 
study: 
- 
Subject is unable to perform the 6MWT due to physical inability 
- 
Subject is unable to complete the 10-metre walk/run test in 30 seconds or less 
without any support or devices (10-metre walk/run test grading ≤2).  


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 27 of 64 
Version: Final 6.0 
ST/form/010/6 
4.3.9 
Correlation between the effect of Givinostat on disease progression 
and the type of DMD mutation, LTBP4 and Osteopontin genotype 
The exploratory endpoint of interest here is to evaluate any correlation between the 
effect of givinostat on disease progression and separately: the type of DMD mutation 
(Deletion, Duplication, Point Mutation); LTBP4 genotype (VTTT, IAAM, Other); 
Osteopontin (SPP1) genotype (TT, GT, GG).  This will be evaluated via summaries, 
plots and analyses for these subgroups of subjects, as described in Section 4.4.6.  If 
deemed of interest, additional investigation into correlation between these subgroups 
and the effect of givinostat on disease progression may be included at a later date as 
post hoc analyses. 
4.3.10 DMD serum biomarker 
A listing will present details regarding sample collection for evaluation of any 
possible DMD serum biomarker.  Summary and analysis of results of the DMD 
serum biomarker assessment will not be included as part of this SAP but in a 
separate dedicated SAP. 
4.4 Statistical Analysis 
4.4.1 
Hypothesis to be Tested 
The null hypothesis being tested for the primary endpoint is that there is no 
difference in mean change in 4SC from baseline to 18 months between the 
givinostat and placebo treatment groups: 
𝐻0: 4𝑆𝐶𝑔𝑖𝑣𝑖𝑛𝑜𝑠𝑡𝑎𝑡= 4𝑆𝐶𝑝𝑙𝑎𝑐𝑒𝑏𝑜 
The alternative hypothesis is that there is a difference in either direction in the mean 
change in 4SC from baseline to 18 months between the givinostat and placebo 
treatment groups: 
𝐻0: 4𝑆𝐶𝑔𝑖𝑣𝑖𝑛𝑜𝑠𝑡𝑎𝑡≠4𝑆𝐶𝑝𝑙𝑎𝑐𝑒𝑏𝑜 
All tests will be two directional and thus references to 1-sided p-values throughout 
this SAP refer to significance in either direction.  For all analyses, 2-sided p-values 
will be presented and will be subject to the relevant significance level in either 
direction, as stated in Section 4.4.5.  Similarly, 2-sided CIs will be presented. 
4.4.2 
Modelling Methods 
All efficacy analyses will be conducted in the target population.  Formal analysis will 
be conducted as described in this Section for the following in the target population: the 
primary efficacy endpoint at 18 months, all key secondary efficacy endpoints at 18 
months.  All other analyses (i.e. for different endpoints or timepoints in the target 
population, sensitivity or supplementary analyses, or any efficacy analyses later added 
for the overall population) will be supportive only and will not be subject to alpha 
control.  Therefore, nominal p-values will be presented.   
The change from baseline to 18 months after treatment with givinostat or placebo for 
the continuous efficacy variables described in Sections 4.1, 4.2 and 4.3 will be 
analysed using an analysis of covariance (ANCOVA).  Note that the ANCOVA analysis 
of muscle strength will be performed on the normalised muscle strength variable 
(measured in N/Kg) only.  In addition, the ANCOVA analysis of NSAA will be performed 
on the total NSAA score only, ANCOVA analysis of PODCI scores will be performed 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 28 of 64 
Version: Final 6.0 
ST/form/010/6 
on the standardised scores only (for each subscale and the global function scale as 
completed by subject and parent), and ANCOVA analysis of MRI parameters will be 
performed for the fat fraction results only.  In each instance, the dependent variable 
will be the outcome being modelled and terms for the corresponding baseline value 
and re-derived age at first dose (in years and months) will be included as independent 
covariates in the model, with randomised treatment group and concomitant steroid use 
(according to the 4 possible strata) included as independent classification factors. 
Where the dependent variable is not the muscle strength test, MRS VL MFF, PODCI 
score or MRI parameters, additional covariates will also be included in the model for 
the following baseline values (where not already included): 4SC, time to rise from floor, 
time to run/walk 10 metres, distance walked in 6 minutes (for the analysis of percent 
predicted 6MWT, this will be replaced with baseline percent predicted distance walked 
in 6 minutes). 
Least squares means and associated 2-sided CIs will be estimated for givinostat and 
placebo.  The treatment effect, being the difference in least squares means (givinostat-
placebo), will be presented along with the associated 2-sided CI and p-value.   
The need for a possible log transformation of these variables will be investigated prior 
to unblinding by assessing the ANCOVA model residuals without a treatment term. 
Where data are transformed for analysis, back transformation will be applied for the 
presentation of results. Presentation of the tables will be amended as needed for this, 
for example with the addition of an explanatory footnote. 
Analysis of cumulative loss of function on the NSAA over 18 months of treatment with 
givinostat or placebo will be performed using negative binomial regression. The 
dependent variable will be the subject cumulative number of failures across all post-
baseline visits.  Total failed items at baseline, baseline values for: 4SC, time to rise 
from floor, time to run/walk 10 metres, distance walked in 6 minutes and re-derived 
age at first dose (in years and months) will be included as independent covariates in 
the model, with randomised treatment group and concomitant steroid use included as 
independent classification factors. The estimated cumulative number of failures across 
18 months and associated 2-sided CIs from the model will be presented for each 
treatment group.  The treatment effect will be presented as the ratio of cumulative 
failures for givinostat relative to placebo along with the associated 2-sided CI and p-
value, where a lower ratio indicates a greater reduction in cumulative number of 
failures across 18 months for givinostat compared with placebo. 
The binary efficacy variables (proportion of subjects with > 10% persistent worsening 
in 6MWT, proportion of subjects losing ambulation during the study) will be analysed 
using logistic regression. In each instance baseline values for: 4SC, time to rise from 
floor, time to run/walk 10 metres, distance walked in 6 minutes and re-derived age at 
first dose (in years and months), will be included as independent covariates.  
Randomised treatment group and concomitant steroid use will be included as 
independent classification factors.  The odds ratio comparing the treatment groups will 
be presented, together with its associated 2-sided CI and p-value. 
The time to event variables (time to 10% persistent worsening in 6MWT, time to 
persistent loss of standing) will be analysed using Cox proportional hazards modelling, 
including baseline values for: 4SC, time to rise from floor, time to run/walk 10 metres, 
distance walked in 6 minutes and re-derived age at first dose (in years and months) 
as independent covariates and randomised treatment group and concomitant steroid 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 29 of 64 
Version: Final 6.0 
ST/form/010/6 
use as independent classification factors.  The hazard ratio will be presented, together 
with its associated 2-sided CI and p-value. 
Where adjustment of alpha is applied to any of the above analyses per the methods 
described in Section 4.4.5, the 2-sided CIs will be subject to the corresponding 
adjustment.  Thus the adjusted 2-sided CIs will be as indicated in the following table: 
 
Analysis 
Time Point 
Endpoint 
Applicable p-
value (1-sided) 
Applicable p-
value (2-
sided) 
CI (2-sided) 
Final 
analysis 
4SC at 18 months 
in the target 
population 
p ≤ 0.025 
p ≤ 0.05 
95% 
Final 
analysis 
Key secondary 
efficacy endpoints 
at 18 months in the 
target population 
p ≤ 0.025/i  
(i = rank 
according to 
Hochberg 
procedure) 
p ≤ 0.05/i  
(i = rank 
according to 
Hochberg 
procedure)  
100(1-0.05/i)% 
(i = rank 
according to 
Hochberg 
procedure) 
General 
All other analysis 
(supportive only) 
p ≤ 0.025 
(nominal p-
values 
presented) 
p ≤ 0.05 
(nominal p-
values 
presented) 
95% 
For the final analysis of key secondary efficacy endpoints at 18 months in the target 
population, unadjusted 95% CIs will be presented in the individual analysis tables.  
However, the applicable adjusted CIs following the Hochberg procedure will be given 
in an overall summary of these endpoints per Section 4.4.5. 
Further, as a reflection of the overall totality of evidence for a treatment effect on 
functional outcomes, the primary endpoint and the functional key secondary endpoints 
(as detailed in Section 4.2.1) will be subject to assessment by Hochberg.  This is 
equivalent to considering the primary and functional key secondary endpoints as 
equally important facets of the disease such that an improvement in any one, or more 
than one, of these endpoints can be considered to reflect a clinically meaningful benefit 
to the patient. 
4.4.3 
Adjustment for Covariates 
All efficacy analyses will be adjusted for covariates as described in Section 4.4.2. 
These will include the corresponding baseline value and re-derived age at first dose 
(in years and months) as covariates, and concomitant steroid use as a factor.  
Additional covariates will also be included for the following baseline values where 
appropriate (see Section 4.4.2): 4SC, time to rise from floor, time to run/walk 10 
metres, distance walked in 6 minutes (for the analysis of percent predicted 6MWT, 
this will be replaced with baseline percent predicted distance walked in 6 minutes). 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 30 of 64 
Version: Final 6.0 
ST/form/010/6 
4.4.4 
Handling of Missing Data 
4.4.4.1 Classification and Imputation 
For the efficacy analyses, any missing data for continuous values for a subject will be 
classified as follows: 
1. the subject has missing data due to reasons other than being non-ambulatory 
or physically unable to perform the test / assessment 
2. the subject has missing data due to being either non-ambulatory or otherwise 
physically unable to perform the test / assessment.  
Any missing values classified as 1 will be imputed using the mean of all non-missing 
values for the respective measurement and timepoint across all subjects randomised 
to the respective treatment and in the respective concomitant steroid stratum and 
Group (i.e. Group A, target population or Group B, off-target population).   
Any missing values classified as 2 will be imputed by setting the value to zero or to 
twice the maximum non-missing value recorded across all subjects depending on the 
directionally of the test. 
In all cases, imputation of any data classified as 1 will be completed first, followed by 
imputation of any data classified as 2. 
Classification and imputation of missing data will be completed prior to any 
transformation of the data for analysis.  For example transformation of the timed 
function test results for presentation of velocity or any log transformation applied as 
needed (per Section 4.4.2). 
For binary or time to event variables where missing data means that the binary 
response or time to event cannot be determined, the missing data from which the 
variable is derived (e.g. 6MWT values) will first be classified and imputed, as described 
above, in order to then derive the binary response or the time to event.  Exceptions to 
this are where the criteria for deriving the binary response themselves refer to 
presence of missing data, for example loss of ambulation.  The classification described 
above will be used for the relevant missing data in these cases in order to confirm 
physical inability to complete the respective test.  Further details are given below 
regarding the rules for derivation of the binary endpoints in the presence of missing 
data. 
For the NSAA assessment, where the total score is a sum of ordinal item scores, 
imputation of Class 1 and Class 2 data will follow a different approach as defined in 
Appendix 7.5.4.   
The rules for classifying missing data from the responses on the eCRF and any 
additional considerations for imputation are given in Appendix 7.5 for each respective 
endpoint.  Unless otherwise stated, only the value of interest for analysis will be 
classified and imputed.  For example, the ‘duration’ for the 4SC assessment will be 
imputed but not the 4-stair ascent grading.   
Note that missing data at any scheduled timepoint should be imputed according to the 
above rules.  This includes any scheduled timepoints after a subject withdraws early.  
In these cases, where the final assessment prior to withdrawal was missing and 
determined to be Class 2 missing data, all missing assessments post withdrawal will 
also be considered Class 2.  Otherwise, these will be considered Class 1.  Note that 
where this applies to an NSAA assessment, ‘Class 1’ will refer to the scenario where 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 31 of 64 
Version: Final 6.0 
ST/form/010/6 
‘Was assessment attempted?’ = ‘No’.  Where a date of assessment is required, the 
predicted date for imputed timepoints post withdrawal will be used.  The same 
approach will be followed for any completely missing visits prior to withdrawal or 
completing the study, where no information has been entered into the respective CRF 
assessment page indicating whether or not it was performed.  
Where data entered into the CRF for an assessment are ambiguous such that they do 
not reflect any of the expected responses outlined in Appendix 7.5 and therefore 
missing data cannot be classified, a worst case approach will be followed and the 
missing data will be assumed Class 2.   
A review will be performed at the BDRM to confirm correct classification of missing 
data.  This may identify data entered into the CRF assessment page which comply 
with Appendix 7.5 but additional information is available to contradict the classification 
(for example in comments).  Any such cases will be assessed on a case by case basis 
to determine the appropriate classification to be applied.     
4.4.4.2 Analysis 
Once classified and imputed, the following procedures will be applied for the analysis 
of endpoints where there are missing data with imputation.  The approach will be 
dependent on the class(es) of missing data present and also the directionality of the 
test where Class 2 missing data are present.  Any analysis of binary or time to event 
variables with missing data, or the cumulative loss of function on the NSAA, will use 
the appropriate procedure described in Section 4.4.2, following any classification and 
imputation per the methods above.  Thus, the below procedures apply only to the 
continuous variables. 
Note that where the endpoint to be analysed is a change from baseline, any imputation 
(per the following procedures) will be applied to the observed values prior to finding 
the corresponding change from baseline. 
Variables with only Class 1 missing data 
For the following variables, only Class 1 missing data will be applicable: 
 VL MFF determined by MRS 
 PODCI standardised scores for each subscale and the global function scale, as 
completed by the parent and the subject 
 Fat fraction in 5 thigh muscles as determined by MRI 
 Cross-sectional area of 5 thigh muscles as determined by MRI 
 Any other variable where all missing values have been classified as 1 and no 
Class 2 missing values have been identified.  
Any missing values will be imputed as per the rules for Class 1 missing data and the 
applicable analysis will be performed as described in Section 4.4.2 and Sections 4.1 
to 4.3.10 as relevant to the respective variable. 
 
Variables with any Class 2 missing data where higher values are worse 
For the following variables, the directionality is such that higher values represent a 
worse outcome: 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 32 of 64 
Version: Final 6.0 
ST/form/010/6 
 4SC 
 Time to rise from the floor 
 Time to run/walk 10 metres 
If any Class 2 missing data are identified for these variables, the analysis of the 
variable will be performed as follows: 
If 𝑥𝑖𝑗𝑘 represents the value of the variable to be analysed for subject 𝑖 randomised to 
treatment 𝑗 at time 𝑘, then missing data will be imputed as 
Class 1:  𝑥𝑖𝑗𝑘= 𝑥̅𝑗𝑘 where 𝑥̅𝑗𝑘 is the mean of all non-missing values for the 
respective measurement at time 𝑘 across all subjects randomised to treatment 
j and in the respective concomitant steroid stratum and Group (i.e. Group A, 
target population or Group B, off-target population). 
Class 2:  𝑥𝑖𝑗𝑘= 2 × 𝑀𝑎𝑥(𝑥) where 𝑀𝑎𝑥(𝑥) is the maximum non-missing value 
recorded for the variable across all subjects, regardless of treatment, stratum 
or Group. 
Following the assignment of imputed values, the data 𝑥𝑖𝑗𝑘 will be analysed as 
described in Section 4.4.2 and Sections 4.1 to 4.3.10, as relevant to the respective 
variable using PROC MIXED, ensuring that reference levels are stated for all class 
variables so that difference in LSmeans is calculated as givinostat-placebo. F-tests 
from PROC MIXED will be based on Kenward-Roger's adjusted degrees of freedom. 
LSmeans for drug and placebo from this model, denoted 𝑥̅𝐷 and 𝑥̅𝑃 respectively, the 
difference in the LSmeans, 𝑥̅𝐷−𝑥̅𝑃, and the associated 2-sided CI and p-value will be 
taken from the LSmeans statement in PROC MIXED.  
Note that for the analysis of these variables on the transformed scale representing 
velocity rather than time, transformation will be applied to the imputed data 𝑥𝑖𝑗𝑘 to give 
the velocity values 𝑢𝑖𝑗𝑘 used in the analysis model described above.  The results from 
the model will be presented on the transformed scale without back transformation and 
will be interpreted as estimates of velocity. 
 
Variables with any Class 2 missing data where lower values are worse 
For the following variables, the directionality is such that lower values represent a 
worse outcome: 
 6MWT 
 Percent predicted 6MWT 
 NSAA 
 Muscle strength evaluated by knee extension and elbow flexion as measured 
by HHM. 
If any Class 2 missing data are identified for these variables, the analysis of the 
variable will be performed as follows: 
If 𝑥𝑖𝑗𝑘 represents the value of the variable to be analysed for subject 𝑖 randomised to 
treatment 𝑗 at time 𝑘, then subjects with missing data will be imputed as 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 33 of 64 
Version: Final 6.0 
ST/form/010/6 
Class 1:  𝑥𝑖𝑗𝑘= 𝑥̅𝑗𝑘 where 𝑥̅𝑗𝑘 is the mean of all non-missing values for the 
respective measurement at time 𝑘 across all subjects randomised to treatment 
j and in the respective concomitant steroid stratum and Group (i.e. Group A, 
target population or Group B, off-target population). 
Class 2:   𝑥𝑖𝑗𝑘= 0 
The exception to this is the NSAA total score which will be derived from imputed item 
scores as described in Appendix 7.5.4. 
Following the assignment of imputed values, these variables will be analysed as 
described in Section 4.4.2 and Sections 4.1 to 4.3.10, as relevant to the respective 
variable, using the same PROC MIXED approach as detailed above. 
4.4.4.3 Tipping Point Sensitivity Analysis 
In addition to the above methods for handling missing data, if the treatment effect on 
the primary analysis is significant, a ‘tipping point’ sensitivity analysis of the primary 
outcome will be performed.  This analysis assesses the impact of missingness across 
a continuum of assumptions until the ‘tipping point’ is identified.  This is the point at 
which the assumption regarding the effect of the treatment in subjects with missing 
data nullifies or reverses the treatment effect obtained in the primary analysis.  
Implementation of this sensitivity analysis mimics standard multiple imputation and is 
described below:  
1. For any Class 1 missing 4SC values, use the mean and SD of all non-missing 
values for the respective treatment group to generate the imputed values from 
a normal distribution.  Note that any Class 2 missing 4SC values should 
continue to be imputed with twice the maximum non-missing value recorded 
across all subjects as applicable per the above rules.   
2. Implement Step 1 10 times so that 10 complete datasets are produced.  For 
each of these datasets, find the change from baseline to 18 months in 4SC 
values for each subject.  
3. Analyse the 10 complete datasets; this should be performed as described in 
Section 4.4.2 using the PROC MIXED approach described in Section 4.4.4.2.  
4. Combine the results from the 10 data sets using Rubins methods via PROC 
MIANALYZE for inference. 
5. Repeat Steps 1 to 4 but now with an appropriate small shift (+) applied to the 
individual subject values for the change from baseline in 4SC in the givinostat 
treatment group (but not to the placebo group).  This shift is applied after step 
2, i.e. after the generation of the datasets including any imputation, and after 
finding the change from baseline values but prior to the analysis of these.  The 
directionality of the shift will be such that this reduces the treatment difference 
between givinostat and placebo.   
6. Display the estimated treatment effect and associated 2-sided CIs vs degree of 
shift. 
7. Repeat Steps 5 and 6, increasing the shift each time as +2, +3,…,+(treatment 
effect seen in the primary analysis).   
8. Identify the tipping point where p>0.025. 


Veristat study no: ICO16001 
Italfarmaco study no: DSC/14/2357/48 
Date: 13APR2022 
Page 34 of 64 
Version: Final 6.0 
ST/form/010/6 
4.4.4.4 Imputation of Date of Birth 
For the purpose of any data presentation and calculations requiring date of birth, any 
partially collected date of birth, or date of birth collected according to quarterly periods, 
will be imputed according to the following rules. 
For all subjects enrolled prior to protocol version 6.0 who did not enrol with the updated 
CRF page to collect quarterly date of birth, any partial date of birth with a non-missing 
month and year was imputed to the first of the month at data entry.  Any partial date 
of birth with a non-missing year was imputed to 1st January at data entry.  Therefore, 
date of birth will be used as collected in the analyses and data presentations. 
For all subjects enrolled under protocol version 6.0 or above, or who enrolled prior to 
protocol version 6.0 but with the updated CRF page to collect quarterly date of birth, 
the collected quarterly date of birth will be imputed to the middle of each quarter as 
follows: 
Collected date of birth = 01JANXXXX, imputed to 14FEBXXXX 
Collected date of birth = 01APRXXXX, imputed to 16MAYXXXX 
Collected date of birth = 01JULXXXX, imputed to 15AUGXXXX 
Collected date of birth = 01OCTXXXX, imputed to 15NOVXXXX 
where XXXX is the collected year of birth.  
4.4.4.5 Imputation of Dates for Calculations or Classification 
Note that where calculations or classification of data relies on the use of partial 
collected dates, imputation of the partial dates may be performed for the purposes of 
the derivation.  Where this is the case, specific details are provided in the relevant 
sections of this SAP.  
4.4.5 
Adjustment for Multiple Comparisons 
The p-value applicable to the final analysis of 4SC at 18 months in the target 
population will be p ≤ 0.025 1-sided.  For final analysis of the key secondary efficacy 
endpoints at 18 months in the target population, adjustment for multiple comparisons 
will be applied as described below.  For all other analyses (i.e. for different endpoints 
or timepoints in the target population, or analyses in the overall population), analysis 
will be considered supportive only.  Therefore, nominal p-values will be presented 
and the significance level applicable will be p ≤ 0.025 1-sided.  
In accordance with EMA (European Medicines Agency, 2002) and FDA guidelines  
(U.S. Food and Drug Administration, 2017), the assessment of multiple key 
secondary efficacy endpoints at 18 months in the target population at the final 
analysis will be accounted for using the Hochberg procedure (Hochberg, 1988).   
The key secondary efficacy endpoints are given in Section 4.2 (time to rise from the 
floor, 6MWT, muscle strength evaluated by knee extension, muscle strength 
evaluated by elbow flexion, physical function as measured by total NSAA score, 
physical function as measured by cumulative loss of function on the NSAA, VL MFF 
as assessed by MRS).  Each of these endpoints will be analysed and the resulting 1-
sided p-values will be ordered in descending order, from least to most significant.  
The highest p-value will then be compared with 0.025, the specified level of 
significance for the primary endpoint at the final analysis for this study, and if it is 
>0.025, the subsequent p-value will be considered in relation to 0.025/2=0.0125.  As


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 35 of 64 
Version: Final 6.0 
ST/form/010/6 
soon as the ith endpoint has a corresponding p-value <0.025/i, the treatment effects 
for that endpoint and all of the endpoints following it are considered to be significant.  
A table will be presented summarising the p-values and associated adjusted 2-sided 
CIs from each of the key secondary efficacy endpoints with significance indicated 
according to the above approach. 
4.4.6 
Examination of Subgroups 
Summaries, plots or analyses of efficacy or safety data presented by subgroup will 
only be produced in each case if there are at least 5 subjects per treatment arm in at 
least 2 of the respective subgroup levels. 
4.4.6.1 Presentation of Efficacy Data by Subgroup 
All repeat summaries and analyses of efficacy data by subgroups will be performed 
on the target population only and will be considered supportive and not subject to 
alpha control.  Therefore, only nominal p-values will be presented. 
In order to determine whether dose interruptions, modifications or starting dose have 
an impact on the efficacy of givinostat, the following subgroups of subjects will be 
defined: 
 Subjects who maintained treatment for greater than 80% of the time versus 
those who did not.  This will be equivalent to total percent compliance 
calculated as described in Section 3.4.   
 Subjects whose total weight adjusted exposure (mg/kg) was < versus >= the 
median total weight adjusted exposure (mg/kg).  For each subject the total 
weight adjusted exposure (mg/kg) will be calculated as: 
∑(duration of dosing period (days) ∗total daily dose for dosing period (mg per kg)) 
The median total weight adjusted exposure (mg/kg) will be calculated and 
used to determine the subgroups.  
 Subjects who started on the higher dose specified in Protocol Versions =< 4.0 
versus those who started on the lower dose specified in Protocol Versions > 
4.0.  
The following endpoints will be summarised, plotted and analysed in the same way 
as described in Sections 4.1, 4.2, 4.3 and 4.4.2 for these subgroups: 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
4SC 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
MRS VL MFF 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
time to rise from the floor 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
6MWT 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
muscle strength evaluated by knee extension and elbow flexion 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 36 of 64 
Version: Final 6.0 
ST/form/010/6 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
NSAA score 
 Time to persistent loss of standing 
 Proportion of subjects who lose ambulation 
In order to determine whether the effects of givinostat versus placebo are related to 
the type of DMD mutation or the LTBP4 and SPP1 genotypes, three further 
subgroups of subjects will be defined: DMD mutation (Deletion, Duplication, Point 
Mutation), LTBP4 (IAMM, VTTT, Other) and SPP1 (TT, GT, GG).  The following 
endpoints will be summarised and plotted for these three subgroups in the same way 
as described in Sections 4.1 and 4.2:   
 Change from baseline to 18 months of treatment with givinostat or placebo in 
4SC 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
MRS VL MFF 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
time to rise from the floor 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
6MWT 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
muscle strength evaluated by knee extension and elbow flexion 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
NSAA score 
In addition, the following endpoints will be summarised and analysed for the DMD 
mutation, LTPB4 and SPP1 subgroups in the same way as described in Sections 
4.3.7, 4.3.8 and 4.4.2): 
 Time to persistent loss of standing 
 Proportion of subjects who lose ambulation 
Finally, the following endpoints will be summarised, plotted and analysed as 
described in Sections 4.1, 4.2, 4.3 and 4.4.2 by baseline age category based on the 
re-derived age at first dose in years and months (6 – 7 years versus > 7 years). Note 
that subjects will be assigned to these subgroups so that any age from 6 to 7.9999 
years is assigned to the 6-7 years group, any ages from 8 years onwards are 
assigned to the > 7 years group: 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
4SC 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
time to rise from the floor 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
6MWT  
 Change from baseline to 18 months of treatment with givinostat or placebo in 
muscle strength evaluated by knee extension and elbow flexion 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 37 of 64 
Version: Final 6.0 
ST/form/010/6 
 Change from baseline to 18 months of treatment with givinostat or placebo in 
NSAA score 
 Percent predicted 6MWT 
 Time to 10% persistent worsening in 6MWT 
 Proportion of subjects with >10% persistent worsening in 6MWT 
 Time to persistent loss of standing 
 Proportion of subjects who lose ambulation 
4.4.6.2 Impact of Age and Baseline Functional Status on Treatment Effect 
Further to the above repeat summaries and analyses by subgroups, an analysis will 
be conducted to better determine the impact on treatment effect of baseline age and, 
separately, baseline functional status.  This may prompt further post hoc analyses by 
specific subgroups should this be deemed worthwhile.  This analysis will be 
conducted as described below for each of the following endpoints: 
 Change from baseline in 4SC 
 Change from baseline in time to rise from the floor 
 Change from baseline in 6MWT 
 Change from baseline in total NSAA score 
 Change from baseline in muscle strength evaluated by knee extension and 
elbow flexion 
 Change from baseline in MRS VL MFF. 
Impact of baseline age on treatment effect:   
To determine the impact of baseline age, for each of the above endpoints the 
ANCOVA model described in Section 4.4.2 will be repeated with the addition of the 
interaction term for treatment by re-derived age at first dose (in years and months). 
The treatment effect and parameter estimates from the model will be used to plot the 
treatment effect as a function of age, using: 
TrtEffect = B1 + B2*Age, where: 
TrtEffect = LS mean difference (givinostat-placebo) for the endpoint 
B1 = Parameter estimate for treatment from the model  
B2 = Parameter estimate for the treatment by age interaction term from the model 
Age = Re-derived age at first dose. 
The parameter estimate covariate matrix will be used to compute the variance of the 
treatment effect as a function of age in order to indicate the confidence interval on 
the plot. 
Impact of baseline functional status on treatment effect: 
To determine the impact of baseline functional status for the same endpoints, the 
ANCOVA model will be repeated again but replacing the treatment by age interaction 
term with the interaction term for treatment by baseline endpoint value (e.g. 
treatment by baseline 4SC for the 4SC endpoint).  The treatment effect and 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 38 of 64 
Version: Final 6.0 
ST/form/010/6 
parameter estimates from this model will be used to plot the treatment effect as a 
function of baseline endpoint value, using: 
TrtEffect = B1 + B2*Base, where: 
TrtEffect = LS mean difference (givinostat-placebo) for the endpoint 
B1 = Parameter estimate for treatment from the model  
B2 = Parameter estimate for the treatment by baseline endpoint interaction term from 
the model 
Base = Baseline of respective functional endpoint value. 
The parameter estimate covariate matrix will be used to compute the variance of the 
treatment effect as a function of baseline endpoint value in order to indicate the 
confidence interval on the plot. 
4.4.6.3 Presentation of Safety Data by Subgroup 
In addition to the above subgroup summaries and analyses of efficacy data, selected 
summaries of safety data as described in Section 5 will also be repeated by 
subgroups, for the overall population only. 
In order to determine any impact of dose interruptions, modifications or starting dose 
on safety, the following summaries will be repeated for the subgroups total weight 
adjusted exposure (mg/kg) < versus >= median total weight adjusted exposure 
(mg/kg), and higher starting dose (Protocol Versions =< 4.0) versus lower starting  
dose (Protocol Versions > 4.0): 
 All adverse event summaries described in Section 5.1 
 All hematology summaries and plots described in Section 5.2.1 
 All clinical chemistry summaries and plots described in Section 5.2.2 but 
restricted to triglycerides only.   
4.4.7 
Supplementary Analyses 
4.4.7.1 Impact of 18 Month Visits Performed Outside of Expected Assessment 
Windows 
As described in Section 2.9, in order to address the impact of the COVID-19 
pandemic in terms of 18 month visits performed outside of the expected visit 
windows, repeated analysis of the primary and key secondary endpoints will be 
performed using the population of subjects excluding those with visits outside of the 
window.  See Section 2.9 for details. 
4.4.7.2 Impact of MRS VL MFF on Functional Treatment Effect Over Time 
Further supplemental analyses may be performed if the following criteria are met: 
- 
A significant treatment effect is demonstrated for the imaging key secondary 
efficacy endpoint (mean change in VL MFF as assessed by MRS before and 
after 18 months of treatment with givinostat versus placebo),  
AND 
- 
Trends over time are observed for the primary endpoint either with or without 
a significant treatment effect. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 39 of 64 
Version: Final 6.0 
ST/form/010/6 
In the case that these criteria are met, the data will be reviewed to determine 
whether to proceed with further supplementary analyses exploring the extent to 
which treatment effect on the primary endpoint is influenced by the treatment effect 
on MRS VL MFF over time, thus suggesting a potential functional benefit over a 
longer follow-up period.  Where this analysis is deemed beneficial, the 
supplementary analysis of the primary endpoint will be conducted as described 
below.        
A mixed effects model with repeated measures (MMRM) will be fitted to the change 
from baseline in the primary endpoint to each post-baseline visit at which the 
endpoint is assessed.  The model will include baseline values for: 4SC, time to rise 
from floor, time to run/walk 10 metres, distance walked in 6 minutes and re-derived 
age at first dose (in years and months) as covariates, concomitant steroid use 
(according to the 4 possible strata), treatment and visit as fixed effects and the 
treatment by visit interaction.  F-tests from PROC MIXED will be based on Kenward-
Roger’s adjusted degrees of freedom. An unstructured variance/covariance matrix 
will be used for the repeated visits within a subject.   
The above model will then be repeated with the addition of the following terms: MRS 
VL MFF value at each visit, MRS VL MFF by visit interaction, MRS VL MFF by 
treatment interaction, MRS VL MFF by treatment by visit interaction. 
For each of the two models, the following will be presented and used to assess 
whether the treatment effect is reduced by the addition of MRS VL MFF to the 
model: for each visit included in the model, adjusted least squares means and 
associated 2-sided CIs will be estimated and presented for givinostat and placebo.  
The treatment effect at each visit, being the difference in adjusted least squares 
means (givinostat-placebo), will also be presented along with the associated 2-sided 
CIs and p-values. 
4.5 Pharmacokinetics 
Blood samples for PK analysis of givinostat (ITF2357) and its major metabolites 
(ITF2374 and ITF2375) will be collected.  There are 5 possible visits where the PK 
samples can be taken: Visits 7, 10, 11, 13 and 15.   
All subjects will have a total of 6 PK specimens drawn during the study: 
 Two samples drawn pre-dose.  These 2 specimens must be drawn at different 
visits 
 One sample drawn between 0 and 2 hours post-dose 
 One sample drawn between 2 and 4 hours post-dose 
 One sample drawn between 4 and 6 hours post-dose 
 One sample drawn between 6 and 10 hours post-dose 
PK parameters will be derived, where data allow, from the plasma concentration data 
for givinostat and its major metabolites.  The actual sampling times will be used in the 
derivation of the PK parameters.     
A listing will present details of PK assessments and plasma concentrations for the PK 
analysis set. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 40 of 64 
Version: Final 6.0 
ST/form/010/6 
Details regarding population PK procedures, the derivation of PK parameters and 
further analyses and summaries of PK data will be given in a separate Population PK 
data analysis plan.  Any evaluation of the relationship of givinostat PK exposure to 
efficacy and safety endpoints will also be documented separately to this SAP. 
5 SAFETY EVALUATION 
All safety listings will be presented for the all enrolled subjects set and all safety tables 
and figures will be presented for the safety analysis set unless specified otherwise.  
Additionally, see Section 2.8 regarding use of the target versus overall population. 
Baseline is defined as the last non-missing value recorded prior to or on the date of 
first study treatment. Where the value is recorded on the same date as first study 
treatment and there is no further information to confirm whether this was prior to start 
of treatment, the value will be considered prior to treatment if this was a screening or 
randomisation assessment and otherwise will be considered post treatment. 
5.1 Adverse Events 
Adverse events (AEs) will be coded using the MedDRA Dictionary Version 24.1. 
A treatment-emergent adverse event (TEAE) is defined as an AE that started or 
worsened on or after the date of start of the administration of the IMP. 
There will be no imputation of unknown dates for the calculation of duration or study 
day.  However, for sorting and assignation, if the start date is unknown then it will be 
assumed to be treatment emergent unless the partial start date, or other data (i.e. stop 
date) indicates differently. 
If the relationship to study drug is unknown, the AE will be assumed to be related to 
the study drug. 
The total number of TEAEs and the total number of subjects with TEAEs, the total 
number of serious TEAEs and the total number of subjects with serious TEAEs, the 
total number of subjects with TEAEs leading to withdrawal, the total number of 
subjects with TEAEs leading to permanent discontinuation with IMP, the total 
number of subjects with TEAEs leading to temporary discontinuation with IMP, the 
total number of subjects with TEAEs leading to dose reduction, the total number of 
subjects with TEAEs leading to death, the number of subjects with TEAEs by 
severity and relationship to study drug will be summarised. 
If a subject experienced more than one TEAE, the subject will be counted once at 
the worst severity and at the most related event.   
The following summary tables will be produced for each treatment group by 
MedDRA system organ class (SOC) and preferred term (PT) within each SOC: 
 total number of TEAEs and the total number of subjects with TEAEs 
 total number of serious TEAEs and the total number of subjects with serious 
TEAEs 
 total number of subjects with TEAEs leading to withdrawal 
 total number of subjects with TEAEs leading to permanent discontinuation 
with IMP 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 41 of 64 
Version: Final 6.0 
ST/form/010/6 
 total number of subjects with TEAEs leading to temporary discontinuation with 
IMP 
 total number of subjects with TEAEs leading to dose reduction 
 total number of subjects with TEAEs leading to death 
 total number of subjects with serious TEAEs leading to withdrawal 
 total number of subjects with TEAEs by severity (Grade 1 Mild, Grade 2 
Moderate, Grade 3 Severe or medically significant but not immediately life-
threatening, Grade 4 Severe or life-threatening, Grade 5 Death related to AE) 
 total number of subjects with TEAEs by relationship to study drug (related to 
study drug, not related to study drug) 
 total number of subjects with TEAEs by steroid type at baseline (deflazacort, 
prednisone, other) 
For all of the above, SOC and PT will be presented in decreasing frequency of the 
total number of subjects with TEAEs and then alphabetically. 
Further details of the above tables are given below: 
1. If a subject experienced more than one TEAE, the subject will be counted 
once for each SOC and once for each PT. 
2. If a subject experienced more than one TEAE, the subject will be counted 
once for each PT. 
3. If a subject experienced more than one TEAE, the subject will be counted 
once for each SOC and once for each PT at the worst severity. 
4. If a subject experienced more than one TEAE, the subject will be counted 
once for each SOC and once for each PT using the most related event. 
A by-subject AE data listing including verbatim term, coded term, treatment group, 
severity, time of onset and cessation of event, whether the AE was serious, action 
taken with study drug, other action taken, outcome and relationship to study 
treatment will be provided.  The dose at onset of each AE will also be presented. 
Where a partial AE start date is recorded and there is more than one dose recorded 
during the possible period of AE onset, the maximum recorded dose taken during 
this time is presented. 
In addition, the number and percentage of subjects with bronchopulmonary AEs 
(BAEs) will be presented by treatment group. Events considered to be BAEs will be 
identified via a medical review conducted prior to database lock (interim and final 
analyses) or data extract for safety reviews. BAEs will include but are not limited to 
respiratory tract infections involving the larynx, trachea, bronchi, lower airways or 
lung.  As a conservative approach, more generic conditions, such as AEs recorded 
as ‘respiratory tract infection’, will be included. Where ‘Influenza’ events have been 
recorded, the concomitant presence of relevant respiratory symptoms (i.e. cough, 
laryngitis, bronchitis) will be verified in order to determine whether to count as a BAE.  
This table will also include the number and percentage of subjects who were given 
antibiotics for BAEs and a summary of the duration of antibiotic use for BAEs by 
treatment group.  Antibiotics given for BAEs will be identified via medical review prior 
to database lock for the final analysis and interim analyses as needed.  Duration of 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 42 of 64 
Version: Final 6.0 
ST/form/010/6 
antibiotic use for BAEs (months) will be calculated for each subject in relation to 
these identified antibiotics as: 
Total duration of antibiotic use for BAEs – Total interruption in antibiotic use for BAEs  
where total duration of antibiotic use for BAEs is calculated as: 
Last antibiotic end date – First antibiotic start date + 1 
and total interruption in antibiotic use for BAEs is calculated as the sum of any time 
that antibiotics were not taken for BAEs between the first antibiotic start date and the 
last antibiotic end date.  
Serious AEs, AEs leading to permanent discontinuation of IMP and AEs leading to 
dose reduction or permanent discontinuation of IMP will be listed separately. 
5.2 Clinical Laboratory Evaluation 
For each laboratory parameter, the baseline value will be defined as the last non-
missing scheduled or unscheduled value available prior to or on the date of first 
study treatment. Where the value is recorded on the same date as first study 
treatment and there is no further information to confirm whether this was prior to start 
of treatment, the value will be considered prior to treatment if this was a screening or 
randomisation assessment and otherwise will be considered post treatment. If no 
measurement is recorded prior to first study treatment administration, the baseline 
value will be considered missing.   
5.2.1 
Hematology 
Hematology parameters will be measured in Système International (SI) units at all 
EU sites and in US conventional units at all US sites.  All results will be converted to 
SI units for the purposes of summaries, plots and listings.  Summary statistics of 
hematology observed values and change from baseline by parameter and visit will 
be presented by treatment group for all subjects in the safety analysis set.   
In addition, the following summaries in relation to post-baseline platelet counts will 
be presented by treatment group: minimum values, time to nadir (days) and time to 
recovery (days).  These will be defined as follows: 
Minimum value = minimum post-baseline platelet count for the subject. 
Time to nadir (days) = time to first minimum value post-baseline regardless if this is 
within the normal range. 
Time to recovery (days) = for subjects whose minimum post-baseline value is below 
the lower limit of normal, the time to recovery is calculated as the time from the 
minimum value below lower limit of normal to the first value within the normal range. 
Furthermore, a table will be presented for subjects in the safety analysis set who 
reduced dose due to platelet count decrease which will summarise the following in 
relation to post-baseline platelet counts by treatment group: minimum values, time to 
nadir (days), time to recovery (days), time on treatment after recovery (days), 
additional platelet decrease after recovery, time on treatment without recovery 
(days), where: 
Time on treatment after recovery = for subjects who record recovery from the 
minimum value below the lower limit of normal, the time on treatment after recovery 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 43 of 64 
Version: Final 6.0 
ST/form/010/6 
is calculated as the time from the date of recovery to the last treatment date or date 
of data cut-off. 
Additional platelet decrease after recovery = number of subjects who record recovery 
from the minimum value below the lower limit of normal and then record a 
subsequent value below the lower limit of normal. 
Time on treatment without recovery = for subjects who do not record recovery from 
the minimum value below the lower limit of normal, the time on treatment without 
recovery is calculated from the date of the minimum value below the lower limit of 
normal to the last treatment date or date of data cut-off. 
A plot of the mean platelet count at each visit will be produced by treatment group. 
Shift in hematology values from baseline to each visit for low, normal, high and total 
results based on reference ranges will be summarised by treatment group.   
A box and whisker plot will present the results for the following parameters over time 
by treatment group: platelets, hemoglobin, neutrophils, leukocytes. 
All hematology values will be listed, flagging all abnormal findings. 
5.2.2 
Clinical Chemistry 
Clinical chemistry results will be summarised in the same way as the hematology 
data.  The box and whisker plot will present the results for the following parameters: 
triglycerides, total cholesterol, total bilirubin, cystatin C and creatinine. 
The separate summaries described for presentation of platelets will be presented in 
relation to triglycerides.  However, these summaries will be adjusted to relate to 
increase in triglycerides.  Therefore, time to nadir will be replaced with time to first 
maximum value post-baseline, and references in the definitions to ‘minimum’, 
‘decrease’ or ‘below lower limit of normal’ should be replaced with ‘maximum’, 
‘increase’ and ‘above the upper limit of normal’ respectively.  The summary of 
platelet data described for subjects in the safety analysis set who reduced dose due 
to platelet count decrease will instead be a summary for subjects in the safety 
analysis set who reduced dose due to triglyceride increase. 
A plot of the mean triglyceride count at each visit will be produced by treatment 
group.  
All clinical chemistry values will be listed, flagging all abnormal findings. 
Data for the following liver function parameters will also be listed separately: 
Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma-
glutamyl transpeptidase (GGT). 
5.2.3 
Urinalysis 
All urinalysis values will be listed, flagging all abnormal findings where reference 
ranges are available. 
5.2.4 
Coagulation 
Summary statistics of observed coagulation results and change from baseline will be 
presented in the same way as the hematology data. A shift table of coagulation 
results will also be presented as described for the hematology data. 
All coagulation values will be listed, flagging all abnormal findings. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 44 of 64 
Version: Final 6.0 
ST/form/010/6 
5.2.5 
Serology 
All serology data will be listed in full. 
5.3 Vital Signs 
Summary statistics of vital sign observed values and change from baseline by 
parameter and visit will be presented by treatment group for all subjects in the safety 
analysis set. 
All vital sign data will be listed in full. 
5.4 Physical Exams 
Details regarding whether or not a physical examination occurred, as well as the 
date of assessment, will be listed. 
5.5 Electrocardiography  
Clinical interpretations of standard 12-lead ECG assessments will be summarised as 
follows.  Shift in ECG interpretation from baseline to each visit for normal, abnormal 
NCS, abnormal CS, missing and total results will be summarised by treatment group 
for all subjects in the safety analysis set using the “worst case” scenario for each set 
of triplicate readings as required.  Subjects will only be included in the missing 
category if they attended the visit but have no data available for the ECG 
interpretation.  Withdrawn subjects will not be included in the missing category.   This 
shift summary will be repeated for the ECG interpretation as recorded on the CRF by 
the investigator and the interpretation recorded by the laboratory. 
Summary statistics of observed values and change from baseline will be presented 
by visit and treatment group for all subjects in the safety analysis set for the following 
parameters: 
 RR interval (msec) 
 PR interval (msec) 
 QRS duration (msec) 
 QT interval (msec) 
 QTcF interval (msec) [Fridericia’s formula for QTcF (Fridericia, 1920)] 
 QTcB interval (msec) [Bazett’s formula for QTcB (Bazett, 1920)]  
 ECG mean ventricular rate (beats/min) 
Where triplicate ECG assessments have been performed, the mean of the non-
missing values will be used in the analyses. 
The mean QTcF values will be plotted over time for each treatment group. 
The incidence of outliers in QTcF intervals (>450, >480, and >500 msec), and the 
change from baseline in QTcF intervals (>30 and >60 msec) will be summarized by 
visit and overall for each treatment group as defined in ICH E14 guideline (ICH_E14, 
2005).  As above, where triplicate ECG assessments have been performed, the 
mean of the non-missing values will be used to determine outliers.  A subject will be 
counted once for each outlier in the overall summary if they experienced at least one 
occurrence of that outlier.  


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 45 of 64 
Version: Final 6.0 
ST/form/010/6 
All ECG interpretations will be listed. Any comments collected with the ECG data will 
not be presented in the listing but will be retained in the data for reference.  
5.6 Echocardiography 
Summary statistics of echocardiography (ECHO) observed values and change from 
baseline by parameter and visit will be presented by treatment group for all subjects 
in the safety analysis set. 
All echocardiography data will be listed in full. 
5.7 Pulmonary Function Test 
Pulmonary function test data (FEV1 (L), FVC (L), FEV1/FVC (%) and PEF (L/min)) 
including change from baseline will be summarised by visit and treatment group.  
Where multiple assessments have been performed at a visit, the best of the 
repeated assessments will be used for summaries.  The best of the repeated 
assessments is defined for each parameter as the assessment with the maximum 
absolute value.   
In addition, the percent predicted value of FEV1, FVC and PEF will be calculated at 
baseline and after 12 and 18 months of treatment according to the following rules.  
Where multiple assessments have been performed at a visit, the best of the 
repeated assessments will be used in the calculation according to the same 
approach as above. 
 FEV1% = FEV1*100 / ((-0.7453 - ( 0.04106 * age )) + (0.004477 * ( age^2 )) + 
((0.00014098 * ( height^2 ))*1)) (Hankinson, Odencrantz, & Fedan, 1999) 
 FVC% = FVC*100 / ((-0.2584 - ( 0.20415 * age )) + (0.010133 * ( age^2 )) + 
((0.00018642 * ( height^2 ))*1)) (Hankinson, Odencrantz, & Fedan, 1999) 
 PEF% = PEF*100 / (-422.8 + 5.288 * height), (Buyse, et al., 2015). 
In each of the above calculations, age refers to the age at the time of the pulmonary 
function test assessment, calculated in years and months from date of birth and 
assessment date.  Date of birth will be subject to the rules given in Section 4.4.4.4 
prior to this calculation.  Height refers to the most recent non-missing height 
measurement in cm at the time of the pulmonary function test assessment. 
Summary statistics of observed values and changes from baseline in FVC%, FEV1% 
and PEF% will be presented by visit and treatment group for all subjects in the safety 
analysis set.   
Plots of the mean PEF, FVC, percent predicted PEF and percent predicted FVC over 
time will be produced by treatment group. 
All pulmonary function test data, including calculated percent predicted values, will 
be listed.  These listings will include the age and height at the time of each 
assessment, as well as the individual triplicate values and the selected best value 
where appropriate. 
5.8 Concomitant Medications 
Concomitant medications will be coded according to the WHO Drug Dictionary 
Version B3 Sept 21.   


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 46 of 64 
Version: Final 6.0 
ST/form/010/6 
Prior medications are defined as those that started and ended prior to the first dose 
of study treatment.  Medications that are ongoing at the first dose of study treatment 
or that started after the time of the first dose of study treatment will be deemed to be 
concomitant medications. 
There will be no imputation of unknown dates.  However, for sorting and assignation, 
if the start date is unknown then the medication will be assumed to be concomitant 
unless the partial start date, or other data (i.e. stop date) indicates differently. 
The number and percentage of subjects taking prior and concomitant medications 
will be summarized separately, each by medication class and standardised 
medication name sorted alphabetically for each treatment group and overall.   
All medications will be listed and concomitant medications will be flagged. 
5.9 Concomitant Steroid Treatments 
Data regarding steroid treatments received by subjects during the course of or prior 
to the study are recorded on the CRF separately to the information regarding initial 
steroid usage at diagnosis (see Section 3.3.2 for details of presentation of data 
regarding initial steroid usage at diagnosis).   
Prior steroid medications are defined as any steroid treatments recorded on the prior 
and concomitant steroid treatments CRF page that started and ended prior to the 
first dose of study treatment.  Steroid treatments that are ongoing at the first dose of 
study treatment or that started after the time of the first dose of study treatment will 
be deemed to be concomitant treatments. 
There will be no imputation of unknown dates.  However, for sorting and assignation, 
if the start date is unknown then the steroid will be assumed to be concomitant 
unless the partial start date, or other data (i.e. stop date) indicates differently. 
A summary table will present the following for prior steroid treatments in each 
treatment group: 
- 
Number and percentage of subjects who recorded taking each type of prior 
steroid (Prednisone, Deflazacort, Other). 
- 
Number and percentage of subjects who change prior steroid type at least 
once (for example Prednisone to Deflazacort). 
- 
Duration from start of first recorded steroid to start of study treatment, 
regardless of break in steroid or changes in regimen, dose or type of steroid 
(note that this may include steroid treatments that continue after first study 
treatment and are therefore classified as concomitant steroid treatments).  
Any breaks in steroid treatment will be excluded from the duration. 
A further summary table will present the following for concomitant steroid treatments 
in each treatment group: 
- 
Number and percentage of subjects who changed concomitant steroid type 
(for example Prednisone to Deflazacort) after the start of study treatment.  
Note that this is expected to be zero.  However, if the number of subjects is 
>0, this will be reviewed to determine whether any further summary should be 
added. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 47 of 64 
Version: Final 6.0 
ST/form/010/6 
- 
Duration from start of study treatment to change in steroid type (calculated as 
End date of first concomitant steroid that was changed – Date of first study 
treatment +1). 
- 
Duration from start of first concomitant steroid to start of study treatment (note 
that subjects are expected to have been taking steroid treatment for >=6 
months at the time of starting study treatment). 
- 
Number and percentage of subjects who stopped steroid treatment between 
the start of study treatment and end of study. 
- 
Duration from start of study treatment to end of concomitant steroid use for 
those who stopped steroid treatment prior to end of study. 
- 
Separate summaries by steroid type (Prednisone, Deflazacort, other) for: 
o Number and percentage of subjects who recorded taking the 
respective concomitant steroid type. 
o Number and percentage of subjects by frequency. 
o Number and percentage of subjects by route of administration.  
o Duration of exposure from start of first concomitant steroid to the end of 
the last concomitant steroid (excluding any breaks in steroid 
treatment). 
o Number and percentage of subjects who changed steroid regimen (i.e. 
frequency) between the start of study treatment and the end of the 
study. 
For calculations of duration, partial dates will be imputed with the first of the month 
for a missing day and January for a missing month. 
All steroid treatment information will be listed and concomitant steroids will be 
flagged. 
5.10 Raven Coloured Progressive Matrices 
The Raven coloured progressive matrices test is a general cognitive function 
assessment which will be performed at screening and at visit 18. 
Summary statistics and change from baseline for the number of right answers for 
Sections A, AB, B and overall, as well as the percentage of right answers for 
Sections A, AB, B and overall will be presented by treatment group for all subjects in 
the safety analysis set. 
All Raven coloured progressive matrices data will be listed in full with the derived 
age at time of each assessment included in the listing. 
5.11 Acceptability and Palatability of the Oral Suspension 
Acceptability and palatability of IMP will be assessed at week 4 and End of 
Study/Early Withdrawal.  Subject perception of the medicine (ranging from dislike 
very much to like very much), parent’s perception of the medicine based on the 
child’s reaction (unpleasant, not sure or pleasant) and whether there were problems 
administering the medication will be summarised by visit and treatment group. 
All acceptability and palatability data will be listed.  
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 48 of 64 
Version: Final 6.0 
ST/form/010/6 
6 REFERENCES 
Bazett, H.C. (1920). An Analysis of the Time-Relations of Electrocardiograms. Heart, 
7, 353-370. 
Buyse, G. M., Voit, T., Schara, U., Straathof, C. S., D'Angelo, G., Bernert, G., . . . 
Meier, T. (2015, May 2). Efficacy of idebenone on respiratory function in 
patients with Duchenne muscular dystrophy not using glucocorticoids 
(DELOS): a double-blind randomised placebo-controlled phase 3 trial. The 
Lancet, 385(9979), 1748-1757. 
D'Agostino, R. B. Jr. (1998). Propensity score methods for bias reduction in the 
comparison of a treatment to a non-randomized control group.  Statistics in 
Medicine, 17(19), 2265-2281. 
European Medicines Agency. (2002, September). CPMP/EWP/908/99 - Points to 
consider 
on 
multiplicity 
issues 
in 
clinical 
trials. 
Retrieved 
from 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/
2009/09/WC500003640.pdf, February 2017 
Fridericia, L. S. (1920). Die Systolendauer im Elektrokardiogramm bei normalen 
Menschen und bei Herzkranken. [The duration of systole in the 
electrocardiogram of normal subjects and of patients with heart disease.]. Acta 
Medica Scandinavica, 53, 469-486. 
Geiger R, S. A. (2007). Six-minute walk testin children and adolescents. Journal of 
Pediatrics, 150(4), 395-9, e391-2. 
Hankinson, J. L., Odencrantz, J. R., & Fedan, K. B. (1999, January). Spirometric 
reference values from a sample of the general U.S. population. American 
Journal of Respiratory and Critical Care Medicine, 159(1), 179-187. 
Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. 
Biometrika, 75, 800-802. 
ICH_E14. (2005, May 12). ICH Harmonised Tripartite Guideline. The clinical 
evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-
antiarrhythimic 
drugs. 
E14. 
Retrieved 
from 
www.ich.org: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Effica
cy/E14/E14_Guideline.pdf 
Mazzone, E. S., Coratti, G., Sormani, M. P., Messina, S., Pane, M., D'Amico, A., . . . 
Mercuri, E. (2016). Timed rise from floor as a predictor of disease progression 
in Duchenne muscular dystrophy: an observational study. PLos ONE, 11(3), 
e0151554. doi: 10.137/journal.pone.0.151445. 
McDonald, C. M., Henricson, E. K., Abresch, R. T., Florence, J. M., Eagle, M., 
Gappmaier, E., . . . Peltz, S. (2013, September). The 6-minute walk test and 
other endpoints in Duchenne muscular dystrophy: longitudinal natural history 
observations over 48 weeks from a multicenter study. Muscle & Nerve, 48(3), 
343-356. 
Rosenbaum, P. R. and Rubin, D. (1985). Constructing a Control Group Using 
Multivariate Matched Sampling Methods that Incorporate the Propensity Score. 
The American Statistician, 39, 33-38. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 49 of 64 
Version: Final 6.0 
ST/form/010/6 
U.S. Food and Drug Administration. (2017, January). Multiple Endpoints in Clinical 
Trials 
Guidance 
for 
Industry. 
Retrieved 
from 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInform
ation/Guidances/UCM536750.pdf, February 2017 
 
 
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 50 of 64 
Version: Final 6.0 
ST/form/010/6 
7 APPENDICES 
7.1 Functional Evaluation Scale: 4SC 
1. Unable to climb up 4 standard stairs 
2. Climbs 4 standard stairs “marking time” (climbs one foot at a time, with both 
feet on a step before moving to next step), using both arms on one or both 
handrails 
3. Climbs 4 standard stairs “marking time” (climbs one foot at a time, with both 
feet on a step before moving to next step), using one arm on one handrail 
4. Climbs 4 standard stairs “marking time” (climbs one foot at a time, with both 
feet on a step before moving to next step), not needing handrail 
5. Climbs 4 standard stairs alternating feet, needs handrail for support 
6. Climbs 4 standard stairs alternating feet, not needing handrail support 
7.2 Functional Evaluation Scale: Time to Rise from the Floor 
1. Unable to stand from supine, even with use of a chair 
2. Assisted Gowers’ – requires furniture for assist in arising from supine to full 
upright position 
3. Full Gowers’ – rolls over, stands up with both hands “climbing up” the legs to 
achieve full upright posture 
4. Half Gowers’ – rolls over, stands up with one hand support on leg 
5. Rolls to the side and/or stands up with one hand or both hands on the floor to 
start to rise up but does not touch legs 
6. Stands up without rolling over or using hands 
7.3 Functional Evaluation Scale: Time to Walk/Run 10 Metres 
1. Unable to walk independently 
2. Unable to walk independently, but can walk with full leg calipers (KAFOs) or 
with support from a person 
3. Highly adapted wide based lordotic gait.  Cannot increase walking speed 
4. Moderately adapted gait.  Can pick up speed but cannot run 
5. Able to pick up speed, but runs with double stance phase i.e. cannot achieve 
both feet off the ground 
6. Runs and gets both feet off the ground (with no double stance phase) 
 
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 51 of 64 
Version: Final 6.0 
ST/form/010/6 
7.4 PODCI Questionnaire Subscales 
The PODCI questionnaire can be completed by either the parent or the subject 
themselves.   
7.4.1 
PODCI Completed by Parent 
7.4.1.1 Upper Extremity Function 
The upper extremity function is comprised of the following 8 items of the parent-
completed questionnaire. 
Question 
Number  
Description 
Q1 
Lift heavy books? 
Q2 
Pour half a gallon of milk? 
Q3 
Open a jar that has been opened before? 
Q4 
Use a fork and spoon? 
Q5 
Comb his/her hair? 
Q6 
Button buttons? 
Q8 
Write with a pencil? 
Q32 
Turn door knobs? 
Note that any item rated “5” (Too young for this activity) is considered missing and is 
not added to the scale.  A minimum of 4 items must have valid answers in order for 
this subscale to be calculated.  The raw and standardised scores for the upper 
extremity function subscale are calculated as: 
 Raw Score: Sum of the scores of each of the non-missing items in this 
subscale. 
 Standardised Score: [(4 – mean of items)/3] * 100, where the mean of the 
items is calculated as (sum of the items)/(number of non-missing items). 
7.4.1.2 Transfer and Basic Mobility 
The following items are included in the transfer and basic mobility subscale: 
Question 
Number  
Description 
Q7 
Put on his/her coat? 
Q21 
Climb one flight of stairs? 
Q24 
Walk one block? 
Q25 
Get on and off a bus? 
Q28 
Stand while washing his/her hands and face at a sink? 
Q29 
Sit in a regular chair without holding on? 
Q30 
Get on and off a toilet or chair? 
Q31 
Get in and out of bed? 
Q33 
Bend over from a standing position and pick up something off the floor? 
Q34 
How often does your child need help form another person for sitting and standing? 
Q35 
How often does your child use assistive devices (such as braces, crutches or 
wheelchair) for sitting and standing? 
Any item with a score of “5” (Too young for this activity) is considered missing and is 
not included in the calculations for this subscale.  A minimum of 7 items must have 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 52 of 64 
Version: Final 6.0 
ST/form/010/6 
valid responses in order for this subscale to be calculated.  In addition, questions 34 
and 35 are to be rescaled as follows: 
 Q34rescaled = [(Q34 – 1) * 3/4] + 1 
 Q35rescaled = [(Q35 – 1) * 3/4] + 1 
The raw and standardised scores for this subscale are calculated as: 
 Raw score: sum of the items Q7, Q21, Q24, Q25, Q28, Q29, Q30, Q31, Q33, 
Q34rescaled, Q35rescaled. 
 Standardised score: [(4 – mean of items)/3] * 100, where the mean of the items 
is calculated as (raw score)/(number of non-missing items). 
7.4.1.3 Sports and Physical Function 
The items included in the sports and physical function subscale are presented below: 
Question 
Number  
Description 
Q18 
Run short distances? 
Q19 
Bicycle or tricycle? 
Q20 
Climb three flights of stairs? 
Q22 
Walk more than a mile? 
Q23 
Walk three blocks? 
Q26 
How often does your child need help from another person for walking and climbing? 
Q27 
How often does your child need assistive devices (such as braces, crutches or 
wheelchair) for walking and climbing? 
Q36 
 
Can your child participate in recreational outdoor activities with other children the 
same age? 
Q44 
Can your child participate in pickup games or sports with other children the same 
age? 
Q52 
Can your child participate in competitive level sports with other children the same 
age? 
Q60 
How often in the last week did your child get together and do things with friends? 
Q66 
How often in the last week did your child participate in gym/recess? 
Any item with a score of “5” (Too young for this activity) is considered missing and is 
not included in the calculations for this subscale.  A minimum of 6 items must have 
valid responses in order for this subscale to be calculated.  In addition, some of the 
items in this subscale are to be recoded and rescaled as follows: 
 Q26 is rescaled as follows:  Q26rescaled = [ (Q26 -1) * 3/4] + 1 
 Q27 is rescaled as follows:  Q27rescaled = [ (Q27 -1) * 3/4] + 1 
 Q36 is recoded to missing if (Q36 = 4 and either [Q42 = 1] or [Q43 = 1]) 
 Q44 is recoded to missing if (Q44 = 4 and either [Q50 = 1] or [Q51 = 1]) 
 Q52 is recoded to missing if (Q52 = 4 and either [Q58 = 1] or [Q59 = 1]) 
 Q60 is recoded and rescaled as follows: 
o Step 1: Q60 is recoded to missing if (Q60 = 3 and Q65 = 1) 
o Step 2: If Q60 is not missing then Q60rescaled = [(Q60 – 1) * 3/2] + 1 
 Q66 is recoded and rescaled as follows: 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 53 of 64 
Version: Final 6.0 
ST/form/010/6 
o Step 1: Q66 is recoded to missing if (Q66 = 4)  
o Step 2: Q66 is recoded to missing if (Q66 = 3 and either [Q72 = 1] or 
[Q73 = 1]) 
o Step 3: If Q66 is not missing then Q66rescaled = [(Q66 – 1) * 3/2] + 1 
The raw and standardised scores for the sports and physical function subscale are 
then calculated as follows: 
 Raw score: Sum of items Q18, Q19, Q20, Q22, Q23, Q26rescaled, 
Q27rescaled, Q36, Q44, Q52, Q60rescaled, Q66rescaled 
 Standardised score: [(4 – mean of items)/3] * 100, where the mean of the items 
is calculated as (raw score)/(number of non-missing items). 
7.4.1.4 Pain/Comfort 
The items included in the pain/comfort subscale are presented below: 
Question 
Number  
Description 
Q17 
Did pain or discomfort interfere with your child’s activities? 
Q75 
How much pain has your child had during the last week? 
Q76 
During the last week, how much did pain interfere with your child’s normal activities 
(including at home, outside of the home, and at school)? 
Note that a minimum of 2 items must have valid answers in order for this scale to be 
scored.  Questions 17 and 75 are to be rescaled as follows: 
 Q17rescaled = [(4 – Q17) * 4/3] + 1 
 Q75rescaled = [(Q75 – 1) * 4/5] + 1 
The raw and standardised scores for the pain/comfort scale are then calculated as: 
 Raw score: sum of items Q17rescaled, Q75rescaled, Q76 
 Standardised score: [(4 – {mean of items – 1})/4] * 100, where the mean of 
the items is calculated as (raw score)/(number of non-missing items). 
7.4.1.5 Happiness 
The following items are included in the happiness subscale: 
Question 
Number 
Description 
Q10 
How he/she looks? 
Q11 
His/her body? 
Q12 
What clothes or shoes he/she can wear? 
Q13 
His/her ability to do the same things his/her friends do? 
Q14 
His/her health in general? 
Note that any item rated “5” (Too young for this activity) is considered missing and is 
not included in the scale.  In addition, a minimum of 3 items must have valid answers 
in order for this subscale to be computed. 
The raw and standardised scores for the happiness subscale are then computed as: 
 Raw score: Sum of items Q10, Q11, Q12, Q13, Q14 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 54 of 64 
Version: Final 6.0 
ST/form/010/6 
 Standardised score: [(5 – mean of items)/4] * 100, where the mean of the 
items is calculated as (raw score)/(number of non-missing items). 
7.4.1.6 Global Function Scale 
The global function scale is comprised of the upper extremity and physical function; 
transfer and basic mobility; sports and physical functioning and the pain/comfort 
subscales.  The standardised score for the global function scale can only be 
calculated if none of the four relevant subscales are missing and is computed as the 
mean of the standardised scores of the 4 subscales included in this scale. 
7.4.2 
PODCI Completed by Subject 
7.4.2.1 Upper Extremity Function 
The upper extremity function is comprised of the following 8 items of the subject-
completed questionnaire. 
Question 
Number  
Description 
Q1 
Lift heavy books? 
Q2 
Pour half a gallon of milk? 
Q3 
Open a jar that has been opened before? 
Q4 
Use a fork and spoon? 
Q5 
Comb your hair? 
Q6 
Button buttons? 
Q8 
Write with a pencil? 
Q32 
Turn door knobs? 
Note that a minimum of 4 items must have valid answers in order for this subscale to 
be calculated.  The raw and standardised scores for the upper extremity function 
subscale are calculated as: 
 Raw Score: Sum of the scores of each of the non-missing items in this 
subscale. 
 Standardised Score: [(4 – mean of items)/3] * 100, where the mean of the 
items is calculated as (sum of the items)/(number of non-missing items). 
7.4.2.2 Transfer and Basic Mobility 
The following items are included in the transfer and basic mobility subscale: 
Question 
Number  
Description 
Q7 
Put on your coat? 
Q21 
Climb one flight of stairs? 
Q24 
Walk one block? 
Q25 
Get on and off a bus? 
Q28 
Stand while washing your hands and face at a sink? 
Q29 
Sit in a regular chair without holding on? 
Q30 
Get on and off a toilet or chair? 
Q31 
Get in and out of bed? 
Q33 
Bend over from a standing position and pick up something off the floor? 
Q34 
How often do you need help form another person for sitting and standing? 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 55 of 64 
Version: Final 6.0 
ST/form/010/6 
Q35 
How often do you use assistive devices (such as braces, crutches or wheelchair) for 
sitting and standing? 
A minimum of 7 items must have valid responses in order for this subscale to be 
calculated.  In addition, questions 34 and 35 are to be rescaled as follows: 
 Q34rescaled = [(Q34 – 1) * 3/4] + 1 
 Q35rescaled = [(Q35 – 1) * 3/4] + 1 
The raw and standardised scores for the transfer and basic mobility subscales are 
then calculated as: 
 Raw score: sum of the items Q7, Q21, Q24, Q25, Q28, Q29, Q30, Q31, Q33, 
Q34rescaled, Q35rescaled. 
 Standardised score: [(4 – mean of items)/3] * 100, where the mean of the items 
is calculated as (raw score)/(number of non-missing items). 
7.4.2.3 Sports and Physical Function 
The items included in the sports and physical function subscale are presented below: 
Question 
Number  
Description 
Q18 
Run short distances? 
Q19 
Bicycle or tricycle? 
Q20 
Climb three flights of stairs? 
Q22 
Walk more than a mile? 
Q23 
Walk three blocks? 
Q26 
How often do you need help from another person for walking and climbing? 
Q27 
How often do you use assistive devices (such as braces, crutches or wheelchair) for 
walking and climbing? 
Q36 
 
Can you participate in recreational outdoor activities with other children the same 
age? 
Q43 
Can you participate in pickup games or sports with other children the same age? 
Q50 
Can you participate in competitive level sports with other children the same age? 
Q57 
How often in the last week did you get together and do things with friends? 
Q63 
How often in the last week did you participate in gym/recess? 
A minimum of 6 items must have valid responses in order for this subscale to be 
calculated.  In addition, some of the items in this subscale are to be recoded and 
rescaled as follows: 
 Q26 is rescaled as follows:  Q26rescaled = [ (Q26 -1) * 3/4] + 1 
 Q27 is rescaled as follows:  Q27rescaled = [ (Q27 -1) * 3/4] + 1 
 Q36 is recoded to missing if (Q36 = 4 and Q42 = 1) 
 Q43 is recoded to missing if (Q43 = 4 and Q49 = 1) 
 Q50 is recoded to missing if (Q50 = 4 and Q59 = 1) 
 Q57 is recoded and rescaled as follows: 
o Step 1: Q57 is recoded to missing if (Q57 = 3 and Q62 = 1) 
o Step 2: If Q57 is not missing then Q57rescaled = [(Q57 – 1) * 3/2] + 1 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 56 of 64 
Version: Final 6.0 
ST/form/010/6 
 Q63 is recoded and rescaled as follows: 
o Step 1: Q63 is recoded to missing if (Q63 = 4)  
o Step 2: Q63 is recoded to missing if (Q63 = 3 and either [Q69 = 1] or 
[Q70 = 1]) 
o Step 3: If Q63 is not missing then Q63rescaled = [(Q63 – 1) * 3/2] + 1 
The raw and standardised scores for the sports and physical function are then 
calculated as follows: 
 Raw score: Sum of items Q18, Q19, Q20, Q22, Q23, Q26rescaled, 
Q27rescaled, Q36, Q43, Q50, Q57rescaled, Q63rescaled 
 Standardised score: [(4 – mean of items)/3] * 100, where the mean of the items 
is calculated as (raw score)/(number of non-missing items). 
7.4.2.4 Pain/Comfort 
The items included in the pain/comfort subscale are presented below: 
Question 
Number  
Description 
Q17 
Did pain or discomfort interfere with your activities? 
Q72 
How much pain have you had during the last week? 
Q73 
During the last week, how much did pain interfere with your normal activities (including 
at home, outside of the home, and at school)? 
Note that a minimum of 2 items must have valid answers in order for this scale to be 
scored.  Questions 17 and 72 are to be rescaled as follows: 
 Q17rescaled = [(4 – Q17) * 4/3] + 1 
 Q72rescaled = [(Q72 – 1) * 4/5] + 1 
The raw and standardised scores for the pain/comfort scale are then calculated as: 
 Raw score: sum of items Q17rescaled, Q72rescaled, Q73 
 Standardised score: [(4 – {mean of items – 1})/4] * 100, where the mean of 
the items is calculated as (raw score)/(number of non-missing items) 
7.4.2.5 Happiness 
The following items are included in the happiness subscale: 
Question 
Number 
Description 
Q10 
How you look? 
Q11 
Your body? 
Q12 
What clothes or shoes you can wear? 
Q13 
Your ability to do the same things your friends do? 
Q14 
Your health in general? 
Note that a minimum of 3 items must have valid answers in order for this subscale to 
be computed. 
The raw and standardised scores for the happiness subscale are then computed as: 
 Raw score: Sum of items Q10, Q11, Q12, Q13, Q14 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 57 of 64 
Version: Final 6.0 
ST/form/010/6 
 Standardised score: [(5 – mean of items)/4] * 100, where the mean of the 
items is calculated as (raw score)/(number of non-missing items) 
7.4.2.6 Global Function Scale 
The global function scale is comprised of the upper extremity and physical function; 
transfer and basic mobility; sports and physical functioning and the pain/comfort 
subscales.  The standardised score for the global function scale can only be 
calculated if none of the four relevant subscales are missing and is computed as the 
mean of the standardised scores of the 4 subscales included in this scale. 
7.5 Missing Data Classification and Imputation Rules 
7.5.1 
Time to Climb 4 Standard Stairs (4SC) 
Class 1 – ‘Was assessment performed and completed?’  = ‘No’.   
Class 2 – Was assessment performed and completed?’  = ‘Yes’ but ‘Duration’ is 
missing and ‘4-stair ascent grading’ response is ‘1 = Unable to climb 4 standard stairs’.  
Note that if the grading is >1 but the ‘Duration’ is genuinely missing, this should be 
treated as Class 1 missing data.    
7.5.2 
Time to Rise from Floor 
Class 1 – ‘Was assessment performed?’ = ‘No’.  
Class 2 - ‘Was assessment performed?’ = ‘Yes’ but ‘Duration’ is missing and ‘Rising 
from floor grading’ response is ‘1= Unable to stand from supine, even with use of a 
chair’ or ‘2= Assisted Gowers’ - requires furniture for assist in arising from supine to 
full upright posture’.  Note that if the grading is >2 but the ‘Duration’ is genuinely 
missing, this should be treated as Class 1 missing data. 
7.5.3 
Distance Walked in 6 Minutes (6MWT) 
Class 1 - ‘Was assessment performed?’ = ‘No’.  
Class 2 - ‘Was assessment performed?’ = ‘Yes’ but ‘Was assessment completed?’ = 
‘Stopped prematurely’ and ‘Duration walked’ is left missing and ‘Distance walked at 
end of test’ is left missing.   
7.5.4 
Physical Function as Measured by NSAA 
For the purposes of calculating total NSAA score, classification of missing data should 
be applied as follows:  
Class 1 - Either of the following: 
- 
‘Was assessment attempted?’ = ‘No’ and the reason given is ‘Declined to 
perform test’ or ‘Other’.  In this case, each item score will be imputed using the 
mode of the non-missing scores for the same item and visit across all subjects 
randomised to the same treatment and in the same concomitant steroid stratum 
and Group (i.e. Group A, target population or Group B, off-target population).  If 
there are multiple mode values then the lowest modal value will be used. The 
total score will be re-derived as the sum of the 17 imputed item scores. 
- 
‘Was assessment attempted?’ = ‘Yes’ but one or more of the item scores is 
missing.  In this case one of two possible methods will be followed: 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 58 of 64 
Version: Final 6.0 
ST/form/010/6 
o If ≥ 9 out of 17 items have been completed with ≤ 8 missing, then the 
missing item scores for that subject at that visit will be imputed using the 
mode of the non-missing item scores for the subject and visit. If there 
are multiple mode values then the lowest modal value will be used. The 
total score will be re-derived as the sum of the 17 non-missing and 
imputed item scores. 
o If ≤ 8 out of 17 items have been completed with ≥ 9 missing, then the 
missing item scores for that subject at that visit will be imputed as zero. 
The total score will be re-derived as the sum of the 17 non-missing and 
imputed item scores. 
Class 2 - ‘Was assessment attempted?’ = ‘No’ and the reason given is ‘Unable to 
physically perform the test’.  In this case all item scores and the total score will be 
imputed to zero. 
For the purposes of calculating cumulative number of failed items, NSAA data will first 
be classified and imputed according to the above rules and the assessment of item 
failure will then be determined using the values after imputation. 
7.5.5 
Muscle Strength Evaluated by Knee Extension and Elbow Flexion as 
Measured by Hand-held Myometry 
Class 1 – Either of the following: 
- 
‘Was assessment attempted?’ = ‘No’ and the reason given is ‘Declined to 
perform test’ or ‘Other’. 
- 
‘Were all 4 elements of the extension/flexion assessment attempted?’ = ‘No’ 
and the reason given is ‘Declined to perform test’ or ‘Other’.  Any missing 
elements of the test (left/right knee extension or left/right elbow flexion) will be 
classified as 1. 
Class 2 – Either of the following: 
- 
‘Was assessment attempted?’ = ‘No’ and the reason given is ‘Unable to 
physically perform the test’.   
- 
‘Were all 4 elements of the extension/flexion assessment attempted?’ = ‘No’ 
and the reason given is ‘Unable to physically perform the test’.  Any missing 
elements of the test (left/right knee extension or left/right elbow flexion) will be 
classified as 2. 
7.5.6 
Fat Fraction of Vastus Lateralis Muscles as assessed by MRS 
All missing data for this endpoint will be Class 1. 
7.5.7 
Time to Run/Walk 10 Metres 
Class 1 – ‘Was assessment performed?’  = ‘No’.   
Class 2 – Was assessment performed?’  = ‘Yes’ but ‘Was assessment completed?’ = 
‘No’ and ‘Distance’ is missing and ‘Duration walked’ is missing and ’10-Metre 
Walk/Run test Grading’ response is ‘1 = Unable to walk independently’ or ‘2 = Unable 
to walk independently, but can walk with full leg calipers (KAFOs) or with support from 
a person’. Note that if the grading is >2 but the ‘Duration walked’ is genuinely missing, 
this should be treated as Class 1 missing data. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 59 of 64 
Version: Final 6.0 
ST/form/010/6 
7.5.8 
Paediatric Outcomes Data Collection Instrument (PODCI) Scores 
All missing data for this endpoint will be Class 1.   
7.5.9 
Percent Predicted 6MWT 
Missing values for the 6MWT will be classified and imputed as described above for 
that endpoint, prior to finding the percent predicted 6MWT values. 
7.5.10 Fat Fraction and Cross-Sectional Area of 5 Thigh Muscles as Assessed 
by MRI 
All missing data for this endpoint will be Class 1. 
7.5.11 Time to 10% Persistent Worsening in 6MWT 
Missing values for the 6MWT will be classified and imputed as described above for 
that endpoint, prior to finding the time to 10% persistent worsening in 6MWT.  Note 
that any imputed 6MWT values post early withdrawal will also be considered for the 
purposes of the time to event analysis. 
7.5.12 Proportion of Subjects with ≥10% Persistent Worsening in 6MWT 
Missing values for the 6MWT will be classified and imputed as described above for 
that endpoint prior to finding the proportion of subjects with ≥10% persistent worsening 
in 6MWT.   
7.5.13 Time to Persistent Loss of Standing (Baseline Through End of Study)  
The following rules will be applied in order to identify subjects who meet the criteria 
specified in Section 4.3.7 for persistent loss of standing.  Note that any imputed values 
post early withdrawal will also be considered for the purposes of the time to even 
analysis: 
- 
Classification and imputation of the NSAA data will be applied as described 
above.  Where Class 2 missing data are identified, the score for the ‘Rise from 
floor’ item on the NSAA assessment will be assumed to be ‘0b - Unable’ for the 
purposes of determining loss of standing.  Where Class 1 missing data are 
identified, the score for the ‘Rise from floor’ item will be carried forward from the 
last non-missing score for this item for the subject.  If the Class 1 missing data 
are from a baseline assessment, the score for this item will be assumed >0. 
- 
Classification and imputation of the Time to Rise from Floor data will be applied 
as described above.  Where there are Class 1 missing data for the Rise from 
Floor assessment and therefore the ‘Rising from floor grading’ is missing, the 
grade will be carried forward from the last non-missing Rising from floor grading 
for the subject.  If the Class 1 missing data are from a baseline assessment, 
the Rising from floor grading will be assumed >1.   
7.5.14 Proportion of Subjects Who Lose Ambulation 
The following steps will be completed in order to identify subjects who meet the criteria 
specified in Section 4.3.8 for loss of ambulation: 
- 
Missing 6MWT values will be classified in order to identify any Class 2 missing 
values, i.e. where the subject meets the criterion for being unable to perform 
the 6MWT due to physical inability.   


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 60 of 64 
Version: Final 6.0 
ST/form/010/6 
- 
Any missing 10-metre walk/run test values will be classified and imputed.  The 
imputed values will be used to identify subjects who meet the criteria for being 
unable to complete the 10-metre walk/run test in 30 seconds or less without 
any support or devices.  Where Class 1 missing data are identified and the 
imputed duration walked is ≤30 seconds, the ‘10-Metre Walk/Run test Grading’ 
will be carried forward from the last non-missing grading for the subject in order 
to determine whether the subject was able to complete the test without any 
support or devices.  If the Class 1 missing data are from a baseline assessment, 
the 10-Metre Walk/Run test Grading will be assumed >2 for the purposes of 
determining loss of ambulation (i.e. able to complete the test without support or 
devices). 
7.5.15 Type of DMD Mutation, LTBP4 and Osteopontin Genotype 
No imputation will be applied to this data.  Any missing values for these assessments 
will be excluded from summaries and analyses as applicable.  Where a subject has a 
missing value such that they cannot be assigned to a group for evaluation of 
subgroups, they will be excluded from the respective subgroup summaries and 
analyses. 
7.5.16 DMD Serum Biomarker 
No imputation will be applied to this data.  Any missing values for this assessment will 
be excluded from summaries and analyses as applicable. 
7.6 Outputs to be Reviewed at the Safety Review Meetings 
The following tables, figures and listings will be reviewed by the IDMC at the 3 
monthly safety review meetings.  The IDMC will meet every 3 months from the first 
subject randomised.  All tables and listings provided to the IDMC at safety reviews 
will be presented for the overall subject population.  
Table 14.1.1.1.1.1 Subject Disposition  
Table 14.1.1.1.2.1 Disposition of Screened Subjects 
Listing 16.2.1.1 Subject Completions and Withdrawals 
Listing 16.2.2.1 Eligibility - Inclusion and Exclusion Criteria 
 
Listing 16.2.3.1 Analysis Sets 
 
Table 14.1.1.2.1 Major Protocol Deviations  
Listing 16.2.3.2 Protocol Deviations 
 
Table 14.1.2.1 Demography 
Listing 16.2.4.1 Demography 
 
Table 14.1.3.1 Medical History 
Listing 16.2.4.2 Medical History 
 
Table 14.1.3.2 DMD Diagnosis 
Listing 16.2.4.3 DMD Diagnosis  
Table 14.1.4.1 Administration of Study Treatment 
 
Table 14.1.4.2 Modifications of Study Treatment 
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 61 of 64 
Version: Final 6.0 
ST/form/010/6 
Table 14.1.4.3 Duration of Modifications of Study Treatment  
Listing 16.2.5.1 Investigational Product Dispensing 
Listing 16.2.5.2 Investigational Product Modifications 
Table 14.1.5 Ankle Range of Motion 
 
Listing 16.2.5.3 Ankle Range of Motion 
Table 14.1.6 Muscle Strength Test Modified MRC Grade 
Listing 16.2.5.4 Muscle Strength Test Modified MRC Grade  
Table 14.3.1.1.1 Summary of Treatment-Emergent Adverse Events  
Table 14.3.1.2.1 Summary of Treatment-Emergent Adverse Events by MedDRA 
System Organ Class and Preferred Term 
Table 14.3.1.3.1 Summary of Serious Treatment-Emergent Adverse Events by 
MedDRA System Organ Class and Preferred Term 
 
Table 14.3.1.4.1 Summary of Treatment-Emergent Adverse Events Leading to 
Withdrawal by MedDRA System Organ Class and Preferred Term  
Table 14.3.1.6.1 Summary of Treatment-Emergent Adverse Events Leading to Death 
by MedDRA System Organ Class and Preferred Term  
Table 14.3.1.7.1 Summary of Treatment-Emergent Adverse Events Leading to 
Discontinuation of IMP by MedDRA System Organ Class and Preferred Term 
 
Table 14.3.1.8.1 Summary of Treatment-Emergent Adverse Events by MedDRA 
System Organ Class, Preferred Term and Severity 
 
Table 14.3.1.9.1 Summary of Treatment-Emergent Adverse Events by MedDRA 
System Organ Class, Preferred Term and Relationship to Study Treatment 
 
Table 14.3.1.11.1 Treatment-Emergent Bronchopulmonary Adverse Events (BAEs) 
Listing 16.2.7.1 Adverse Events  
Listing 16.2.7.2 Serious Adverse Events  
Listing 16.2.7.3 Adverse Events Leading to Discontinuation of IMP  
Listing 16.2.7.4 Adverse Events Leading to Dose Reduction or Discontinuation of IMP 
Table 14.3.2.1 Haematology Values and Change from Baseline over Time  
Table 14.3.2.2 Haematology Values and Change from Baseline over Time  
Table 14.3.2.3 Platelets Count Values over Time 
 
Figure 14.2.7.1 Plot of Mean Platelets Count by Treatment over Time 
 
Table 14.3.2.4 Shift in Haematology Values over Time 
Figure 14.2.7.2.1 Box and Whisker Plot of Selected Haematology Results by 
Treatment over Time 
Figure 14.2.7.2.2 Patient Plots of Selected Haematology Results over Time* 
Listing 16.2.8.1 All Haematology Values  
Table 14.3.3.1 Clinical Chemistry Values and Change from Baseline over Time 
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 62 of 64 
Version: Final 6.0 
ST/form/010/6 
Table 14.3.3.2 Shift in Clinical Chemistry Values over Time 
Figure 14.2.7.3.1 Box and Whisker Plot of Selected Clinical Chemistry Results by 
Treatment over Time 
Figure 14.2.7.3.2 Patient Plots of Selected Clinical Chemistry Results over Time* 
Listing 16.2.8.2 All Clinical Chemistry Values 
 
Table 14.3.4.1 Coagulation Values and Change from Baseline over Time 
Listing 16.2.8.4 All Coagulation Values 
Listing 16.2.8.6 All Liver Function Values 
 
Table 14.3.5 Summary of Vital Signs and Change from Baseline over Time 
Listing 16.2.9.1 Vital Signs  
Table 14.3.6.1 Summary of ECG Results and Change from Baseline over Time  
Table 14.3.6.2 Shift in ECG Interpretation 
 
Table 14.3.6.3 Incidence of Outliers in ECG Results 
 
Figure 14.2.8 Plot of Mean QTcF Values by Treatment over Time 
 
Listing 16.2.9.3 ECG Results 
 
Table 14.3.7 ECHO Values and Change from Baseline over Time 
 
Listing 16.2.9.4 All Echocardiography (ECHO) Values  
Table 14.3.8.1 Pulmonary Function Test and Change from Baseline over Time 
 
Table 14.3.8.2 Percent Predicted Values for Pulmonary Function Test and Change 
from Baseline over Time 
 
Figure 14.2.9.1 Plot of Mean Peak Expiratory Flow (L/min) Values by Treatment over 
Time 
Figure 14.2.9.2 Plot of Mean Forced Vital Capacity (L) Values by Treatment over Time 
Figure 14.2.9.3 Plot of Mean % Predicted Peak Expiratory Flow (%) Values by 
Treatment over Time 
Figure 14.2.9.4 Plot of Mean % Predicted Forced Vital Capacity (%) Values by 
Treatment over Time 
 
Listing 16.2.9.5 All Pulmonary Function Test Values 
 
Table 14.3.9.1.2 Concomitant Medications 
 
Table 14.3.9.2.2 Concomitant Steroid Treatments 
 
Listing 16.2.9.6.1 Prior and Concomitant Medications  
Listing 16.2.9.6.2 Prior and Concomitant Steroid Treatments  
Excel listings of selected laboratory parameter results by visit for each subject in the 
all enrolled subjects analysis set.  This will include the dose administered at each visit 
alongside the results.* 
Excel listing of site level deviations. 
* Output is only to be produced for safety reviews and not as part of the final analysis. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 63 of 64 
Version: Final 6.0 
ST/form/010/6 
 
In addition to the above list, the following repeat tables presented by country will also 
be provided once 30 subjects have been randomised:  
Table 14.1.1.1.1.2 Subject Disposition by Country 
Table 14.1.1.1.2.2 Disposition of Screened Subjects by Country 
Table 14.1.1.2.2 Major Protocol Deviations by Country 
Table 14.1.2.2 Demography by Country 
Table 14.3.1.1.2 Summary of Treatment-Emergent Adverse Events by Country 
Table 14.3.1.2.2 Summary of Treatment-Emergent Adverse Events by Country, 
MedDRA System Organ Class and Preferred Term 
Table 14.3.1.3.2 Summary of Serious Treatment-Emergent Adverse Events by 
Country, MedDRA System Organ Class and Preferred Term 
Table 14.3.1.4.2 Summary of Treatment-Emergent Adverse Events Leading to 
Withdrawal by Country, MedDRA System Organ Class and Preferred Term 
Table 14.3.1.6.2 Summary of Treatment-Emergent Adverse Events Leading to 
Death by Country, MedDRA System Organ Class and Preferred Term 
Table 14.3.1.7.2 Summary of Treatment-Emergent Adverse Events Leading to 
Discontinuation of IMP by Country, MedDRA System Organ Class and 
Preferred Term 
Table 14.3.1.8.2 Summary of Treatment-Emergent Adverse Events by Country, 
MedDRA System Organ Class, Preferred Term and Severity 
Table 14.3.1.9.2 Summary of Treatment-Emergent Adverse Events by Country, 
MedDRA System Organ Class, Preferred Term and Relationship to Study 
Treatment 
Table 14.3.1.11.2 Treatment-Emergent Bronchopulmonary Adverse Events 
(BAEs) by Country 
 
The following additional tables will also be provided once at least 50 subjects have 
been randomised and have completed at least one month of treatment: 
Table 14.3.1.10.1 Summary of Treatment-Emergent Adverse Events by Steroid 
Type at Baseline, MedDRA System Organ Class and Preferred Term 
Table 14.3.1.10.2 Summary of Treatment-Emergent Adverse Events by 
Country, Steroid Type at Baseline, MedDRA System Organ Class and 
Preferred Term 
For the purposes of IDMC safety reviews, the summaries relating to antibiotic use will 
be excluded from the above two tables as this is not relevant to safety.  These 
summaries will only be included for the final analysis (and interim analyses if required). 
 
The summary tables listed above will be repeated using the blinded (dummy) 
randomisation so that the blind is maintained, and these outputs will be sent to 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 13APR2022 
Page 64 of 64 
Version: Final 6.0 
ST/form/010/6 
Italfarmaco at each safety review.  Italfarmaco will not receive any figures or listings 
for the safety reviews.  
At each safety review, individual outputs will be compiled into a single pdf file for tables, 
figures and listings respectively with hyperlinks applied to navigate to each output.  
The compiled files will be provided alongside the individual output files.   
7.7 Outputs to be Reviewed at the Interim Analysis 
The outputs to be included in the interim analysis will consist of:  
Summary table for observed values and change from baseline in VL MFF as 
assessed by MRS over time 
Analysis table presenting results from an ANCOVA on mean change from 
baseline to 12 months in VL MFF as assessed by MRS. 
In addition the following output will be prepared in order to provide to the IDMC if 
requested following their review of the above tables:  
Listing of subject results for VL MFF as assessed by MRS over time. 
Specific details regarding the presentation of these outputs are given in a separate 
‘Interim Analysis 1 Table, Figure and Listing Shells’ document. 
 


Certificate Of Completion
Envelope Id: 31CA21F120454F95B0FFF2C2ECFF243F
Status: Completed
Subject: DSC_14_2357_48 (ICO16001): Please DocuSign: Statistical Analysis Plan Final 6.0
Source Envelope: 
Document Pages: 64
Signatures: 3
Envelope Originator: 
Certificate Pages: 5
Initials: 0
Rebecca Williamson
AutoNav: Enabled
EnvelopeId Stamping: Disabled
Time Zone: (UTC) Dublin, Edinburgh, Lisbon, London
134 Turnpike Road
Southborough, MA  01772
rebecca.williamson@veristat.com
IP Address: 62.232.1.93    
Record Tracking
Status: Original
             13 April 2022 | 17:54
Holder: Rebecca Williamson
             rebecca.williamson@veristat.com
Location: DocuSign
Signer Events
Signature
Timestamp
Rebecca Williamson
rebecca.williamson@veristat.com
Principal Statistician
SQN Ltd
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signed by link sent to 
rebecca.williamson@veristat.com
Signature ID: 
C7FC1738-7B43-4E70-A99B-8828D90C01BB
Using IP Address: 62.232.1.93
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I am the author of this document
Sent: 13 April 2022 | 18:26
Viewed: 13 April 2022 | 18:32 
Signed: 13 April 2022 | 18:33
Electronic Record and Signature Disclosure: 
      Not Offered via DocuSign
Dr Kevin J Carroll
kevin.carroll@kjcstatistics.co.uk
Security Level: Email, Account Authentication 
(Required), Logged in
Signature Adoption: Pre-selected Style
Signed by link sent to 
kevin.carroll@kjcstatistics.co.uk
Signature ID: 
DE4A2C4C-7F4B-42A0-AC53-69BE7794B88D
Using IP Address: 185.192.69.15
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this document
Sent: 13 April 2022 | 21:06
Viewed: 14 April 2022 | 14:23 
Signed: 14 April 2022 | 14:25
Electronic Record and Signature Disclosure: 
      Accepted: 14 April 2022 | 14:23
      ID: ccd8dff0-69bc-4fb9-82ca-95422d3ded2b


Signer Events
Signature
Timestamp
Maurizio Caserini
m.caserini@italfarmaco.com
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signed by link sent to m.caserini@italfarmaco.com
Signature ID: 
DE5C96C0-EB71-4C74-9DA6-DE7D4CD3B1B8
Using IP Address: 185.212.107.47
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   Approvo il documento
Sent: 13 April 2022 | 18:33
Viewed: 14 April 2022 | 10:47 
Signed: 14 April 2022 | 10:49
Electronic Record and Signature Disclosure: 
      Accepted: 04 February 2022 | 08:42
      ID: 652078dd-9364-42e4-be41-76beaeb4188e
In Person Signer Events
Signature
Timestamp
Editor Delivery Events
Status
Timestamp
Agent Delivery Events
Status
Timestamp
Intermediary Delivery Events
Status
Timestamp
Certified Delivery Events
Status
Timestamp
Carbon Copy Events
Status
Timestamp
Witness Events
Signature
Timestamp
Notary Events
Signature
Timestamp
Envelope Summary Events
Status
Timestamps
Envelope Sent
Hashed/Encrypted
13 April 2022 | 18:26
Certified Delivered
Security Checked
14 April 2022 | 10:47
Signing Complete
Security Checked
14 April 2022 | 10:49
Completed
Security Checked
14 April 2022 | 14:25
Payment Events
Status
Timestamps
Electronic Record and Signature Disclosure


ELECTRONIC RECORD AND SIGNATURE DISCLOSURE  
From time to time, Veristat (we, us or Company) may be required by law to provide to you 
certain written notices or disclosures. Described below are the terms and conditions for providing 
to you such notices and disclosures electronically through the DocuSign system. Please read the 
information below carefully and thoroughly, and if you can access this information electronically 
to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please 
confirm your agreement by selecting the check-box next to ‘I agree to use electronic records and 
signatures’ before clicking ‘CONTINUE’ within the DocuSign system. 
 
Getting paper copies  
At any time, you may request from us a paper copy of any record provided or made available 
electronically to you by us. You will have the ability to download and print documents we send 
to you through the DocuSign system during and immediately after the signing session and, if you 
elect to create a DocuSign account, you may access the documents for a limited period of time 
(usually 30 days) after such documents are first sent to you. After such time, if you wish for us to 
send you paper copies of any such documents from our office to you, you will be charged a 
$0.00 per-page fee. You may request delivery of such paper copies from us by following the 
procedure described below. 
 
Withdrawing your consent  
If you decide to receive notices and disclosures from us electronically, you may at any time 
change your mind and tell us that thereafter you want to receive required notices and disclosures 
only in paper format. How you must inform us of your decision to receive future notices and 
disclosure in paper format and withdraw your consent to receive notices and disclosures 
electronically is described below. 
 
Consequences of changing your mind  
If you elect to receive required notices and disclosures only in paper format, it will slow the 
speed at which we can complete certain steps in transactions with you and delivering services to 
you because we will need first to send the required notices or disclosures to you in paper format, 
and then wait until we receive back from you your acknowledgment of your receipt of such 
paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to 
receive required notices and consents electronically from us or to sign electronically documents 
from us. 
 
All notices and disclosures will be sent to you electronically  
Electronic Record and Signature Disclosure created on: 09 July 2020 | 20:25
Parties agreed to: Dr Kevin J Carroll, Maurizio Caserini


Unless you tell us otherwise in accordance with the procedures described herein, we will provide 
electronically to you through the DocuSign system all required notices, disclosures, 
authorizations, acknowledgements, and other documents that are required to be provided or made 
available to you during the course of our relationship with you. To reduce the chance of you 
inadvertently not receiving any notice or disclosure, we prefer to provide all of the required 
notices and disclosures to you by the same method and to the same address that you have given 
us. Thus, you can receive all the disclosures and notices electronically or in paper format through 
the paper mail delivery system. If you do not agree with this process, please let us know as 
described below. Please also see the paragraph immediately above that describes the 
consequences of your electing not to receive delivery of the notices and disclosures 
electronically from us. 
 
How to contact Veristat:  
You may contact us to let us know of your changes as to how we may contact you electronically, 
to request paper copies of certain information from us, and to withdraw your prior consent to 
receive notices and disclosures electronically as follows: 
To contact us by email send messages to: vincent.hughes@veristat.com 
 
To advise Veristat of your new email address  
To let us know of a change in your email address where we should send notices and disclosures 
electronically to you, you must send an email message to us at vincent.hughes@veristat.com and 
in the body of such request you must state: your previous email address, your new email 
address.  We do not require any other information from you to change your email address.  
If you created a DocuSign account, you may update it with your new email address through your 
account preferences.  
 
To request paper copies from Veristat  
To request delivery from us of paper copies of the notices and disclosures previously provided 
by us to you electronically, you must send us an email to vincent.hughes@veristat.com and in 
the body of such request you must state your email address, full name, mailing address, and 
telephone number. We will bill you for any fees at that time, if any. 
 
To withdraw your consent with Veristat  
To inform us that you no longer wish to receive future notices and disclosures in electronic 
format you may: 


i. decline to sign a document from within your signing session, and on the subsequent page,
select the check-box indicating you wish to withdraw your consent, or you may;
ii. send us an email to vincent.hughes@veristat.com and in the body of such request you must
state your email, full name, mailing address, and telephone number. We do not need any other
information from you to withdraw consent..  The consequences of your withdrawing consent for
online documents will be that transactions may take a longer time to process..
Required hardware and software 
The minimum system requirements for using the DocuSign system may change over time. The 
current system requirements are found here: https://support.docusign.com/guides/signer-guide-
signing-system-requirements.  
Acknowledging your access and consent to receive and sign documents electronically 
To confirm to us that you can access this information electronically, which will be similar to 
other electronic notices and disclosures that we will provide to you, please confirm that you have 
read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for 
your future reference and access; or (ii) that you are able to email this ERSD to an email address 
where you will be able to print on paper or save it for your future reference and access. Further, 
if you consent to receiving notices and disclosures exclusively in electronic format as described 
herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before 
clicking ‘CONTINUE’ within the DocuSign system. 
By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm 
that: 

You can access and read this Electronic Record and Signature Disclosure; and

You can print on paper this Electronic Record and Signature Disclosure, or save or send
this Electronic Record and Disclosure to a location where you can print it, for future
reference and access; and

Until or unless you notify Veristat as described above, you consent to receive exclusively
through electronic means all notices, disclosures, authorizations, acknowledgements, and
other documents that are required to be provided or made available to you by Veristat
during the course of your relationship with Veristat.


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 14JUL2022 
Page 1 of 6 
Version: Addendum 1 Final 1.0 
ST/form/038/3 
 
 
 
Randomised, Double Blind, Placebo Controlled, Multicentre Study 
to Evaluate the Efficacy and Safety of Givinostat in Ambulant 
Patients with Duchenne Muscular Dystrophy 
 
Italfarmaco Study No: DSC/14/2357/48 
Veristat Study No: ICO16001 
EudraCT No: 2016-000401-36 
IND No: 126598 
 
Statistical Analysis Plan Addendum 1 
 
Version: Final 1.0 
Date: 14th July 2022 
 
For Veristat 
Author 
 
 
 
 
 
 
For Italfarmaco 
Approved by 
 
 
 
 
 
 
 
Maurizio Caserini  
Position: Clinical Research & Development Director 
 
For KJC Statistics Ltd 
Approved by 
 
 
 
 
 
 
Dr Kevin Carroll 
 
Position: Consultant Statistician 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 14JUL2022 
Page 2 of 6 
Version: Addendum 1 Final 1.0 
ST/form/038/3 
 
Contents 
 
1 
INTRODUCTION ............................................................................................................................. 4 
2 
CHANGES TO THE FINAL SAP ..................................................................................................... 4 
2.1 
Change 1 .................................................................................................................................... 4 
2.2 
Change 2 .................................................................................................................................... 5 
2.3 
Change 3 .................................................................................................................................... 6 
2.4 
Change 4 .................................................................................................................................... 6 
 
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 14JUL2022 
Page 3 of 6 
Version: Addendum 1 Final 1.0 
ST/form/038/3 
 
LIST OF ABBREVIATIONS 
 
NSAA 
North Star Ambulatory Assessment 
NTF 
Note to file 
PODCI 
Paediatric Outcomes Data Collection Instrument 
SAP 
Statistical Analysis Plan 
TFL 
Table, Figure and Listing 
 
 
 
 
 
 
 
 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 14JUL2022 
Page 4 of 6 
Version: Addendum 1 Final 1.0 
ST/form/038/3 
 
1 INTRODUCTION 
This is an addendum to both the final statistical analysis plan (SAP) Version 6.0, 
dated 13th April 2022, and the following key file notes (NTF) which were agreed prior 
to study unblinding: 
 SOP-CLIN-16-FORM-NTF_muscle_strength_SIGNED, dated 4th May 2022 
 SOP-CLIN-16-FORM-NTF_hardcoding_07_FE, dated 9th May 2022 
 SOP-CLIN-16-FORM-NTF_hardcoding_17_FE, dated 4th May 2022 
 SOP-CLIN-16-FORM-NTF_hardcoding_19_FE, dated 11th May 2022 
 SOP-CLIN-16-FORM-NTF_hardcoding_21_FE, dated 12th May 2022 
 SOP-CLIN-16-FORM-NTF_hardcoding_24_FE, dated 18th May2022 
 SOP-CLIN-16-FORM-NTF_hardcoding_30_FE, dated 7th May 2022 
 SOP-CLIN-16-FORM-NTF_hardcoding_38_FE, dated 5th May 2022 
 SOP-CLIN-16-FORM-NTF_PODCI_SIGNED, dated 23rd May 2022 
This addendum documents key changes, corrections or further clarification regarding 
specific derivations and analyses described in the SAP or file notes following 
database lock. Full details of the changes and the reasons for these are detailed 
below. 
2 CHANGES TO THE FINAL SAP 
2.1 Change 1 
According to the SAP Sections 4.3.2 and 4.4.2, for the Paediatric Outcomes Data 
Collection Instrument (PODCI) endpoint, change from baseline over time for raw and 
standardised subscale scores are to be presented and analysed separately for ‘parent’ 
or ‘self’ evaluator. However, on review of the data following database lock and prior to 
unblinding, it was confirmed that there are a number of cases where a subject has 
completed a mixture of questionnaires by different evaluators from screening to end 
of study. Unfortunately, the SAP does not cover this type of scenario. 
Italfarmaco and Veristat discussed possible solutions with consideration that a subject 
will only have a baseline questionnaire completed for one type of evaluator even 
though this may differ from the evaluator for the post-baseline visit. In order to avoid 
limitation to only subjects with consistent evaluator across baseline and post-baseline 
for calculating change from baseline values, a pooled approach has been identified.  
This was supported by the assumption that scores from questionnaires completed by 
‘self’ where the subject is <10 years of age are considered not fully reliable.  However, 
scores from questionnaires completed by ‘self’ where the subject is >=10 years old 
can be considered reliable and comparable to scores from questionnaires completed 
by ‘parent’. 
In the data we will have a mixture of questionnaires completed by: ‘Parent’, ‘Self >=10 
years’, ‘Self <10 years’, ‘Missing’ (where missing evaluator applies to completely 
imputed results where the assessment/visit was not done).  Therefore, the approach 
will be as follows.  


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 14JUL2022 
Page 5 of 6 
Version: Addendum 1 Final 1.0 
ST/form/038/3 
 
Questionnaires will be divided into two groups based on the type of evaluator: 
 Group 1: ‘Parent’ + (‘Self’ >=10 years old) 
 Group 2: ‘Missing’ + (‘Self’ <10 years old) 
Group 1 non-missing subscale scores will remain unchanged.  Group 1 missing 
subscale scores will be imputed as described in the SAP Sections 4.4.4.1, 4.4.4.2 and 
7.5.8 using the approach for Class 1 missing data based on Group 1 non-missing 
results (for the respective subscale, visit, treatment, concomitant steroid and target/off-
target group). 
Group 2 subscale scores (both non-missing or missing scores) will be replaced with 
imputed values using the same approach for Class 1 missing data but also based on 
Group 1 non-missing results (for the respective subscale, visit, treatment, concomitant 
steroid and target/off-target group), rather than Group 2 non-missing results. 
All values (Group 1 and Group 2 non-missing and imputed values) will then be 
analysed together as equivalent measures, i.e., all are included in calculation of 
change from baseline and summaries/analyses. The analysis tables will be presented 
based on these values without distinction between different evaluators.  The amended 
table, figure and listing (TFL) shells for these presentations are supplied in the 
separate document ‘TFL Shells Addendum 1’.  These replace the following equivalent 
planned outputs in the TFL Shells Final 4.0: Tables 14.2.8.1.1 to 14.2.8.5.6 and 
Listings 16.2.6.8.1 to 16.2.6.8.4.   
Reason for the change 
As detailed above, this change has been implemented as the SAP defined approach 
did not allow for the mixture of questionnaires completed by different evaluators per 
subject as collected in the data.  
2.2 Change 2 
Section 7.4.1 of the SAP (PODCI Completed by Parent) includes the following 
instruction when describing the required derivations for some of subscale scores on 
the parent completed questionnaires: “any item rated “5” (Too young for this activity) 
is considered missing and is not added to the scale”.   
It was noted that for some questions on the parent completed questionnaire, the 
response indicating that the subject was too young for the activity is given a different 
number, for example ‘6’ rather than ‘5’.  In addition, there are some questions where 
the response is phrased slightly differently, for example: “Child is too young”.  Affected 
questions are questions 10 to 14 used for the ‘Happiness’ subscale.  
To accommodate these differences, the approach was therefore corrected to consider 
any item as missing for subscale calculation if the text response contains the phrase 
‘too young’ (regardless of the number of the response or exact phrasing of the full 
response).  This was agreed to be the intention of the SAP instructions.   
Reason for the change 
The differences between question responses regarding ‘too young’ were overlooked 
in the SAP instructions for calculating subscale scores on the parent completed 
PODCI questionnaire.  This change was implemented in order to correct this and 
ensure that any such responses were handled consistently in the scoring. 


Veristat study no: ICO16001 
 
Italfarmaco study no: DSC/14/2357/48 
 
Date: 14JUL2022 
Page 6 of 6 
Version: Addendum 1 Final 1.0 
ST/form/038/3 
 
2.3 Change 3 
Section 7.4.2.3 of the SAP (Sports and Physical Function) describes the derivations 
required for calculating the sports and physical function subscale scores for the subject 
completed PODCI questionnaires.  This includes the following instruction: 
 Q50 is recoded to missing if (Q50 = 4 and Q59 = 1) 
However, it was noted that the question 59 relates to the response regarding ‘Doing 
things with friends’ limited by ‘Health’, whereas it was agreed that this instruction 
should instead refer to question 56 which is related to ‘participating in sports’ limited 
by ‘Activity not in season’.  
Therefore, this derivation was corrected to the following: 
 Q50 is recoded to missing if (Q50 = 4 and Q56 = 1). 
Reason for the change 
This was a correction due to an erroneous question reference in the SAP instructions. 
2.4 Change 4 
It was noted that some of the rules for imputation in the SAP Section 7.5.13 (Time to 
Persistent Loss of Standing (Baseline Through End of Study)) are no longer relevant 
given the approach to impute individual missing North Star Ambulatory Assessment 
(NSAA) item scores as described in the SAP Section 7.5.4 (Physical Function as 
Measured by NSAA).   
The rules for imputation of the NSAA rise from floor item in Section 7.5.13 were written 
to handle the situation where there are remaining missing individual NSAA item scores 
prior to deriving the time to persistent loss of standing endpoint.  However, after this 
text was written and prior to SAP finalisation and database lock, the approach in 
Section 7.5.4 was updated to ensure that all item scores will be populated following 
imputation of the NSAA endpoint.  Therefore, there is no requirement to apply the 
additional rule to carry forward item scores as described in Section 7.5.13.  Instead, 
the decision was taken to use the values already imputed per the rules in Section 7.5.4 
so that this is consistent.   
It should be noted that, in some cases, the imputation rules in Section 7.5.4 mean that 
the rise from floor item score could be imputed to zero but without distinction between 
'0a' or '0b'.  In these cases, the following approach was agreed: 
 If item score = ‘0’ and the class of missing data = ‘Class 2’ then assume ‘0b – 
Unable’ for the purposes of the time to persistent loss of standing derivation. 
 If item score = ‘0’ and the class of missing data = ‘Class 1’ then assume ‘0a - 
Needs external support of object e.g., chair’ for the purposes of the time to 
persistent loss of standing derivation. 
Reason for the change 
This change was considered appropriate to ensure consistency within the SAP across 
the imputation approaches for related endpoints. 


Certificate Of Completion
Envelope Id: 0900440C9A174EFDAE00EC082FB7F0FD
Status: Completed
Subject: DSC_14_2357_48 (ICO16001): Please DocuSign: SAP Addendum 1 Final 1.0
Source Envelope: 
Document Pages: 6
Signatures: 3
Envelope Originator: 
Certificate Pages: 5
Initials: 0
Rebecca Williamson
AutoNav: Enabled
EnvelopeId Stamping: Disabled
Time Zone: (UTC) Dublin, Edinburgh, Lisbon, London
134 Turnpike Road
Southborough, MA  01772
rebecca.williamson@veristat.com
IP Address: 20.0.168.239   
Record Tracking
Status: Original
             14 July 2022 | 18:53
Holder: Rebecca Williamson
             rebecca.williamson@veristat.com
Location: DocuSign
Signer Events
Signature
Timestamp
Dr Kevin J Carroll
kevin.carroll@kjcstatistics.co.uk
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 
DE4A2C4C-7F4B-42A0-AC53-69BE7794B88D
Using IP Address: 205.220.129.243
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this document
Sent: 14 July 2022 | 18:56
Viewed: 18 July 2022 | 20:53 
Signed: 18 July 2022 | 20:53
Electronic Record and Signature Disclosure: 
      Accepted: 18 July 2022 | 20:53
      ID: b94a9e26-d695-46ac-a5c7-c35cb7c13953
Maurizio Caserini
m.caserini@italfarmaco.com
Clinical Research and Development Director 
Italfarmaco Group
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 
DE5C96C0-EB71-4C74-9DA6-DE7D4CD3B1B8
Using IP Address: 185.125.227.47
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   Approvo il documento
Sent: 14 July 2022 | 18:56
Viewed: 15 July 2022 | 08:51 
Signed: 15 July 2022 | 08:52
Electronic Record and Signature Disclosure: 
      Accepted: 04 February 2022 | 08:42
      ID: 652078dd-9364-42e4-be41-76beaeb4188e


Signer Events
Signature
Timestamp
Rebecca Williamson
rebecca.williamson@veristat.com
Principal Statistician
SQN Ltd
Security Level: Email, Account Authentication 
(Required), Logged in
Signature Adoption: Pre-selected Style
Signature ID: 
C7FC1738-7B43-4E70-A99B-8828D90C01BB
Using IP Address: 20.0.168.239
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I am the author of this document
Sent: 14 July 2022 | 18:56
Viewed: 14 July 2022 | 18:57 
Signed: 14 July 2022 | 18:57
Electronic Record and Signature Disclosure: 
      Not Offered via DocuSign
In Person Signer Events
Signature
Timestamp
Editor Delivery Events
Status
Timestamp
Agent Delivery Events
Status
Timestamp
Intermediary Delivery Events
Status
Timestamp
Certified Delivery Events
Status
Timestamp
Carbon Copy Events
Status
Timestamp
Witness Events
Signature
Timestamp
Notary Events
Signature
Timestamp
Envelope Summary Events
Status
Timestamps
Envelope Sent
Hashed/Encrypted
14 July 2022 | 18:56
Certified Delivered
Security Checked
14 July 2022 | 18:57
Signing Complete
Security Checked
14 July 2022 | 18:57
Completed
Security Checked
18 July 2022 | 20:53
Payment Events
Status
Timestamps
Electronic Record and Signature Disclosure


ELECTRONIC RECORD AND SIGNATURE DISCLOSURE  
From time to time, Veristat (we, us or Company) may be required by law to provide to you 
certain written notices or disclosures. Described below are the terms and conditions for providing 
to you such notices and disclosures electronically through the DocuSign system. Please read the 
information below carefully and thoroughly, and if you can access this information electronically 
to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please 
confirm your agreement by selecting the check-box next to ‘I agree to use electronic records and 
signatures’ before clicking ‘CONTINUE’ within the DocuSign system. 
 
Getting paper copies  
At any time, you may request from us a paper copy of any record provided or made available 
electronically to you by us. You will have the ability to download and print documents we send 
to you through the DocuSign system during and immediately after the signing session and, if you 
elect to create a DocuSign account, you may access the documents for a limited period of time 
(usually 30 days) after such documents are first sent to you. After such time, if you wish for us to 
send you paper copies of any such documents from our office to you, you will be charged a 
$0.00 per-page fee. You may request delivery of such paper copies from us by following the 
procedure described below. 
 
Withdrawing your consent  
If you decide to receive notices and disclosures from us electronically, you may at any time 
change your mind and tell us that thereafter you want to receive required notices and disclosures 
only in paper format. How you must inform us of your decision to receive future notices and 
disclosure in paper format and withdraw your consent to receive notices and disclosures 
electronically is described below. 
 
Consequences of changing your mind  
If you elect to receive required notices and disclosures only in paper format, it will slow the 
speed at which we can complete certain steps in transactions with you and delivering services to 
you because we will need first to send the required notices or disclosures to you in paper format, 
and then wait until we receive back from you your acknowledgment of your receipt of such 
paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to 
receive required notices and consents electronically from us or to sign electronically documents 
from us. 
 
All notices and disclosures will be sent to you electronically  
Electronic Record and Signature Disclosure created on: 09 July 2020 | 20:25
Parties agreed to: Dr Kevin J Carroll, Maurizio Caserini


Unless you tell us otherwise in accordance with the procedures described herein, we will provide 
electronically to you through the DocuSign system all required notices, disclosures, 
authorizations, acknowledgements, and other documents that are required to be provided or made 
available to you during the course of our relationship with you. To reduce the chance of you 
inadvertently not receiving any notice or disclosure, we prefer to provide all of the required 
notices and disclosures to you by the same method and to the same address that you have given 
us. Thus, you can receive all the disclosures and notices electronically or in paper format through 
the paper mail delivery system. If you do not agree with this process, please let us know as 
described below. Please also see the paragraph immediately above that describes the 
consequences of your electing not to receive delivery of the notices and disclosures 
electronically from us. 
 
How to contact Veristat:  
You may contact us to let us know of your changes as to how we may contact you electronically, 
to request paper copies of certain information from us, and to withdraw your prior consent to 
receive notices and disclosures electronically as follows: 
To contact us by email send messages to: vincent.hughes@veristat.com 
 
To advise Veristat of your new email address  
To let us know of a change in your email address where we should send notices and disclosures 
electronically to you, you must send an email message to us at vincent.hughes@veristat.com and 
in the body of such request you must state: your previous email address, your new email 
address.  We do not require any other information from you to change your email address.  
If you created a DocuSign account, you may update it with your new email address through your 
account preferences.  
 
To request paper copies from Veristat  
To request delivery from us of paper copies of the notices and disclosures previously provided 
by us to you electronically, you must send us an email to vincent.hughes@veristat.com and in 
the body of such request you must state your email address, full name, mailing address, and 
telephone number. We will bill you for any fees at that time, if any. 
 
To withdraw your consent with Veristat  
To inform us that you no longer wish to receive future notices and disclosures in electronic 
format you may: 


i. decline to sign a document from within your signing session, and on the subsequent page,
select the check-box indicating you wish to withdraw your consent, or you may;
ii. send us an email to vincent.hughes@veristat.com and in the body of such request you must
state your email, full name, mailing address, and telephone number. We do not need any other
information from you to withdraw consent..  The consequences of your withdrawing consent for
online documents will be that transactions may take a longer time to process..
Required hardware and software 
The minimum system requirements for using the DocuSign system may change over time. The 
current system requirements are found here: https://support.docusign.com/guides/signer-guide-
signing-system-requirements.  
Acknowledging your access and consent to receive and sign documents electronically 
To confirm to us that you can access this information electronically, which will be similar to 
other electronic notices and disclosures that we will provide to you, please confirm that you have 
read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for 
your future reference and access; or (ii) that you are able to email this ERSD to an email address 
where you will be able to print on paper or save it for your future reference and access. Further, 
if you consent to receiving notices and disclosures exclusively in electronic format as described 
herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before 
clicking ‘CONTINUE’ within the DocuSign system. 
By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm 
that: 

You can access and read this Electronic Record and Signature Disclosure; and

You can print on paper this Electronic Record and Signature Disclosure, or save or send
this Electronic Record and Disclosure to a location where you can print it, for future
reference and access; and

Until or unless you notify Veristat as described above, you consent to receive exclusively
through electronic means all notices, disclosures, authorizations, acknowledgements, and
other documents that are required to be provided or made available to you by Veristat
during the course of your relationship with Veristat.